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Abstract 
The intersection of HPV and sexual assault: An opportunity for practice change 
Holly B. Fontenot 
Dissertation chair: Ann Wolbert Burgess, D.N.S, RNCS, FAAN 
 
Background: There is an opportunity for nurses to integrate HPV education and prevention 
strategies into the routine care for adolescent and young adult sexual assault patients. 
Study design: An exploratory, cross-sectional, electronic mail survey was conducted to explore 
forensic nurses’ knowledge, beliefs, and attitudes about HPV, the HPV vaccine, and HPV 
preventative strategies, as well as identify facilitators and barriers that may influence nurses’ 
level of support regarding incorporating HPV preventative strategies into their care. Eligibility 
criteria for inclusion were: nurse members of the International Association of Forensic Nurses 
(IAFN) and stakeholders in the care of sexual assault patients. 
Results: 541 nurses completed the survey; 98% (n= 508) were supportive of at least providing 
written educational information regarding HPV and the HPV vaccine during post sexual assault 
care, 86% (n= 446) were supportive of providing written information plus making changes to the 
written discharge instructions to incorporate HPV vaccination recommendations, and 53% (n= 
273) were supportive of providing written information, making changes to the discharge 
instructions, and initiation of HPV vaccination at point of care. The strongest predictor of level 
of support was having positive perceived benefits of HPV and vaccination.  A one standard 
deviation increase in perceived benefit was associated with a 50% increased odds of having the 
highest level of support (support for vaccination initiation) (OR=1.5, CI= 1.1-1.9). 
 
 
 
Conclusions: Forensic nurses provide care for many adolescents and young adults who are at 
risk for acquiring HPV and are within the age range for HPV vaccination.  There is an 
opportunity to update current practice guidelines and recommendations.  Nurses in this national 
sample demonstrated a high level of HPV knowledge, as well as positive attitudes and beliefs.  
The nurses were overwhelmingly supportive of integrating HPV prevention strategies into their 
care.  
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Chapter 1: Introduction 
Statement of the Problem 
 Nurses who care for both adolescents and young adults need to be aware of the many 
factors that put their patients’ sexual health and well being at risk.  Both sexually transmitted 
infections (STI), including the human papillomavirus (HPV), and sexual assault occur at 
disproportionately large rates in American youth and create serious physical and psychological 
problems for the victims.  There are many factors that contribute to risks for HPV among young 
victims of sexual assault including: increased risk for being a victim of sexual assault again, 
increased numbers of lifetime sexual partners, increased risk of STIs including HPV, lower odds 
of being screened for cervical cancer, and increased risks for abnormal cervical cytology (Farley, 
Golding, & Minkoff, 2002; Fisher, Daigle, Cullen &Turner, 2003; Kahn, Zimet, Bernstein, 
Riedese, Lan, et al., 2005; Sadler, Mengeling, Syrop, Torner, & Booth, 2011). 
 Researchers have advanced our understanding of the HPV virus family and vaccine, and 
are beginning to uncover facilitators and barriers for obtaining the vaccine.  Vaccination efforts 
are currently targeting two equally significant groups: primary prevention (vaccination for those 
who have not had sexual contact), and secondary prevention or “catch up” vaccination 
(vaccination for those who have already had sexual contact and/or exposure).  Provider 
recommendation has been identified as a vaccine facilitator.  However, little is known about 
nurses’ roles in dissemination of information about HPV, as well as their impact on vaccination 
rates.  One unique group of nurses, forensic nurses, provides care for many adolescents and 
young adults still in the age range for “catch up” vaccinations (up to age 26) who are at risk for 
acquiring HPV.  Forensic nurses who care for sexual assault patients currently screen, offer 
treatment for, and provide education and instructions about STIs, prophylactic medications, and 
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various vaccines.  However, at this time forensic nurses who care for this population have not yet 
updated guidelines to assess for and educate patients about HPV.  
Summary Information on HPV  
The human papillomavirus and vaccine have recently become a major focus in health 
research as well as in public health campaigns.  HPV is a virus family that includes over 150 
different strains.  Forty strains are known to be sexually transmitted, and have been established 
as the cause of cervical cancer and genital warts.  Recently this virus has also been implicated as 
the cause of other types of cancers including: vulvar, vaginal, penile, anal, and head and neck.  In 
the United States, HPV each year is the cause of 21,700 cancers in women and 11,700 cancers in 
men.  There are four significant strains of HPV that produce the vast majority of the HPV related 
cancers and warts in men and women.  Two strains (16 and 18) are known as high-risk 
oncogenic (cancer causing) and have been associated with 70% of cervical and anal cancers, and 
60% of oropharyngeal squamous cell cancers.  Two low risk strains (6 and 11) have been 
associated with 90% of genital, anal, and oral warts (CDC, 2009; Gillespie, Rubinchik, Hoel & 
Sutkowski, 2009; National Cancer Institute, 2011a).  
In the United States, HPV is the most common sexually transmitted infection.  Roughly 
20 million Americans are currently infected with HPV, with 6 million new cases each year. 
Researchers and epidemiologists have estimated that at least 50% of both sexually active men 
and women will contract this virus at some point in their lives (CDC, 2009; Weinstock, Berman, 
& Cates, 2004).  The incidence of HPV infection for females ages 15-19 is approximately 25% 
and increases to 45% by 20-24 years of age (Gillespie, Rubinchik, Hoel, & Sutkowski, 2009).  In 
one recent study, the incidence rate of HPV for the 409 female participants (ages 13-26) was 
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68%, and only 5% of these participants had received at least one dose of the HPV vaccine (Kahn, 
Rosenthal, Jin, Huang, Namakydoust, & Zimet, 2008).   
 HPV infection rates for males are more difficult to determine related to a lack of easy 
screening methods, but anal, penile, and cancers of the head and neck, specifically oropharyngeal 
(tonsil and tongue base), are on the rise in the US and disproportionately affect younger men 3:1 
(Gillespie, Rubinchik, Hoel, & Sutkowski, 2009; Marur, D’Souza, Westra, & Forastiere, 2010).   
 Within the past decade, a vaccine has been developed to help prevent acquisition of this 
virus and its sexually transmitted complications, including cancer and genital warts.  The FDA in 
2006 approved a vaccine (Gardisil®) to prevent the four significant strains of HPV (16, 18, 6, 
and 11) in women, and in 2010 this vaccine was approved for men.  Currently, the FDA approval 
for vaccination includes all adolescents and young adults ages 9-26.   
The Centers for Disease Control and Prevention (CDC) guidelines recommend HPV 
vaccine for all children ages 11-12 with catch- up vaccination for those ages 13-26 who have not 
been previously vaccinated (CDC, 2011a).  Vaccination represents a significant step toward the 
reduction of the HPV public health burden if widespread uptake occurs.  The CDC’s Advisory 
Committee on Immunization Practices (ACIP) is concerned that at the current rate of adolescent 
vaccination (an increase from 26.7% in 2009 to 32.0% in 2010), the Healthy People 2020 targets 
for vaccination (80% coverage among females) will not be met.  HPV vaccination rates have not 
been increasing at the same rates as those for other recommended adolescent vaccines.  Potential 
barriers related to adolescent HPV vaccination may include race and ethnicity, poverty and 
access to health care, living in the Southeastern U.S., and concern for safety, as well as parental, 
patient, and provider knowledge, attitudes, and beliefs, and societal influences about this virus 
and the sexual routes of transmission (Allen, Othus, Shelton, Li, Norman, Tom, et al., 2010; 
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Dorell, Stokley, Yankey, Liang, & Markowitz, 2011; McCave, 2010).  With these barriers in 
mind, the CDC Advisory Committee suggested continued evaluation of vaccination promotion 
initiatives.   
HPV vaccination efforts are focusing on two specific groups: primary vaccination at ages 
9-11 and catch up vaccination for those ages 13-26 regardless of previous sexual exposure or 
diagnosis of one or more HPV strains.  Employing all unique ways to capture adolescents and 
young adults within the catch up group is necessary to help reduce the HPV burden.  Protocols 
and programs to help educate patients and facilitate their awareness of and understanding about 
HPV in primary, secondary, and tertiary care settings are needed.  
Summary Information on Sexual Assault and Its Relation to HPV 
Roughly 8% of high school students have reported being forced to have sex, 54% of 
female victims had been sexually assaulted prior to the age of 18, and 20 to 25% of college 
women are at risk for some type of sexual assault, attempted or completed rape (a legal term for 
sexual assault that includes penetration however slight) (Eaton, Kann, Kinchen, Shanklin, Ross, 
& Hawkins, 2008; Fisher, Cullen, & Turner, 2000; Tjaden & Thoennes, 2000).  Adolescent 
victims of rape are more likely than others to be repeat victims (Fisher, Daigle, Cullen & Turner, 
2003), and approximately 105,187 females ages 10-24 received medical care in an emergency 
department (ED) for sexual assault during the years 2004 to 2006 according to the latest 
available data (Gavin, MacKay, Brown, Harrier, Ventura, Kann, et al., 2009).   
Schwarcz and Whittington (1990) described the difficulties of attempting to quantify 
risks of acquiring STIs from sexual assault, and these pathological difficulties remain true today. 
Many times due to varied incubation rates for infection, in particular long incubation periods for 
viral infectious agents, clinicians do not know if infection occurred during the assault.  Also, 
5 
 
viral infectious agents including HPV and herpes simplex virus may remain asymptomatic in 
some patients, and some HPV infections may only be revealed through DNA typing of cervical 
or other exposed tissues at a later date.  Lastly, a patient’s individual sexual history is also not 
fully explicated at times of sexual assault examination, because it is not pertinent for the 
medical/nursing legal examination.  However, currently existing and subsequent sexual assault 
risks for developing HPV will remain unknown without appropriate follow up. 
 Adding to the health concern is the link between sexual assault and STIs, and therefore 
HPV.  A history of child and adolescent sexual assault and subsequent mental health problems 
has been related to increased sexual health risks including higher rates of STIs and numbers of 
lifetime partners (Kahn, Huang, Rosenthal, Tissot, & Burk, 2005; Trent, Clum, & Roche, 2007).  
Also, a history of rape or sexual assault places adolescents at increased risk for re-victimization 
(Fisher, Daigle, Cullen, & Turner, 2003).  These associations strongly support the need for STI 
screening and “catch-up” HPV vaccination in youth especially those with a history of sexual 
assault. 
 Trent, Clum, and Roche (2007), in their secondary data analysis of the Young Adult 
Survey of the Baltimore Prevention Program, investigated a sample of 1698 male and female 
youth (ages 19-20), with 54% females, 71% Black, and 29% White.  In this sample, 19% had a 
history of STI and 16% reported a history of sexual assault.  Of those with a history of 
victimization, 51% also reported forced intercourse and 32% reported a history of STI.  Finally, 
in this study females with a history of both sexual assault and rape were significantly more likely 
to report a history of STI (thereby having an increased risk for HPV). 
 Kahn, Huang, et al. (2005) examined associations between coercive sexual experiences 
and subsequent HPV infection in adolescent women.  These researchers defined coercive sexual 
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experiences as childhood sexual abuse, sexual assault or rape.  In this sample of 537 women with 
an average age of 20 years, the mean number of lifetime partners equaled 7.7, 22% reported a 
history of coercive sex, and prevalence of HPV was approximately 50%.  Coercive sex was 
significantly associated with HPV and those with this history were 73% more likely to acquire 
HPV.  However, when number of lifetime partners was entered into the analytical model, it 
mediated the association between coercive sex and HPV.  The findings highlighted coercive sex 
as a significant problem particularly related to its associated risk of higher numbers of lifetime 
sexual partners.  
 Also contributing to the problem from a unique perspective, Farley, Golding, and 
Minkoff (2002) reported that women with a history of sexual assault may be less likely to seek 
routine cervical cancer screening.  They hypothesized that a history of sexual trauma functioned 
as a barrier for future gynecologic examination.  For this case controlled study of women (ages 
21-64), the researchers divided the women into two groups: 364 who did receive recommended 
screening and 372 who did not.  Women who reported rape prior to age 18 and who had been 
sexually assaulted prior to age 18 were less likely to have been screened for cervical cancer.  
Childhood sexual abuse was also associated with lower odds of screening.  However in Sadler, et 
al.’s (2011) sample of 999 female Midwestern military veterans, 97% reported having had a Pap 
test, 57% reported they had at least one abnormal Pap during their lifetime, and 62% reported a 
history of sexual assault.  A history of sexual assault was a significant risk factor for abnormal 
cervical cytology on these women’s Pap tests, but was not related to lack of screening. 
 It is apparent that adolescents and young women with a history of sexual assault are at 
risk for re-victimization, STIs (including HPV), increased numbers of lifetime partners, 
decreased cancer screenings, and abnormal cervical cytology.  All of these factors combined 
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create a complex risk matrix that may greatly increase a woman’s chance of acquiring HPV and 
subsequent cancer related diseases.  It is apparent that vaccination should be considered a 
priority for this population.  
Provider Influence and Forensic Nursing Role 
To date, rates of vaccination have not met the national goals and researchers are testing 
novel approaches and investigating barriers to and facilitators for vaccination.  Recommendation 
from a provider, in particular a physician, has been demonstrated in the literature to be a 
facilitating factor for HPV vaccination (Conroy, Rosenthal, Zimet, Jin, Bernstein, Glynn, et al., 
2009; Reiter, Brewer, Gottlief, McRee, & Smith, 2009).  However, if a provider does not 
recommend vaccination, then all other research related to patient and parent acceptance may be 
irrelevant.  Therefore, more studies are needed to understand providers’ knowledge, behaviors, 
and beliefs related to HPV vaccination (Allen, Coronado, Williams, Glenn, Escoffery, 
Fernandez, et al., 2010).  Currently, researchers have for the most part not included nurses’ roles 
and abilities to help disseminate information and impact vaccination rates.  In general, all nurses 
who care for patients who have had or will eventually have sexual experiences should be aware 
of and understand this virus family, but little is known about nurses’ level of knowledge and 
what potential beliefs, attitudes, and perceived barriers they may have. 
One particular group of nurses, forensic nurses, understands the care for sexual assault 
patients and the intersections of STIs and violence in a unique way.  In general, this group of 
nurses has been educated to care for a patient population of both adolescents and young adults 
who have had unwanted sexual contact, may have been exposed to HPV, and are in the “catch 
up” vaccination group.  The major professional organization for these nurses is the International 
Association of Forensic Nurses (IAFN).  This association is the national credentialing body for 
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sexual assault nurse examiners (SANEs), sets educational standards for sexual assault care, and 
is one of the major nursing advocacy groups for victims of sexual assault.   
 Forensic nurses who are involved in the care for sexual assault patients may have many 
different roles including: direct patient care, counseling, education, follow up care, research, and 
policy development.  SANEs specifically care for patients with a chief complaint of sexual 
assault, primarily in the emergency departments, already follow guidelines and policies that are 
in line with and have the potential to include HPV education, recommendation and/ or initiation 
of a vaccination series.  Currently these nurses discuss prophylactic treatment with patients for 
STIs including: Chlamydia, gonorrhea, bacterial vaginal infections, trichomoniasis, and HIV.  
They also routinely screen patients for vaccination updates including: Tetanus and Hepatitis B.  
Lastly, they already provide written educational materials and comprehensive day by day and 
week by week written discharge instructions that include both medical, including ongoing STI 
care, and psychological follow up.  
Presently, scientific knowledge about HPV and its consequences has not yet been fully 
integrated into direct nursing practice and, therefore, SANEs do not currently address all of the 
health needs for their sexual assault patients.  It is possible to screen patients by asking if they 
have ever had the HPV vaccine, provide patients with written information, make 
recommendations for vaccination as part of discharge instructions, and/or begin the vaccination 
series at the time of care.  The HPV vaccine is not curative, nor does it provide post exposure 
prophylaxis.  However, due to the increased risk related to current exposure and future exposure 
for this patient population and the current otherwise comprehensive treatment for all other 
sexually related infections, there is a preventative window of opportunity to incorporate HPV 
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education into current care, which may provide future cancer protection for this high-risk 
population and contribute to the vaccination catch up efforts.  
It is not a novel idea to begin to explore the possibility of HPV vaccination and/or 
education in EDs.  In one study designed to assess caregivers’ knowledge and attitudes about 
HPV in ED patients, the investigators specifically chose this setting because other researchers 
had indicated that many underinsured individuals representing racial and ethnic minorities with 
lower socioeconomic status were most likely to use the ED for medical care (Millen, Ginde, 
Anderson, Fang, & Camargo, 2009).  This population has also been identified as most at risk for 
not being screened for cervical cancers and the related morbidities and mortalities (Millen, 
Ginde, Anderson, Fang, & Camargo, 2009).  In this sample of 387 patients, 63% had heard of 
HPV, 61% knew it was an STI, but only 16% of eligible patients had been vaccinated.  
 It is also not a novel idea to incorporate public health vaccination efforts into various 
windows of opportunity for care.  For example, pregnancy is a point of entry into the healthcare 
system.  This period is often viewed as a window of opportunity to update vaccinations, screen 
for physical and sexual abuse, intervene with smoking cessation efforts, and make referrals to 
nutritionists for changes in dietary habit.  For example, currently Pertussis remains an endemic 
disease in the U.S., Tdap (Tetanus, Diphtheria and Pertussis) is the combination vaccine given 
once during a lifetime, and Td boosters are given every 10 years. To protect the woman and the 
newborn and reduce the public health burden, Tdap vaccination guidelines have recently been 
revised to include routine postpartum Tdap screening and vaccination (ACOG, 2009).  
 Care post sexual assault provides a window of opportunity for HPV related cancer 
education and catch up vaccination.  Incorporating information about HPV into forensic nursing 
care highlights the importance of HPV as a public health burden, sets a precedent for vaccination 
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with the understanding that not all sexual activity is consensual, and contributes to efforts to 
inform patients about cancer risks associated with this virus. 
 The purpose of this study was to explore forensic nurses’ knowledge, beliefs, and 
attitudes about HPV, the HPV vaccine, and HPV prevention strategies. The objective was to 
identify factors that may influence nurses’ level of support for incorporation of HPV 
preventative strategies into routine post sexual assault care.  A major goal of the project was to 
increase forensic nurses’ HPV awareness, as well as assess their need for future educational 
interventions to increase these nurses’ decision making about HPV vaccination for their patients 
and create policy change in current practice guidelines to incorporate HPV prevention strategies.   
Research Questions and Aims 
The research questions and specific aims for the study follow:  
Research question: What are forensic nurses’, knowledge, beliefs, and attitudes 
regarding HPV, the HPV vaccine, and their level of support regarding integration of HPV 
preventative strategies into sexual assault practice guidelines? 
Aim 1: Describe forensic nurses’ level of knowledge, attitudes, and beliefs about HPV 
and the HPV vaccine. 
Aim 2: Determine the level of forensic nurses’ support for incorporating HPV 
preventative strategies into the routine care for sexual assault patients. 
Aim 3: Identify factors that are associated with (knowledge, attitude, experience, 
normative beliefs, self efficacy, perceived barriers, and perceived benefits) nurses’ support of 
integrating HPV prevention strategies into the routine care for sexual assault patients.  
The dependent variable for this study was forensic nurses’ level of support regarding 
incorporation of preventative strategies into routine care of sexual assault patients.  In this study 
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the dependent variable was membership into one of the four ordinal support groups: (1) there 
should not be any change to practice; 2) nurses should provide written educational information; 
3) nurses should provide written recommendation for HPV vaccine in discharge instructions; and 
4) nurses should begin the vaccination series at point of care.  The independent variables are 
those identified in the theoretical model for this study.  The independent variables include: 
demographic characteristics, knowledge, attitudes, normative beliefs, experience, perceived 
barriers, and perceived benefits of HPV and the HPV vaccine.  
 The knowledge gained from this study may be used to help influence changes in 
education, practice, and policy/guidelines development for forensic nurses.  Based on the 
findings, it may be necessary to increase forensic nurses’ knowledge about HPV and the HPV 
vaccine.  It may be necessary to develop and implement educational interventions and programs.  
Findings will also help frame recommendations to begin discussions related to changes in 
education and practice guidelines with IAFN leaders and other nursing leaders who are 
stakeholders in sexual assault care.  This research will contribute to the developing prevention 
science for HPV related cancers, and help to highlight a unique group of at risk patients.   
Definition of Terms 
Forensic Nurse: The forensic nurse for purposes of this study is the forensic nurse who 
specifically cares for sexual assault patients (direct care, counseling, follow up) or is a 
stakeholder in sexual assault care (education, research, and policy development).  Care for this 
population will be identified with a question in the survey asking if the nurse cares for sexual 
assault patients in any way and in any setting including: direct patient care, counseling, 
education, follow up care, research and/ or policy development.  Forensic nurses who care for 
sexual assault patients practice in many different settings including but not limited to: hospitals, 
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health centers, urgent care facilities, emergency departments, schools, departments of public 
health and other government agencies, as well as outreach programs.  Forensic nurses are 
registered nurses who may have been educated at different levels (associate, bachelor, masters or 
doctoral degree levels).  More descriptions and scope of practice are discussed subsequently in 
the literature review. There are other types of forensic nurses, who are members of IAFN, (for 
example: legal nurse consultants, medical examiners, prison nurses), but these nurses will be 
excluded from the sample.  
 Sexual Assault Nurse Examiner (SANE): This is a sub-type of forensic nurses who care for 
sexual assault patients as well, but have also completed additional training specifically in the 
forensic medical/nursing legal examinations for sexual assault victims presenting for care within 
120 hours post assault.  The majority of SANEs work in EDs; however some SANEs work in 
rural outpatient settings and universities.  According to the IAFN clinical and educational 
competencies of SANEs include psycho-social-emotional impact of sexual assault, normal 
anatomy and physiology, testing and treatment for STIs, forensic evidence collection techniques, 
and forensic photography.  The IAFN certifies SANEs as either SANE-A (caring for adult 
patients ages 12 and over) or SANE-P (caring for pediatric patients ages 11 and younger).  
Nurses may be educated and certified at the national level by the IAFN or at the local level by 
state government agencies, and/ or universities.  SANEs provide medical and legal care based on 
protocols and guidelines.  
Perceived benefits: Beliefs about the effectiveness of taking action to reduce risk of HPV to 
maintain health and prevent cancers and genital warts.  Examples of HPV perceived benefits for 
forensic nurses include: benefit of HPV vaccine outweighs the risks, the vaccine will prevent 
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most cases of cervical cancer and genital warts, and obtaining the vaccine will help patients stay 
healthier. 
Perceived barriers: Beliefs about the material and psychological costs of taking action to reduce 
the risk of HPV.  These may include: safety, efficacy, media, education, mistrust, financial cost, 
and recommendations. 
Self efficacy: Confidence in one’s ability.  For this study, self efficacy was defined as confidence 
in the nurses’ ability to support a change in practice or incorporate new strategies into the routine 
care for sexual assault patients.  For example: confidence in ability to adapt to practice change, 
confidence in discussing and bringing forward new ideas for practice change. 
HPV Knowledge: Level of familiarity and understanding of a subject (HPV), including: 
knowledge about HPV pathology, transmission, risk factors, infection sequelae/consequences 
and prevention strategies. 
Attitudes:  The positive or negative evaluation of vaccines in general as well as the HPV vaccine; 
the importance of vaccines; vaccine acceptance and recommendation.  
Normative beliefs:  Individuals’ beliefs about a behavior that are influenced by judgment of 
significant others and professional organizations (family, friends, colleagues, nursing and 
medical organizations); the individuals' beliefs about the extent to which other people who are 
important to them think they should or should not provide recommendation for the HPV vaccine.  
Experience with HPV: Having personal or professional familiarity with HPV, including: 
personal experiences, family or friends with HPV related diseases, professional experiences 
caring for patients with HPV.   
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Chapter 2: Theoretical Framework and Literature Review 
Theoretical Framework 
A conceptual or theoretical framework is a necessary part of quantitative research design.  
It is important for the theory basis of nursing science, significance and relevance to findings, and 
to support the transfer of findings into clinical practice.  Using a well known theoretical 
framework helps to build science and maximize utility of findings in practice (Becker, 2005).  
According to Polit and Beck (2008), this theoretical rational is essential because “Design 
decisions and data collection strategies cannot be developed in a vacuum--there must be an 
underlying conceptualization of people’s behaviors and characteristics, and how these affect and 
are affected by interpersonal and environmental forces” (p. 139).  A conceptual model that 
integrates concepts from both the Health Belief Model and the Theory of Planned Behavior was 
used to guide this dissertation study.   
Health Belief Model.  The Health Belief Model (HBM) was developed in the early 
1950s by social psychologists at the U.S. Public Health Service (Janz & Becker, 1984).  It 
addresses perceptions of “threat posed by a health problem (susceptibility, severity), the benefits 
of avoiding the threat, and factors influencing the decisions to act (barriers, cues to action, and 
self-efficacy)” (National Cancer Institute, 2005, p.12).  Janz and Becker described this model as 
a “conceptual formulation for understanding why individuals did or did not engage in a wide 
variety of health related actions” (p.1).  This model is a widely recognized by researchers as a 
framework to explain health behaviors, as well as helping to explain and predict acceptance of 
health recommendations.  The HBM includes six main constructs: perceived susceptibility, 
perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy.  
These six constructs have been demonstrated to be useful when applying the model to planning 
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interventions (National Cancer Institute, 2005).  Perceived susceptibility is personal vulnerability 
or one’s subjective perception of the risk of contracting a condition.  Perceived severity includes 
one’s beliefs about how serious a condition is and what its consequences are (including both 
medical and social consequences).  Perceived benefits are one’s beliefs about effectiveness or 
feasibility of taking action or acceptance of the recommended health action that is necessary to 
reduce the risk.  Perceived barriers are beliefs about the costs for taking action (when the 
individual weighs the action’s effectiveness against perceived cost including danger, expense, 
and inconvenience).  The last two concepts are cues to action (actions that trigger the decision 
making process including internal and external forces) and self-efficacy (conviction or 
confidence in one’s ability to be successful in taking actions) (Janz & Becker, 1984; National 
Cancer Institute, 2005). 
This model has commonly been used by HPV researchers and has been identified as a 
useful conceptual framework to study vaccination behavior (Brewer & Fazekas, 2007).  In Allen, 
Coronado, and colleagues’ (2010) systematic review of HPV measures, among those studies that 
were theory-based, the HBM was identified as one of the most commonly used.  This model’s 
ability to predict and explain health behaviors for patients, as well as to elucidate health 
providers’ perceived benefits of and barriers to HPV and the HPV vaccine was useful to guide 
this dissertation research. 
Barriers and benefits of vaccination have been explored previously in the provider 
studies.  For example, some of the barriers examined included: coverage or cost, insufficient 
supply, ability to comfortably discuss or feel the need to discuss sexual activity, and numerous 
parental factors (Daley, Crane, Markowitz, Black, Beaty, Barrow, et al., 2011; Kahn, Cooper, 
Vadaparampil, Pence, Weinberg, LoCoco, et al.,2009; Riedesel, Rosenthal, Zimet, Bernstein, 
16 
 
Huang, Lang, et al.,2005).  Likewise, benefits previously assessed include: prevention of cancer, 
prevention of warts, cost effectiveness and personal beliefs about benefits (Feemster, Winters, 
Fiks, Kinsman, & Kahn, 2008; McCave, 2010).  
 Theory of Planned Behavior.  According to Ajzen (1991), the Theory of Planned 
Behavior (TPB) is a useful theory linking attitudes and behaviors, and was designed to help 
clinicians and researchers predict and explain human behavior.  It was proposed by Icek Ajzen in 
1985, and is an extension of Fishbein and Ajzen’s, 1975 Theory of Reasoned Action (TRA).  
The central factor is the individual’s intent to perform a particular behavior.  Intentions are 
assumed to capture the factors that influence the behavior, such as motivation, and the ability to 
perform this behavior must be something under a person’s control.  The authors of this theory 
proposes three conceptually independent determinants of intention: attitude toward behavior, 
subjective norm, and perceived behavioral control.  Attitude refers to the degree to which one 
has a favorable or adverse evaluation or appraisal of the behavior in question.  The subjective 
norm refers to the perceived social pressure to perform or not perform the behavior; it is a social 
factor and normative beliefs make up the underlying determinants of subjective norms.  
Normative beliefs are concerned with the likelihood that important individuals or groups approve 
or disapprove of performing a particular behavior.  Lastly, perceived behavioral control refers to 
perceived ability or difficulty of carrying out the behavior and it reflects on past experience 
(Ajzen, 1991).  
   This conceptual model has been identified as useful in predicting physicians’ intentions 
and recommendations for HPV vaccination.  Kahn and colleagues have used this model 
numerous times to examine attitudes, normative beliefs, and intentions of physicians (Texas 
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physicians, family physicians, pediatricians) (Kahn, et al. 2009; Kahn, Zimet, et al., 2005; 
Riedesel, et al., 2005).  
Theoretical framework for current study.  Many leading HPV researchers have used 
concepts from the TPB in conjunction with the HBM to guide their work (Kahn, 2009; Kahn, 
Rosenthal, Hamann, & Bernstein, 2003; Riedesel, et al., 2005). 
The concepts derived from the HBM used to help inform this study are the nurses’ 
perceived benefits, perceived barriers, and self efficacy.  It is important to understand the nurses’ 
perceived benefits or barriers related to HPV and the HPV vaccine, as well as self efficacy 
related to practice changes prior to considering changes in practice guidelines.  The other 
concepts in the HBM including perceived susceptibility and perceived severity are useful to 
describe individuals’ own behavior (i.e., how they perceive their own susceptibility for HPV), 
and these were examined in this study.  Lastly, cues to perform an action were not measured. 
 The concepts derived from the TPB included attitudes and normative beliefs.  It is 
necessary to understand an individual’s attitudes toward the behavior and subjective norms as 
part of the first step of uncovering the nurse’s level of support for changing practice behavior.  
Ajzen (1991) described how the TPB is open to the inclusion of additional predictors that help to 
capture significant proportions of variance in the outcome variable.  Ajzen discussed an example 
of this being the role of past behavior, and “a measure of past behavior can be used to test the 
sufficiency of any model designed to predict future behavior” (p.202).  These past behaviors can 
be measured as experience.  The nurse’s experience with HPV and the HPV vaccine was 
measured as an independent variable. 
 The TPB’s concept of perceived behavioral control was not measured.  Perceived 
behavioral control is closely tied to self efficacy, which is also a concept in the HBM.  
18 
 
Behavioral control is linked to intentions.  In this study, it was not feasible to measure intentions 
as the outcome variable.  In order to measure the intention that the nurse will perform the 
behavior of incorporating HPV prevention into routine care, the guidelines for practice would 
already have had to change.     
  Lastly, knowledge was measured.  Knowledge is a salient variable measured in almost 
every study whose investigators are examining HPV.  To understand what providers, patients, 
parents, and communities know about HPV is a basic core concept.  Advances in HPV science 
have continued at a rapid pace, and assessing for knowledge is a baseline litmus test prior to 
assessing attitudes, beliefs, and intentions.  It is also necessary to understand providers’ 
knowledge in order to plan for effective intervention.  In one systematic review of predictors of 
HPV vaccine acceptability in 20 out of the 28 studies reviewed, Brewer and Fazekas (2007) 
assessed for knowledge.  
 Using these consistent constructs was helpful in providing conceptual clarity and enabled 
greater comparability of findings across this and other studies.  Figure 1 illustrates the theoretical 
framework that guided this study. 
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Figure 1: Conceptual Framework 
 
Review of the Literature  
This chapter will include a review of the latest scientific information about HPV and 
HPV vaccination.  Provider knowledge and influence on HPV education and vaccination will be 
reviewed in relation to the conceptual framework, and finally an extensive summary of the 
development and description of forensic nursing will be presented.   
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HPV and HPV Vaccinations.  A large number of both men and women are infected, 
capable of spreading the virus, and of suffering from potential consequences of HPV.  The 
Centers for Disease Control and Prevention (CDC) (2009) have published statistics establishing 
strains of HPV as the cause of: cervical cancer that affects 12, 000 women; vulvar cancer 3,700; 
vaginal cancer, 1000; penile cancer 1000 men; anal cancer 2,700 women and 1,700 men; and 
cancers of the head and neck, 2,300 women and 9,000 men.  The burden of this virus family is 
also poignant globally.  Worldwide, HPV can account for 5% of all cancers (Parkins, 2006).   
Finally, the reported rates may under-represent the actual figures because of a lack of appropriate 
screening for the HPV virus, particularly in the male population.  
 Cervical cancer is the most common cancer caused by HPV, with approximately 70% 
caused by high-risk oncogenic types 16 and18 (National Cancer Institute, 2011a).  This is largely 
related to health providers’ ability to accurately screen for and appropriately treat precancerous 
cellular changes to the cervix, done with Papanicolaou (Pap) testing and now HPV DNA typing.  
In spite of advances in detection and treatment, in 2011, the National Cancer Institute estimated 
that more than 12,000 women would be diagnosed with cervical cancer and more than 4,000 
women would die from this cancer in the U.S.  Globally, this cancer disproportionately affects 
women in developing countries (85% occurring in Central and South America, Caribbean, Sub-
Saharan Africa, and Southern Asia) where access to screening is low.  In 2008, cervical cancer 
globally was the third most common diagnosis of cancer in women with 529,000 cases and the 
fourth leading cancer causing death taking 275,000 lives (American Cancer Society, 2011). 
The same HPV high-risk oncogenic types (16, 18) have been associated with head and 
neck squamous cell carcinoma (HNSCC).  Incidence of HNSCC, specifically oropharyngeal 
(tonsil and tongue base), is on the rise in the US and disproportionately affects younger men 3:1 
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(ages 20-50) and accounts for 60% of oropharyngeal squamous cell cancers.  Researchers have 
suggested that HPV-related HNSCC is becoming more widespread, occurs in men with limited 
tobacco but greater marijuana exposure, those who engage in oral sex, and/or who have multiple 
sexual partners (Gillespie, Rubinchik, Hoel & Sutkowski, 2009; Marur, D’Souza, Westra & 
Forastiere, 2010; Weiss & Dym, 2011).  The primary mode of transmission is oral genital 
contact.  Lesions appear strawberry-like and exopytic (outward growing tumor).  
Likewise, anal cancer caused primarily by type 16 is a problem for both men and women.  
Globally, this invasive cancer’s annual rates for men are 0.1 to 2.8 cases per 100,000 as 
compared to 0.0 to 2.2 for women, and for men who have sex with men (MSM) rates are even 
higher.  A positive HIV status exacerbates this problem even further, pushing the rates to roughly 
70 cases per 100,000 in MSM.  HPV screening is done with anal Pap tests and prevalence of 
types 16, 18 occurs in approximately 72% of cases (Hoots, Palefsky, Pimenta, & Smith, 2008). 
 Currently, there are two FDA approved HPV vaccines, Cervarix ® (GlaxoSmithKline) 
and Gardasil ® (Merck & Co.), and both include coverage for HPV types 16 and 18, but Gardasil 
® adds additional protection against genital warts by covering for HPV types 6 and 11.  Both 
vaccines have been determined to be safe and effective and have been tested in tens of thousands 
of people in the U.S. as well as many other countries.  To date, since FDA approval in 2007, no 
serious side effects have been demonstrated and the most common problems have been brief 
soreness and/or other local symptoms at the site of injection (National Cancer Institute, 2011b).  
Authors of a post licensure safety surveillance of adverse events following immunization 
reported to a national voluntary passive surveillance system (2006-2008) a rate of 53.9 reports 
per 100,000 doses of Gardasil®.  The adverse events rates per dose included: 8.2 for syncope; 
7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for 
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hypersensitivity reactions; 2.6 for urticaria (an itching/inflammation skin reaction); 0.2 for 
venous thromboembolic event, autoimmune disorders, and Guillain-Barre syndrome; 0.1 
anaphylaxis and death; 0.04 transverse myelitis and pancreatitis; and 0.009 for motor neuron 
disease.  These adverse event rates were not greater than other vaccines’ background rates 
(Slade, Leidel, Vellozzi, Woo, Hua, Sutherland, et al., 2009). 
 Total cost for vaccination may vary depending on the type of medical insurance the 
patient has or if the patient qualifies for free vaccines through the Vaccines for Children Program 
or the Merck Vaccine Patient Assistance program that provides free Gardasil ® for patients in 
need.  Also many settings have administrative or injection fees; for example, one clinic may 
charge a $30 injection fee at time of visit despite patient qualification for free medication.  The 
retail price of the HPV vaccine is $130 per injection, totaling $390 for the vaccination series 
(CDC, 2011b) 
 Vaccination has been established by the CDC as the primary preventative strategy to 
reduce the burdens of HPV related diseases.  However, the ACIP is concerned about the rates of 
vaccination and targeted goals are not on track to be met.  Researchers evaluating parental 
decision to vaccine their dependents have reported mixed results.  Allen, Othus, et al. (2010) 
reported that 19% of parents of girls ages 9-17 years had vaccinated their daughters, 34% 
intended to vaccinate, 24% were undecided, and 24% were against vaccination (N=476).  
Constantine and Jerman (2007) reported from their sample of 522 parents that 75% were likely 
to vaccinate their daughters before age 13; 6% before age 16; and 18% were unlikely to 
vaccinate at all.  
Outside of vaccination, other preventive strategies to reduce HPV transmission include 
not having genital to genital or oral to genital contact with another person, maintaining mutually 
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monogamous relationships between uninfected partners, and correct and consistent condom use 
from beginning to end of sexual contact.  Condom use has been shown to be protective; however, 
transmission may still occur in areas that are not covered by the condom.  It is possible for 
persons who have only ever had one sexual partner to acquire HPV; it all depends on the status 
of their single partner (CDC, 2009; National Cancer Institute, 2011a).  
 The latest biological research on HPV vaccine is very promising.  Authors of the recent 
studies have indicated that current vaccines may offer even broader protection than originally 
thought.  Herrero, Wacholder, Rodriquez, Solomon, Gonzalez, Kreimer, and colleagues (2011) 
reported on a large community-based randomized trial in a high HPV incidence area of Costa 
Rica.  In the group that was given HPV vaccine for 16 and 18 according to protocol (n= 3,727) 
where women were fully vaccinated prior to HPV exposure, protection against 12-month 
persistent infections was 90% for HPV 16/18 (supporting other evidence), but in addition these 
researchers observed nearly 50% cross protection for other oncogenic HPV types including HPV 
31, 33, and 45, which are associated with approximately 10% of cancers.  Kreimer, Rodriguez, 
Hidesheim, Herrero, Porras, Schiffman, et al. (2011) reported another analysis of the same 
original Herrero et al. data.  These researchers reported the first clinical evidence that two and 
even one dose of HPV 16, 18 vaccine was highly efficacious in the prevention of HPV infections 
and that protection persisted for at least one year.  The two dose vaccine efficacy was 84.1% and 
100% for one dose.  More researchers need to explore efficacy, but this clinical trial provides an 
exciting beginning.   
According to the National Cancer Institute (2011b), the HPV vaccines have proved to be 
highly effective, preventing nearly 100% of precancerous cervical cell changes that would have 
been caused by types 16 and 18, as well as cancers of the anus.  Longitudinal tracking of 
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immunization effectiveness is ongoing, but currently the protective effects have been confirmed 
up to eight years. 
HPV Vaccine and Provider Factors. Health care providers are gatekeepers for 
vaccination.  In recent research, provider recommendation has been highlighted as a facilitating 
factor for patients and parents who intend to or have received the HPV vaccine (Conroy et al., 
2009; Reiter, Brewer, Gottlief, McRee, & Smith, 2009).  In other non HPV vaccine related 
literature, provider recommendation has been discussed as one of the most important factors for 
vaccine acceptance (Kahn, et al., 2009).  A small number of studies of U.S. providers have been 
published after vaccine approval in 2006.  The studies that have been published provide a 
beginning understanding of provider factors that may influence HPV vaccine uptake.  The 
factors reviewed included: knowledge, attitudes, experience, self efficacy, normative beliefs, 
perceived benefits, and perceived barriers.  Despite this beginning understanding, a major gap in 
the research is apparent.  Greater understanding of physicians’, but especially nurses’ knowledge 
and behaviors related to HPV vaccination is still needed.  
 Knowledge.  Increasing providers’ level of HPV knowledge has been identified as one 
important way to potentially increase rates of vaccination.  Kahn, Zimet, et al. (2005) reported 
higher level of knowledge as a variable associated with intention to vaccinate.  Reiter, Stubbs, 
Panazzo, Whitesely, and Brewer (2011) conducted an HPV and HPV vaccination educational 
intervention with a pre and post-test design directed at stakeholders in a school community.  The 
participants included 118 health care staff comprised of nurses, health educators, and various 
professional medical societies.  Their results indicated that the educational intervention increased 
participants’ self rated knowledge of HPV and highlighted health staff knowledge weakness 
about the epidemiological aspects of HPV and HPV related disease, which increased after the 
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educational intervention.  In another study, the researchers surveyed both family (n=331) and 
pediatric (n=349) physicians on knowledge, attitudes, and practices.  Both sets of physicians 
were knowledgeable about HPV; however only 43% of pediatricians and 58% of family 
physicians knew that genital warts were caused by different strains of the HPV other than those 
that cause cancers (Daley et al., 2011).  Finally, Kahn et al. (2009) reported that 44% of 
physician respondents (N=1,122) indicated that more education about HPV vaccines would be 
beneficial. 
Saraiya, Rosser, and Cooper (2012) examined physicians’ baseline knowledge on what 
cancers they believed the HPV vaccine prevented.  This survey of 1500 physicians 
(pediatricians, family practitioners, internists, and obstetrician-gynecologists [OB/GYNs]) 
identified characteristics associated with their belief that the vaccine prevented cervical, vaginal, 
vulvar, anal, and oral-pharyngeal cancers.  Of these physicians, 98.9% reported treating patients 
between the ages of 9 to 26; 97.8% knew the vaccine prevented cervical cancer; and the 
OB/GYNs were significantly more likely to select correct responses for all cancers as compared 
to physicians in any other specialty.  The results of physicians knowing that the HPV vaccine 
prevents: vulvar and vaginal cancer was highest for OB/GYNs at 52.4% and lowest for internists 
at 18.2%; anal cancer was highest for OB/GYNs (52.4%) and lowest for internists (19.2%); 
oropharyngeal cancer was highest for OB/GYNs (27.6%) and lowest for internists (9.2%).  
Unfortunately, pediatricians, who are the most likely to see patients in the recommended 
vaccination time could only identify other cancers besides cervical about a quarter of the time. 
Clearly educational interventions to address all providers’ knowledge deficits are still needed. 
 Experience.  Provider type and level of experience can be a marker for vaccine 
behaviors.  For example, Kahn et al. (2009) reported that variables associated with positive 
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vaccination of 11-12 year old girls included an academic practice and a higher number of office 
procedures to maximize vaccination.  Provider experience with patients who are sexually active 
may also be a factor associated with intention to recommend vaccination.  Kahn, Zimet, et al. 
(2005) reported that higher estimates of sexually active adolescent patients in a provider’s 
practice was also associated with intention to vaccinate.  This was also highlighted by Saraiya, 
Rosser, and Cooper (2012) who reported that ob-gyn providers (who arguably have the most 
experience caring for sexually active patients) were more likely than any other type of physician 
surveyed to have complete knowledge about HPV and HPV vaccination. 
Attitudes.  A provider’s personal or professional attitudes may be a factor associated with 
vaccination.  McCave (2010) reported one support to vaccination as the providers’ personal 
belief in the positive impact of the HPV vaccine.  Goff, Mazor, Gagne, Corey, and Blake (2011) 
described and explored the relationship between the content and character of patient/provider 
communication about HPV vaccination and vaccine uptake.  Providers shared positive and 
negative comments about the vaccine, and Goff et al. discussed how negative comments can 
impact patients’ and parents’ decisions about vaccination.  When providers expressed negative 
attitudes, these were comprised of concerns related to: cost and insurance coverage, newness of 
the vaccine, vaccine effectiveness, and marketing (Goff et al.) 
Normative belief.  Normative beliefs, approval or disapproval of vaccination by 
individuals (colleagues) or organizations important to providers, are related to vaccine behaviors.  
Kahn et al. (2009) reported that provider belief in mandated vaccination programs was positively 
associated with male vaccination, and McCave (2010) described providers’ belief in the 
importance of adhering to professional and federal guidelines for vaccination as a supportive 
factor associated with vaccination. 
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The CDC and ACIP have set specific guidelines for vaccine administration in the U.S.  
Also professional organizations including the American Academy of Family Physicians (AAFP), 
American Academy of Pediatrics (AAP), and the American Congress of Obstetricians and 
Gynecologists (ACOG) have all made recommendations related to HPV vaccination.  In a 
sample of pediatricians (N=513), Kahn, Zimet, et al. (2005) reported that the likelihood of 
following recommendations of important individuals and organizations increased intention to 
recommend vaccination.  Likewise, Riedesel, et al. (2005) from a survey of 155 physicians 
reported a very high influence on behavior related to recommendations of professional 
organizations.  The physicians reported being extremely or somewhat likely to follow vaccine 
recommendations from the AAFP at 97.9%, AAP at 95%, CDC at 91%,  ACIP at 84%, and 
ACOG at 72.7%. 
In one study, a planned parenthood organization in the Midwest initiated internal 
protocols (set by the organization itself and colleagues), as well as increased vaccine availability 
at the clinics.  Despite these efforts, only 38% of unvaccinated patients had clinician-documented 
recommendation for HPV vaccination at their annual examination time, but effectively there was 
an overall increase in rate of vaccination (11% to 16%).  The researchers reported that this rate 
differed almost entirely by individual clinician and provider recommendation and was 
statistically significant (p=0.006) between those who received the vaccine at the exam and those 
who did not (Small & Patel, 2012).  
 Despite the normative beliefs related to following recommended guidelines, providers in 
the many of the studies reviewed were consistent in their practices of vaccinating older 
adolescents rather than the recommended age of 11-12.  This delay only adds to the numbers of 
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adolescents and young adults without vaccination prior to potentially becoming sexually active 
and increases the burden of the catch up vaccination efforts.  
 Daley et al. (2011) reported that the vast majority of physicians were offering the 
vaccine to their patients, but they were primarily offering it to older adolescents (13-15 years) 
rather than to younger adolescents (11-12 years).  Likewise, among McCave’s (2010) sample of 
227 providers (57.3% physicians, 33.5% nurse practitioners, and 8.4% physician assistants), 
57.1% vaccinate girls at ages 13-17 as compared to 33.7% at ages 9-12.  Finally, Kahn et al. 
(2009) reported that of the surveyed Texas primary care physicians (N=1122), most (81%) have 
recommended the HPV vaccine to a patient of any age; however, only 48.5% always 
recommended it to girls ages 11-12, whereas 64.4% recommend to girls ages 13-17.  Likewise, 
42.1% are extremely likely to intend to recommend vaccination for boys ages 11-12 and 60.9% 
for boys ages 13-17. 
Self efficacy. Perhaps self efficacy may be related to the trend among providers to not 
recommend vaccination until later adolescence.  This may be related to a physician’s comfort or 
experience counseling patients about sexual health, or beliefs that older adolescents are more 
susceptible to HPV infection due to greater potential for sexual activity.  McCave (2010) 
identified feeling comfortable talking to parents about the sexual nature of the vaccine as a 
facilitator of vaccination.  A provider’s knowledge level may be linked to comfort; if providers 
know more about HPV and are confident in their knowledge, then they may have higher 
confidence in their ability to vaccinate.  However, it would be of greater benefit to vaccinate 
youth prior to this sexual debut. 
Perceived benefit.   If providers believe the vaccine benefits their patients and or society 
at large, the assumption is that they will attempt to promote vaccination measures.  Kahn et al. 
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(2009) reported on Texas physicians’ belief that HPV vaccination should become mandatory.  
Almost half of the physicians (N=1,122) agreed or strongly agreed that the vaccine be mandated 
for girls ages 11-12 years.  Additionally, McCave (2010) examined personal and professional 
supports in 227 providers.  Those supports for vaccination included a positive personal 
experience with the vaccine and a belief that the vaccine saves lives.  The most commonly 
reported support was the personal belief in the positive impact of the vaccination. This belief was 
reported by 84.3% of physicians who provide vaccine for 9-12 year olds and 85.2% of 
physicians who provide vaccine for 13-17 year olds.   
 Perceived barriers. Overall high (vs. low) barriers to HPV vaccination measured in 
physicians have a negative impact on vaccination rates.  Vadaparampil, Kahn, Salmon, Lee, 
Quinn, et al. (2011) reported that those perceiving a low level of barriers exhibit greater odds of 
recommending the HPV vaccine (OR= 1.8).  One barrier to vaccination physicians report is 
related to believing they have to discuss sexual activity with adolescents prior to vaccination 
(Daley et al., 2011).  In this study, physicians did not think that vaccination would increase 
adolescent sexual behavior, but 42% of pediatricians and 54% of family physicians considered it 
necessary to discuss sexuality prior to recommending the vaccine.  However, in one study in an 
emergency department, patients’ awareness that HPV is transmitted sexually actually enhanced 
support of vaccination (Millen, Ginde, Anderson, Fang, & Camargo, 2009).  
 Another barrier is perceived cost for patients.  Across the board, providers reported 
patient barriers to vaccination related to cost and insurance coverage (Daley et al., 2011; Kahn et 
al., 2009; McCave, 2010).  However, Daley et al. reported that providers who participated in the 
Federal Vaccine for Children Program were more likely to strongly recommend the vaccine to 
the 11-12 year old group and Kahn et al. (2009) reported that a higher percentage of Medicaid 
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use in the practice was associated with vaccination also at ages 11-12.  Finally, Vadaparampil et 
al. (2011) found that physicians who were not Vaccine for Children providers, as compared to 
those who were, had lower odds of recommending vaccination (OR= 0.5). 
Kahn et al. (2009) reported that providers perceived parental barriers as: safety (69.2%), 
lack of education and understanding (65.2%), refusal related to negative media (60.4%), mistrust 
of vaccines in general (60.4%), and concern that vaccination implies condoning premarital sex 
(54%).  McCave (2010) reported providers encountering patients, but more often parents, who 
have negative perceptions of the vaccine as a frequent barrier. 
Finally, level of provider knowledge as described previously is a barrier.  Saraiya, 
Rosser, and Cooper’s (2012) research highlighted this barrier for vaccination.  If provider 
recommendation has been established as a vaccine facilitator, having providers not understand 
the full utility (all cancers preventable) of the HPV vaccination is an enormous barrier to 
vaccination uptake.  Thankfully, findings from their study are serving to guide a new public 
awareness campaign by the CDC to help providers get the facts about HPV related cancers.  
 Other influences on HPV vaccination: The patient and parent.  Currently, when 
patients present to an emergency department with a chief complaint of sexual assault, they are 
considered emancipated minors (ages 12 and older seeking care for threat of pregnancy and STI) 
and can make their own informed health care decisions.  These youths can make decisions about 
the medications they would like to receive without parental consent.  Therefore, it is important 
for nurses to understand patients’ perceptions and what may influence their decisions about the 
HPV vaccine. 
 Patient perceived social norms, normative beliefs, and practical benefits may be 
facilitators in vaccination.  In a small sample (N=34) of predominantly Black females (mean age 
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21), family, friends, and health providers were described frequently as supporting girls’ intention 
to receive the vaccine (Teitleman, Stringer, Nguyen, Hanlon, Averbuch, & Stimpfel, 2011).  
Likewise, in a much larger sample (N=1401) of women ages 18-22, social norm, the perception 
that peers had been or were planning to be vaccinated, was the strongest predictor of intention to 
vaccinate (Allen, Mohllajee, Shelton, Othus, Fontenot, & Hanna, 2009).  Similarly, in Kahn, et 
al.’s  (2008) sample of 409 women (mean age 18), those with higher normative beliefs that 
people who were important to them or influential in their lives would approve of the vaccination, 
were positively associated with a greater intention to vaccinate.  Ability to follow through with 
vaccination was enhanced if the vaccine was offered at routine appointments, if appointments 
were not hard to get and were available at convenient times, and if the youths had insurance 
coverage (Teitleman et al., 2011).  
 Patient perceived barriers to vaccination have been explicated in the literature.  
Knowledge levels in particular have been highlighted as a large problem.  Teitleman et al. (2011) 
described participants’ lack of clarity and understanding about vaccine purpose and confusion 
related to HPV and the herpes virus.  Allen et al. (2009) also found a greater lack of knowledge 
about HPV in those who had decided against vaccination, and Kahn et al. (2008) found higher 
knowledge to be an independent predictor of intention (increased odds of 5.2).  Bertram and 
Niederhauser in their study (2008) focused on HPV knowledge and reported overall very low 
levels of understanding by male and female college students (N=492, 75.8% female and 24.1% 
male) in Hawaii.  Males (26% correct) had even lower knowledge scores than the females (37% 
correct) and about half of the sample did not know that HPV is a virus, has different strains, and 
that some strains cause warts and others cause cancer.  Females in this study with a history of 
abnormal Pap tests and higher risk behaviors had the highest levels of knowledge.  Parental 
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permission for vaccination was identified as a barrier (Teitleman et al., 2011).  Lack of insurance 
and practical issues including safety were associated with low intention as reported by Kahn et 
al. (2008), who identified those with high risk behaviors as having low vaccine intentions. 
Despite patient emancipated status for sexual assault care, parents may be accompanying 
patients to the ED for sexual assault care and in this situation, forensic nurses need to understand 
the parental influences related to HPV decision making.  However, hopefully more and more 
providers will be providing vaccination at the recommended schedules (ages 11-12), which is 
prior to adolescent/adult sexual assault care.  Researchers are beginning to explore these 
influences and some general themes have emerged.  Concerns and barriers parents have reported 
include age for vaccination, vaccine concerns in general, HPV vaccine concerns, cost, and 
attitudes towards sexual behavior.  Facilitators of vaccination include knowledge, provider 
recommendation, acknowledgement of need and perceived risk for children, and positive 
attitudes towards vaccination (Allen, Othus, et al., 2010; Constantine & Jerman, 2007; Reiter, et 
al., 2009).  
 Parental perceived barriers to vaccination were similar across studies.  Reiter et al. (2009) 
reported that parents were less likely to vaccinate their daughters if they perceived more barriers, 
perceived more potential harm, did not have health insurance coverage, and had a higher level of 
anticipated regret if their daughters became more sexually active after receiving the vaccine. 
Allen, Othus, et al. (2010) and Constantine and Jerman (2007) also reported negative parental 
attitudes toward vaccines in general as a barrier.  Cost was also noted by Allen et al. and moral 
beliefs about sexual behaviors in general, concerns about effects vaccination would have on 
sexual behavior, HPV specific vaccination concerns, and denial of risk and need to vaccinate 
were reported by Constantine and Jerman (2007). 
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 Facilitators for parental acceptance of vaccination were the opposing viewpoints.  Reiter 
et al. (2009) reported that provider recommendation and perceived lower likelihood of daughters 
getting cancer if they received the vaccine were both facilitators of vaccination.  Allen, Othus, et 
al. (2010) reported that a positive decision to vaccinate was influenced by parental knowledge 
level, positive attitudes toward vaccination in general, not viewing any risks for side effects as 
deterrents, higher level of trust in drug companies, and perceptions that family and friends would 
also endorse vaccination.  Parents in this study with intention to vaccinate were also less worried 
about adverse behavioral consequences related to sexual activity resulting from HPV 
vaccination.  
Understanding of influences on HPV vaccination is in the early stages of development.  
With projected rates of vaccination not meeting CDC and Health People 2020 targeted goals, the 
public health burden of HPV-related diseases including cancers will continue to persist without 
significant improvement.  Strong and novel approaches are necessary to continue to develop this 
science and little is known about nursing’s role in contributing to vaccine uptake. 
Description of the Role and Evolution of Forensic Nursing: Sexual Assault in Particular 
Historically, the care of sexual assault victims and the care of women fell to the medical 
doctors practicing in primary care settings, obstetrical or gynecologic offices, and emergency 
departments.  This care under the medical model focused on diagnosing illness and treating 
disease and injury.  With the emergence of women’s health as a focus in health care and research 
in the 1970s, nurses have taken on a greater role in leading that movement and expanding care 
for this population.  Taylor and Woods (1996) stated:  “nurses, as patient advocates, have had a 
long history of improving access to health care services, especially health services to women, 
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children, and families” (p.793).  The following account describes the evolution of the role of 
forensic nurses and the historical elements that led to Sexual Assault Nurse Examiners. 
Beginning in the 1970s and extending beyond 2000, there was an increase in medical and 
nursing research in the area of sexual assault and victimization.  The idea that rape affected 
persons emotionally, cognitively, spiritually, sexually, and re-traumatization or re-victimization 
of patients was being uncovered (Campbell, 2004; Frampton, 1998; Girardian, 2005).  Burgess 
and Holmstrom (1974) began studying victims’ experiences related to rape and the rape trauma 
syndrome, describing the acute and long term processes of physical and psychological symptoms 
post rape.  According to Frampton (1998) “sexual assault has far-reaching effects including the 
potential for sexually transmitted diseases, pregnancy, major depression, alcohol and drug abuse, 
chronic pelvic pain, chronic headaches, eating disorders, irritable bowel syndrome, and even 
suicide” (p. 178).  
Then, in the 1980s, the growing threats of communicable diseases and their treatments 
were being acknowledged for this population and treatment for known STIs became a priority. 
The subsequent development of antiretroviral agents and their use in prophylactics for medical 
personnel post exposure to potentially HIV infected fluids led to standardized HIV prophylactic 
treatment for sexual assault patients as well.  
At the same time, other researchers demonstrated increasing patient numbers presenting 
for care and overcrowding of EDs.  Magid et al. (2003) stated: “ . . .there was a 60% increase in 
the incidence of sexual assault victims presenting for emergency care in 1991 compared to 1974, 
primarily due to an incidence of women presenting to the ED after rapes by known assailants” 
(p.3).  The issues of general patient overcrowding in the ED led to longer wait times, increasing 
costs, and poorer outcomes in terms of evidence collection, besides the physical, emotional, and 
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societal consequences.  “A busy ED with varying levels of physician response and exposure to 
the process of rape management contributed to a lack of standardized, objective, timely, and 
compassionate medical management of sexual assault victims” (Derhammer, Lucente, Reed, & 
Young, 2000, p. 49).  These problems contributed to the growing focus of researchers on patient 
re-victimization or re-traumatization, as well as higher incidences of non-reporting and patients 
not seeking appropriate care.  
Then, the development of DNA testing by geneticist Alec Jeffreys in the early 1980s and 
the eventual use of this technology for forensic science led to the development and 
standardization of the ‘rape kit’.  This placed an increased focus on the medico-legal aspects of 
care for the sexual assault patient in the ED.  Now care had to include collection and 
documentation of forensic evidence.  Also, developments in Federal DNA tracking programs 
such as the Combined DNA Index System (CODIS) were putting external pressures on the health 
system to not only address the physical needs of patients, but the evidentiary needs as well.  
Demands for physicians’ time, increased knowledge, training, and expertise in forensic science 
emerged because of the importance of a comprehensive forensic examination. 
With all of the possible physical, psychosocial, and community implications related to 
sexual assault, members of the nursing profession believed that they were best positioned to 
address the needs of this population.  Nurses have always focused on a holistic approach to 
patient care, with the concept of caring at the forefront.  Nurses’ care encompasses addressing 
the physical, psychological, and social aspects of the individual, family, and community, 
focusing on disease prevention and education.  Therefore, a new paradigm for the care of sexual 
assault patients emerged and the role of the Sexual Assault Nurse Examiner (SANE) evolved.  
The first SANE program was developed in 1976 and the numbers of programs have been 
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growing ever since.  According to the International Association of Forensic Nurses (2011), there 
were at least 276 SANE programs in the United States as of 2011.  SANEs are addressing issues 
of re-traumatization, by giving the patients a greater sense of control and empowerment during 
the exam.  Also, where available, they provide on call service to any ED twenty-four hours a 
day, will respond to a case within 45 minutes, and provide all comprehensive physical, 
psychosocial, and forensic care.  
According to Campbell (2004) “it appears that the SANE programs are having beneficial 
effects on rape survivors’ psychological well-being and that they are improving the prosecution 
rates of sexual assault crimes” (p.6).  There is accumulating evidence of the importance of the 
educational support SANEs give their patients.  SANEs “help link victims with community 
services and increase patients’ self-efficacy for the use of such services, so that these programs 
have the potential to facilitate victims’ longer-term recovery outcomes” (Patterson, Campbell, & 
Townsend, 2006, p.185).  Finally, Eriksen et al. (2002) focused on the female sexual assault 
patients’ perceived needs, demonstrating several implications associated with the need for 
specialty nursing care.  Those included: “(1) the importance of holistic, women-centered care; 
(2) the impact of nursing presence; (3) the importance of caring touch; and (4) the need for an 
effective, sensitive, and coordinated response by police and community services” (p.89). 
SANEs are meeting the medico-legal aspects of care effectively as well.  Sievers, 
Murphy, and Miller (2003) examined the differences in SANE care verses non-SANE or 
physician care.  They found that evidence collected by SANEs was more likely to have a 
complete chain of custody, properly sealed individual specimens, and contain appropriate 
amounts of pertinent evidence.  Thus, there is accumulating evidence that “the specialized 
education, training, and experience of SANEs will result in the improved collection of forensic 
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evidence” (p. 514).  Gibson (2000) corroborated this in his statement: . . . “through effective 
health care response to violence, promotion health and well-being of victims of violence, and 
delivery of sensitive, victim-centered responses, forensic nursing has dramatically improved the 
criminal justice response to crimes of violence across the United States” (p.26). 
Today roles for forensic nurses are expanding, continue to evolve, and may include: 
death investigation, correctional health, forensic psychiatric nurses, legal nurse consultants, nurse 
attorneys, and the care for sexual assault victims.  The care for sexual assault patients is still at 
the core of forensic nursing and nurses (SANEs and non-SANEs) are involved in direct care, 
follow up, counseling, education, and research.  Today many SANEs provide care for persons 
considered adult sexual assault victims (patients ages 12 and older) presenting to emergency 
departments.  The role of pediatric SANE has also been developed and those nurses care for 
patients up to age 12 years and have their own set of protocols.  All nurses assess for and address 
the physical and psychological needs of patients at this acute time in addition to collecting and 
processing any medico-legal evidence.  They also recommend medications for treatment of STIs 
based on protocols.  
Adolescent and adult sexual assault care guidelines include treatment for gonorrhea, 
Chlamydia, bacterial vaginosis, trichomoniasis, hepatitis, and HIV, as well as assessing for and 
providing vaccinations for Hepatitis B and tetanus when necessary.  Emergency contraceptives 
are now also offered to every patient.  With the latest advances in science and understanding 
about the HPV virus family, there is room to improve and change existing guidelines.  Evidence 
supports recommendation of the HPV vaccine and forensic nurses are uniquely positioned to 
educate patients about this virus family and offer the vaccine.   
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Conclusion 
It is apparent that HPV is a significant health problem and scientists are now developing 
strategies to facilitate vaccination efforts.  Nurses who provide sexual assault care are in a 
position to positively impact the HPV education and vaccination efforts.  Overall, providers are 
instrumental in helping to disseminate information and facilitate vaccination.  Nurses are 
respected and influential members of health care teams and are responsible for much of the 
health education that patients receive.  Barriers for comprehensive vaccination still exist and 
novel approaches are necessary.  Nursing care individuals receive in the aftermath of sexual 
assault may provide yet one more opportunity to help facilitate education and increase vaccine 
availability for adolescents and young adults at risk for HPV. 
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Chapter 3: Research Design and Methods 
Design 
For this exploratory research, I utilized a cross-sectional design and electronic mail 
survey to explore forensic nurses’ knowledge, beliefs, and attitudes about HPV, the HPV 
vaccine, and HPV preventative strategies, as well as identify facilitators and barriers that may 
influence nurses’ level of support regarding incorporating HPV preventative strategies into their 
care.  In a cross sectional study, data are collected on a single occasion, and these designs are 
appropriate for the goal of describing variables and their relationships.  An advantage of this 
design is the ease and low cost associated with one time data collection, and the disadvantage is 
the inability to establish causal relationships from the data (Burns & Grove, 2001).  This study 
was guided by a conceptual framework that integrates concepts from both the Health Belief 
Model and the Theory of Planned Behavior, as previously discussed. 
Sampling  
Participants for this study were recruited through the International Association of 
Forensic Nurses (IAFN) membership electronic list serve.  Inclusion criteria were: nurses at any 
level of education who care for sexual assault patients in any capacity (direct sexual assault care, 
counseling, follow up, education, research and policy development), and membership in the 
IAFN.  It was my intent to include all nursing stakeholders for sexual assault care in this sample, 
and nurses, who are vested in the care for sexual assault patients are those involved with direct 
care, counseling, follow up, education, research, and policy development.  It was important to 
seek participation from all stakeholders because one of the goals of this research was to gather a 
comprehensive understanding of stakeholders’ beliefs related to HPV and the HPV vaccine. This 
information will help frame discussions with IAFN leadership about policy and practice changes 
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in the future.  Exclusion criteria were forensic nurses who do not care for sexual assault patients 
and any IAFN members who are not nurses.   
 The IAFN membership represents a diverse sample of nurses from all of the United 
States.  There are also a few members from 24 other countries, including Canada.  HPV and 
sexual assault are global problems and all IAFN members, national and international, were 
eligible to participate in the study.   
There are approximately 3000 members and according to the IAFN, the majority of 
members provide some type of care for sexual assault victims.  Nurses who are specifically 
SANEs comprise approximately 55% of the membership (Marisa Raso, personal communication,   
October, 12, 2011).  This organization is the national credentialing body for SANEs, sets 
educational standards for sexual assault care, scope of practice and standards for forensic nurses, 
and is the major nursing advocacy group for victims of sexual assault.  Any nursing member 
regardless of educational preparation can currently be formally trained and credentialed as 
SANE-A (adult, caring for patients 12 and older) and SANE-P (pediatric, caring for patients less 
than 12). 
 There are multitudes of forensic nursing roles and due to the new and evolving nature of 
the specialty many roles are continuing to be expanded and developed.  Currently, there is not an 
Advanced Forensic Nurse credentialing examination for forensic nurses; however the IAFN is 
working on a credentialing process now.  This advanced credentialing will be for master’s 
prepared forensic nurses and above.  Nurses who are members of IAFN may have a variety of 
educational backgrounds including: associate’s degree, bachelor’s degree, master’s degree, and 
doctoral degrees (DNP or PhD).   
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Sample Size 
Sample size for the study was calculated using Optimal Design Plus (Spybrook, Bloom, 
Congdon, Hill, Martinez, & Raudenbush, 2011) with a moderate effect size (0.4), α of 0.05 and 
with an upper and lower prediction for the R 2 (0.0 to 0.6).  This range provides the lower and 
upper bounds for the proportion of variance explained by the control variables and therefore 
provides the upper and lower bounds of the required sample size.  An R 2 of 0.0 means that the 
other variables in the model (i.e., all other independent variables except the treatment variable) 
explain nothing (0%).  When the independent variables explain 0%, it is harder to find a 
treatment effect, so the researcher will need a larger sample size.  The sample size required to 
achieve 80% power when R-squared is 0.0 serves as the most conservative estimate.  The power 
analysis revealed that a sample size of 80 nurses would yield 80% power with an R 2 = 0.6 and a 
sample size of 200 would yield 80% power with a R 2 = 0.0.  This initial calculation was based 
upon principles used for ordinary least squares (OLS) regression.  An ordinal logistic regression 
was used in this study, because the dependent variable is not continuous, but instead measured in 
ordered categories (4) (O’Connell, 2006).  There is a potential for loss of power when using a 
continuous dependent variable that is coarsely categorized into ordinal levels.  According to 
Taylor, West, and Aiken (2006), the required increase in sample size (relative to the OLS power 
calculations) to achieve a comparable power with an ordinal outcome variable is dependent of 
number of ordered categories and shape of the outcome distribution.  It was predicted that the 
outcome variable distribution shape in this study would be symmetrical or rectangular; therefore 
sample size was expected to increase by 20% from OLS calculations to maintain a power of 80% 
(Taylor, West, & Aiken).  Application of this increase to the conservative sample size of 200 
yielded an adjusted sample size of approximately 240 for this study. 
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A sample size of 240 is approximately 8% of the 3000 nurses who are members in IAFN.  
Approximately 55% of IAFN members specifically are SANEs. The additional percentage of the 
membership besides SANEs that also specifically cares for sexual assault patients is unknown.  
Other researchers who have sampled the IAFN membership have had response rates ranging 
from 1% to 33%.  With effective marketing techniques and survey incentives, the goal was to at 
least achieve a 20% response rate ensuring an adequate sample of forensic nurses who care for 
sexual assault patients. 
Measures 
The survey development was primarily guided by the theoretical framework. When 
possible, existing measures with previously documented validity and reliability to assess 
variables of interest were utilized to guide the survey development.  Also, a recent systematic 
review of measures used in studies on HPV vaccine acceptability helped to guide the survey 
development (Allen, Coronado, et al., 2010).  Existing survey questions from published research 
in this field were evaluated for psychometrics, and were compiled and adapted to help create this 
study survey.  Appendix F shows the construct measured based on the theoretical framework, 
references from preexisting studies, their reported psychometrics, and the questions generated for 
this survey.  
  Questions for knowledge were guided by Denny-Smith, Bairan, and Page (2006) (α= 
0.95) and the CDC HPV fact sheet.  Questions for experience were guided by Bertram and 
Niederhauser (2008) and Allen, Coronado et al. (2010), no psychometrics reported.  Questions 
for attitudes (α=0.76) were adapted from Allen, Othus, et al. (2010), and normative beliefs were 
from Allen, Othus, et al. (2010) (α=0.84) and Riedesel, et al. (2005) (α=0.84).  Questions for 
perceived benefits were guided by Gerend, Shepherd, and Monday (2008) (α=0.86) and 
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Feemster, et al., (α=0.74).  Questions for perceived barriers were adapted from Kahn, Cooper, et 
al. (2009) (α=0.82) and Feemster, et al. (2008) (α=0.86 clinical barriers, α=0.81 social barriers, 
α=0.72 system barriers).  The four questions designed to elicit information on level of support for 
potential changes to practice were developed as the dependent variable for this survey.  All 
survey questions were reviewed and critiqued by an expert cancer (HPV) researcher enhancing 
face and content validity.  In addition to expert review, all measures were pre-tested among 
members of the intended audiences, revised, and re-tested. 
 General demographic questions included age, race/ ethnicity, and country of residence. 
Professional demographics (years as a nurse and highest degree earned), type of forensic 
practice, and type of primary nursing practice were also included.  Participants were also asked if 
they have ever heard of HPV and what their primary source of information has been (adapted 
from Kahn, Cooper, et al., 2009, no psychometrics reported) (Refer to Appendix E for complete 
survey). 
Procedures and Data Collection 
After IRB approval was granted, a list of electronic mail (e-mail) addresses for all IAFN 
members was available for access through the IAFN membership office.  As a current member of 
IAFN, I was able to have the director of IAFN member services distribute the survey emails to 
the membership.  E-mail confirmation from the director of IAFN member services supporting 
access to this database (see Appendix A) was secured prior to IRB submission and approval.  
The cost for each e-mail to the membership was $100.  The list was an accurate accounting of 
the current e-mails provided by the members on the membership applications.   
First, an e-mail was sent to all IAFN members with information about the survey and a 
URL address where they could access the survey (see Appendix B for text of first e-mail 
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contact).  Then, those who chose to view additional information about the study accessed the 
URL address and viewed informed consent information (see Appendix C for informed consent 
information).  Those who chose to continue were required to check a box stating that they had 
reviewed and understood the informed consent information prior to proceeding to the actual 
survey (set up on Qualtrex ®).  They were prompted to enter responses to survey questions via 
‘point-and-click’ with the mouse or from drop down menus.  When completed, survey data were 
downloaded to a protected site and checked for quality and completeness.  
Approximately one to two weeks later, a second e-mail was sent to all members as a 
thank you for those who had already completed the survey and a reminder for those who had not 
yet participated.  A final e-mail was sent in the following week to all members again thanking all 
participants (Appendix D).  Individuals were notified that all those who completed the survey 
will be provided with an additional URL address to be entered into a prize drawing and that they 
might be selected to receive one of two Apple i-Pads ®, worth up to $400 each.  The link to the 
prize drawing was at the end of the survey and participants could choose to enter the drawing or 
not.  Only those who accessed the prize drawing separate survey site were asked to provide an 
identifying email address.  There was no way to link prize participants back to the study survey.  
After data collection was complete with the online survey software (Qualtrex ®), it was 
exported to SPSS 19 for analysis.  The data were managed, cleaned, and stored only on the 
primary researcher’s secure computer.  There was not any way to link the data back to the 
participants.   
Human Subjects 
The risks of participation in this study were minimal.  The major risk was related to 
possible distress over heightened perceptions of risk of HPV.  Lack of confidentiality was not a 
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risk for the on-line survey, as it was anonymous.  Individuals who participated in the study were 
asked about their knowledge about HPV, their beliefs about incorporating HPV prevention 
strategies into routine sexual assault care, and to share demographic characteristics relevant to 
the study.  While there might have been a slight potential for psychological distress among 
individuals participating in this study, I did not anticipate that these reactions would be common 
or severe.  Actions taken to minimize the potential for psychological distress as a result of 
participating in this study were: 1) individuals volunteered to participate (if the topic was too 
stressful for some individuals to contemplate, they may have chosen not to participate), and 2) 
nurses were fully informed about the nature of questions that were included on the survey 
(participants were informed that they could skip any question that they would rather not answer, 
and that they could choose to terminate their involvement with the study at any time).  No reports 
of psychological distress or negative outcomes have been reported post completion of the study. 
There were individual benefits to participating in this study, besides the chance of 
winning a prize incentive.  Societal benefits include improved methods for promoting informed 
decision making about vaccination.  Individuals who chose to participate may have benefited 
from increased awareness of HPV and subsequently might choose to learn more on this topic.   
Statistical Analysis 
The dependent variable for this study was the forensic nurse’s level of support regarding 
incorporating preventative strategies into routine care of sexual assault patients.  The 
independent variables were knowledge, attitudes, normative beliefs, experience, perceived 
benefits and barriers, and demographic characteristics. 
Due to the possibility that missing data can introduce risks for problems related to 
reduced power, biases, and/or problems of colinearity, adjustment and replacement strategies for 
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missing values were determined.  If there was relatively few missing values, then statistical 
estimates might not be greatly affected by their presence; but if there were enough missing data 
to begin to affect the analysis, then considerations for either complete case method, list-wise or 
pair-wise deletion, or value replacement strategies such as mean substitution, regression 
imputation, hot-deck imputation, and/ or cold-deck imputation were considered (Ludlow, 2009). 
Outliers related to the independent variables, or unusual or extreme values at either end 
of the sample distribution were identified and addressed if found.  The strategies to assess for 
outliers included: looking for data entry errors, reviewing subjects to ensure they are members of 
the target population being sampled, and determining if the subject is simply unique or different 
from others in the sample (Mertler & Vannatta, 2005).  Data were visually inspected, frequency 
distribution assessed, and histograms were evaluated for unusual values.  If outliers were found 
then values were corrected, dropped from analysis depending on Mahalanobis distance, or 
explained thoroughly.  Steps to reduce the relative influence of outliers were considered. 
Next, preliminary analyses were checked on generalizability of the sample.  Univariate 
assessment of the variables using graphics and summary statistics to describe the sample were 
performed.  The statistical analyses included descriptive statistics (mean and standard deviations 
for continuous level variables and frequencies and percents for categorical variables).  
Cronbach’s alpha reliability coefficients were calculated to check internal consistency of the 
seven scales used.   
Bivariate correlations (Pearson r) with a significance value less than or equal to 0.05 were 
used to understand how the six scales related to each other, and assess the presence of 
collinearity.  When appropriate and reasonable, determinations were made whether or not to 
combine highly associated scales to avoid collinearities in the outcome model.  
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The final model was run with ordinal logistic regression.  Ordinal logistic regression is an 
extension of multiple linear regression and is used when the outcome/dependent is an ordinal, 
categorical variable.  Logistic regressions evaluate the extent that independent variables increase 
the odds of membership in a certain group (dependent variable).  In this study, the dependent 
variable is membership in one of the four support groups (1) do not support any change to 
practice; 2) support for providing written educational information; 3) support for providing 
written recommendation for HPV vaccine in discharge instructions; and 4) support for initiation 
of the vaccination series at point of care.  These groups are ordinal in nature, with the first being 
no support for changing practice to incorporate HPV prevention strategies and the last being the 
highest level of support, to begin to initiate vaccination at point of care immediately post sexual 
assault.  The goal was essentially to predict, based on the independent variables, which nurses 
fall into the different groups along the ordinal scale (Mertler & Vannatta, 2005) based on their 
vector of independent variable values. 
 Unlike linear regressions, logistic regression produces a regression equation that will 
predict the probability of whether the nurse will fall into a category.  Also, unlike linear 
regression, there are no assumptions of the independent variables, and these variables may be 
continuous, dichotomous, or discrete.  The strength of this analysis is that it does not require the 
independent variables to be normally distributed, linearly related, or have equal variances 
(Mertler & Vannata, 2005).   
 Results from logistic regressions are also different from other types of multivariate 
analyses.  The output for logistic regression was separated into three parts: the statistics for 
overall model fit, a classification table, and the summary of model variables.  The results from 
the model were evaluated using goodness of fit tests.  This was done in three phases.  First, when 
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a stepping method was applied, variables were entered into the model one variable at a time 
resulting in significance at each step.  This indicates if the variables are significant predictors of 
the dependent variable.  Because this was an exploratory investigation, a forward stepping 
method was used, meaning only the independent variables that significantly predicted the 
dependent variable were included in the model.  Next the overall model fit was measured using -
2 log likelihood, goodness-of fit, Cox & Snell –R^2 and Nagelkerke-R^2.  A classification table 
for the dependent variable was developed and used to compare predicted values for the 
dependent variable based on the model with actual observed data.  The third phase of analysis 
was the interpretation of the table of coefficients for variables in the model, and this was done 
with a Wald statistic and the associated significance value (Mertler & Vannata, 2005).  The 
results were summarized in a narrative format describing the results of the analysis and what 
predictors were statistically reliable in predicting how the nurses fell into each category. 
This study provides a foundational background that will guide future educational 
interventions for nurses, as well as potentially reveal a consensus of information that could lead 
to policy and practice change.   
Conclusion 
 Chapter 3 outlines the methodology for this cross sectional international electronic mail 
survey of nurses who are members of the IAFN.  This study is a beginning effort to uncover the 
knowledge levels, experience levels, attitudes, and beliefs related to the HPV virus and vaccine 
of a sample of forensic nurses who care for sexual assault patients.  Permission and coordination 
of the emails sent to the IAFN membership was done with assistance from the IAFN 
administrative offices, and IRB approval was granted from Boston College.  The three aims were 
explored with the appropriate descriptive statistics, bivariate and/ or multivariate analyses 
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including ordinal logistic regression.  The psychometrics of the survey scales were examined and 
are reported in the results chapter.  This dissertation was funded by the Alpha Chi Chapter of 
Sigma Theta Tau International. 
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Chapter 4: Results 
 This chapter describes the results of the data analyses.  Descriptive, bivariate, and 
multivariate analyses are reviewed along with construction of the final models that explicate 
forensic nurses’ level of support for integrating HPV prevention strategies into the routine care 
for sexual assault patients.  
 The survey was available to the IAFN membership for a total of three weeks, and during 
that time, a total of 1042 persons (roughly 35% of the IAFN population) accessed the 
information and consent page on the survey site and 1029 gave consent to participate.  Of those 
providing consent 876 (58% of the IAFN SANE population) identified themselves as nurses who 
care for sexual assault patients.  Data for 876 nurses who cared for sexual assault patients were 
cleaned, recoded when necessary, and missing data were systematically reviewed in detail.  A 
complete case method to address missing data was determined to be the best fit for this 
dissertation study.  The final sample size was 519. 
Description of the Sample 
 The final sample of nurses was predominantly Caucasian (93.4%) and all were female. 
Only 3.7% identified as Hispanic, 1.9% Black, 1% Asian, and 1% other.  The mean age was 45 
years with a range of 24-70 years old.  The vast majority of participants were from the United 
States (93.4%), but 4.8% identified as Canadian and 1% as other.  These forensic nurses have a 
high level of nursing experience with 54.1% reporting 17 or more years of experience.  Others 
reported 11-16 years (19.7%), 5-10 years 17.9%, and 0-4 years 6.6%.  These nurses have slightly 
less forensic nursing experience: 40.7% reported 0-4 years as a forensic nurse, 5-10 years 
(33.9%), 11-16 years (16.4%), and 7.9% reported 17 or more years.  
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 Nursing education was measured in two ways: educational degree at entry into nursing 
and the highest nursing degree earned.  For entry into practice, 13.5% reported entry as a 
Licensed Practical Nurse, 42% Associate degree, 39.5% Baccalaureate degree, and 1% Master’s 
degree.  Advancement in education was evident by the reported highest degree earned: 28.9% 
Associate, 37.2% Baccalaureate, 28.5% Master’s, and 4.6% with doctoral degrees (PhD or 
DNP).  The participants were also asked about their highest non-nursing degree: 53% reported 
no other non-nursing degrees, 14.1 % reported another associate degree, 20.8% bachelor’s 
degree, 8.1% master’s, and 1.7% a non-nursing doctoral degree. 
 The type of primary nursing practice was also evaluated, as many forensic nurses perform 
forensic care as an additional role; however 8.1% reported their primary role to be in forensics.  
Other types of primary practice roles included: 4% medical surgical, 6% pediatrics, 12.3% 
women’s health, 40.8% emergency care, 8% psychiatric, 4.2% primary care, 2.9% community 
health, and 18.1% identified as other. 
 Among these nurses, all of whom care for sexual assault patients, 73% identified 
themselves as SANE-A, and 41.4% as SANE-P providers (these were not mutually exclusive 
categories). Other types of forensic practice focus participants identified (not mutually exclusive 
categories) included: 32% child abuse; 4.8% corrections; 6% death investigations; 40.3% 
emergency practice; 8.7% geriatrics; 14.5% education; 2.5% psychology; 29.3% interpersonal 
violence; 6.9% legal nurse consulting; and18.3% assessment of injury (see Table 1). 
Table 1: Demographics of Sample (N= 519) 
 Mean SD 
Age (in years) (n=496) 45 9.78 
 N % 
Race/ ethnicity (n=519) 
        Caucasian 
        Hispanic 
 
480 
19 
 
92.5 
3.7 
52 
 
        Black/ African American 
        Asian 
        Other 
10 
5 
5 
1.9 
1.0 
1.0 
First degree, nursing (n=499) 
        LPN 
        Associate 
        Bachelor’s 
        Master’s 
 
70 
219 
205 
5 
 
13.5 
42.2 
39.5 
1.0 
Highest degree, nursing (n=505) 
       Associate 
       Bachelor’s 
       Master’s 
       Doctoral 
 
150 
188 
144 
23 
 
28.9 
36.2 
27.7 
4.4 
Years as a nurse (n=510) 
       0-4 
       5-10 
       11-16 
       17 or more 
 
34 
93 
102 
281 
 
6.6 
17.9 
19.7 
54.1 
Years as a forensic nurse (n=513) 
       0-4 
       5-10 
       11-16 
       17 or more 
 
211 
176 
85 
41 
 
40.7 
33.9 
16.4 
7.9 
Type of forensic practice  
(not mutually exclusive)(n=519) 
      Child abuse 
      Corrections 
      Death investigation 
      Emergency 
      Geriatrics 
      Education 
      Psychology  
      Intra-personal violence 
      Legal nurse consulting 
      Assessment of injury 
      Sexual assault 
      SANE-A 
      SANE-P 
 
 
166 
25 
31 
209 
45 
75 
13 
152 
36 
95 
412 
379 
215 
 
 
32 
4.8 
6.0 
40.3 
8.7 
14.5 
2.5 
29.3 
6.9 
18.3 
79.4 
73.0 
41.4 
Type of primary practice (n=517) 
      Forensics only 
      Medical/surgical 
      Pediatrics 
      Women’s health 
      Emergency 
      Psychiatric  
      Primary care 
 
42 
21 
31 
64 
212 
16 
22 
 
8.1 
4.0 
6.0 
12.3 
40.8 
3.1 
4.2 
53 
 
      Community health 
      Other 
15 
94 
2.9 
18.1 
 
 Other descriptive data gathered on the sample included a question on whether or not 
participants have ever heard of HPV and if so where participants acquired their information on 
HPV.  Almost unanimously, participants had heard of HPV (99.8%).  The reported sources of 
HPV information included (not mutually exclusive responses): 66.5% academic articles, 43.9% 
professional organizations, 35.8% professional conferences, 29.7% media, 28.7% colleagues, 
28.5% personal knowledge, 27.6% other health care professionals, 24.1% promotional materials  
from industry, and 22% academic lectures (see Table 2). 
Table 2: Primary Sources of HPV Information 
 N % 
Primary sources of HPV information 
(not mutually exclusive) (n= 519) 
       Professional organization 
       Academic articles 
       Professional conferences 
       Academic lectures 
       Promotional materials, industry 
       Colleagues 
       Other health professionals 
       Media 
       Personal knowledge 
 
228 
343 
186 
114 
125 
149 
143 
154 
148 
 
 
43.9 
66.5 
35.8 
22.0 
24.1 
28.7 
27.6 
29.7 
28.5 
 
Aim 1: Describe forensic nurses’ level of knowledge, attitudes, and beliefs about HPV and 
the HPV vaccine 
 Description of the independent variables. 
 Knowledge.  Six core components of the nurses’ knowledge about HPV and the HPV 
vaccine were assessed (see Table 3).  These components included: transmission, cervical cancer 
viral association, infectious consequences (including signs and symptoms), if HPV can live in 
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the skin without visual signs and symptoms, risk factors, and preventative strategies.  Overall 
these forensic nurses’ level of knowledge was high.  Of the possible 32 items, the mean score 
was 26.61, averaging an overall score of 83% correct (N=519). 
Table 3: Summary of HPV Knowledge Scores (N=519) 
HPV knowledge questions N (answered correct) % correct 
Transmission: 
     Sexual intercourse* 
     Oral to genital contact* 
     Genital to genital contact* 
     Blood transfusions 
     Sharing needles 
 
517 
438 
510 
484 
484 
 
99.6 
84.4 
98.3 
93.3 
93.3 
Cervical CA is associated with the 
presence of: 
     Herpes simplex virus (HSV) 
     Human papillomavirus (HPV)* 
     Chlamydia 
     HIV 
 
 
406 
517 
410 
395 
 
 
78.2 
99.6 
79.0 
76.1 
HPV can live on the skin without causing 
growths or changes* 
513 98.8 
Prevention strategies: 
     Delay onset of sexual activity* 
     Use condoms* 
     Annual Pap testing* 
     Obtain the HPV vaccine* 
 
507 
498 
255 
513 
 
97.7 
96.0 
49.1 
98.8 
HPV can cause: 
     Cervical cancer* 
     Genital warts* 
     Anal cancer* 
     Cancer of glands of head and neck* 
     Vaginal discharge 
     Burning with urination 
     Itching 
     Open sores 
 
519 
472 
399 
258 
307 
317 
231 
319 
 
100.0 
90.0 
76.9 
49.7 
59.2 
61.1 
44.5 
61.5 
Risk factors: 
     Multiple sexual partners* 
     Sexual intercourse prior to age 18* 
     Taking illegal drugs 
     Having a history of STI* 
     Smoking cigarettes 
     Having genital warts* 
     Using tampons 
     Using oral contraceptives 
 
519 
485 
312 
498 
386 
466 
489 
456 
 
100.0 
93.4 
60.1 
96.0 
74.4 
89.8 
94.2 
87.9 
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     Poor diet 
     Having sex without a condom* 
420 
515 
80.9 
99.2 
* indicates an question item that would be correct (true) 
 As depicted in Table 3, key basic HPV knowledge was extremely high and every nurse 
knew that HPV could cause cervical cancer.  For the transmission subset of knowledge, the 
scores for this section were extremely high, with a total score of 93.8% correct on transmission 
items.  A huge majority of the nurses (98.8%) knew that HPV could live in the skin without 
causing growths or changes and almost 100% could correctly identify that cervical cancer and 
precancerous cells of the cervix are associated with the HPV virus.  All nurses could identify that 
risk factors included multiple sexual partners, and nearly everyone could identify other risk 
factors including: sexual intercourse prior to age 18 (93.4%), having a history of a STI (96.0%), 
and having sex without a condom (99.2%). 
 The nurses almost unanimously identified the key HPV prevention strategies including: 
delaying the onset of sexual activity (97.7%), using condoms (96.0%), and receiving the HPV 
vaccine (98.8%).  The CDC does include having an annual Pap test as a prevention strategy; 
however confusion may occur.  The Pap test is screening tool to identify the presence of 
abnormal cellular changes.  HPV would have already been acquired by the patient prior to the 
Pap test uncovering the presence of any type of HPV or abnormal cellular change.  Having a Pap 
test in its self is not a preventive strategy to avoid to contracting the virus; however routine Pap 
testing can certainly help prevent an HPV infection progressing into a cancerous state through 
identification of HPV and treatment of precancerous and cancerous cells.  This confusion 
possibly accounted for the low level of nurses identifying “having annual Pap screening tests” 
(49.1%) as an HPV prevention strategy.  
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 The areas in which the nurses had lower scores included the more complex and less 
straightforward information and questions.  Besides identifying HPV correctly as the causative 
agent for cervical cancers, many nurses also identified Herpes Simplex Virus (HSV), Chlamydia, 
and HIV incorrectly.  The nurses were less likely to correctly identify that taking illegal drugs 
and smoking cigarettes do not increase an individual’s specific risk for acquiring HPV.  Taking 
illegal drugs, having a history of STIs, and having multiple sexual partners are associated with an 
increased risk for acquiring STI; however these are not the causative agent. 
 Recently, there has been increasing press attention related to HPV causing other types of 
cancers besides cervical.  However, only 76.9% of the nurses knew that HPV can cause anal 
cancers and 49.7% could correctly identify that HPV can cause cancers in the glands of the head 
or neck.  Nurses also had trouble identifying correctly that HPV does not cause: vaginal 
discharge, burning with urination, open sores, and itching.  The mean total correct score for HPV 
causative factors was the lowest at 68%. 
 Attitudes.  Data on vaccine attitudes were gathered with 8 Likert scale questions (1= 
“strongly disagree” to 5= “strongly agree”).  Mean scores for each question range from 3.81 to 
4.51, all above the median score of 3.0.  Vaccine attitudes total score if all items were summed 
was 33.69 out of 40, roughly a score of 84.23% total, which represents a positive level of vaccine 
attitude.  The nurses had the lowest mean scores for statements: “If there was a vaccine that 
prevented the common cold I would want my patients to get vaccinated” (3.81) and “I believe 
that vaccines should be required for contagious diseases that can be spread person to person” 
(3.85).  Despite being one of the lowest mean scores for vaccine attitudes it was surprising that 
68.6% (n=356) were in some level of agreement for requiring vaccines for contagious diseases 
(see Table 4). 
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Table 4: Vaccine Attitudes 
 (n) % Mean 
score 
 
Questions from instrument: 
Strongly 
disagree 
Disagree Neither Agree Strongly 
agree 
 
Vaccines are important to 
prevent diseases that can be 
spread person to person  
(21) 4.0 (1) 0.2 (14) 2.7 (141) 
27.2 
(342) 
65.9 
4.51 
If there was a vaccine that 
prevented the common cold I 
would want my patients to get 
vaccinated 
(30) 5.8 (53) 10.2 (102) 
19.7 
(136) 
26.2 
(198) 
38.2 
3.81 
If there were a vaccine that 
prevented cancer I would want 
my patients to get vaccinated 
(19) 3.7 (3) 0.6 (35) 6.7 (123) 
23.7 
(339) 
65.3 
4.46 
I believe that vaccines should 
be required for contagious 
diseases that can be spread 
person to person 
(27) 5.2 (43) 8.3 (93) 
17.9 
(172) 
33.1 
(184) 
35.5  
3.85 
In general, I would recommend 
the HPV vaccine to persons in 
my family 
(23) 4.4 (18) 3.5 (47) 9.1 (142) 
27.4 
(289) 
55.7 
4.26 
In general, I would recommend 
the HPV vaccine to my friends 
(23) 4.4 (26) 31.0 (52) 
10.0 
( 141) 
27.2 
(287 ) 
55.3 
4.26 
In general, I would recommend 
the HPV vaccine to any patient 
(20) 3.9 (5) 1.0 (51) 9.8 (155) 
29.9 
(288) 
55.5  
4.32 
Specifically, I would 
recommend the HPV vaccine 
to SA patients 
(22) 4.2 (10) 1.9 (68)13.1 (150) 
28.9 
(269) 
51.8 
4.22 
 
 Normative Beliefs. The nurses’ reported positive normative beliefs regarding the HPV 
vaccine.  The means for each question ranged from 3.38 to 4.57.  The majority of the nurses 
reported that their family and friends would either “approve” or “strongly approve” of them 
recommending the HPV vaccine to others.  The lowest mean was for approval or disapproval 
from the nurses’ religious or faith organization.  Answer choices “neither approve nor 
disapprove” and “not applicable” were combined for only the questions regarding approval of 
family, friends or faith organizations.  Originally in the data set, the answer choice for “not 
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applicable” was coded as a 6.  This led to a skewed effect of normative beliefs, therefore in order 
to neutralize this effect “not applicable” was coded the same as “neither approve nor disapprove” 
which was the median value of 3.  The total number of respondents for this category was the 
largest at 49.7%, prior to recoding “not applicable” alone accounting for 113 nurses (21.8%). 
The nurses overall were likely to follow recommendations from colleagues, the CDC, and the 
IAFN.  The CDC was apparently the most influential (see Table 5). 
Table 5: Normative Beliefs 
 (n) % Mean 
scores 
Thinking of the following 
individuals/groups, how 
much would they approve 
or disapprove of you 
recommending the HPV 
vaccine:  
Strongly 
disapprove
Disapprove Neither 
or N/A 
Approve Strongly 
approve 
 
Family (6) 1.2 (13) 2.5 (101) 
19.5 
(184) 
35.5 
(215) 
41.4 
4.13 
Friends (4) 0.8 (7) 1.3 (96) 
18.5 
(183) 
35.3 
(229) 
44.1  
4.20 
Religious/ faith 
organizations 
(14) 2.7 (55) 10.6 (258) 
49.7 
(103) 
19.8 
(89) 
17.1 
3.38 
You would most likely 
make HPV vaccine 
recommendations to your 
patients if you were 
following 
recommendations from: 
Very 
unlikely 
Unlikely  Neither Likely  Very 
likely 
 
Nursing and medical 
colleagues 
(10) 1.9 (5) 1.0 (59) 
11.4 
(225) 
43.4 
(220) 
42.4 
4.23 
CDC (9) 1.7 (4) 0.8 (17) 
3.3 
(141) 
27.2 
(348) 
67.1 
4.57 
IAFN (9) 1.7 (5) 1.0 (48) 
9.2 
(213) 
41.0 
(244) 
47.0 
4.31 
 
 Perceived Benefits. Specific perceived benefits related to the HPV vaccine were 
examined.  Overall, the participants reported positive perceived benefits from the HPV vaccine; 
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mean scores ranged from 4.29 to 3.77.  In general, the nurses indicated that the HPV vaccine was 
beneficial (either “agreed” or “strongly agreed”) regarding: the vaccine will help patients stay 
healthier (84.8%), obtaining the vaccine outweighed the risks (81.5%), and the vaccine will 
prevent cervical cancer (77.3%).  Less reported perceived positive benefits (“agreed” or 
“strongly agreed”) regarding: preventing genital warts (67.7%) and cost effectiveness (71.7%).   
Lastly, specific perceived benefits related to sexual assault patients were evaluated with two 
questions.  The nurses positively perceived a benefit for sexual assault patients to learn more 
about HPV and the vaccine (highest mean score of 4.29) as well as positively perceived a benefit 
for sexual assault patients to become vaccinated against HPV (mean score 4.07) (see Table 6).  
Table 6: Perceived Benefits 
 (n) % Mean 
score 
 Strongly 
disagree 
Disagree Neither Agree Strongly 
agree 
 
Getting the HPV vaccine will 
help patients stay healthier 
(5) 1.0 (9) 1.7 (65) 
12.5 
(238) 
45.9 
(202) 
38.9 
4.20 
Benefits of the HPV vaccine 
outweigh potential risks 
(4) 0.8 (11) 2.1 (81 ) 
15.6 
(218) 
42 
( 205) 
39.5 
4.17 
HPV vaccination will prevent 
most cases of cervical cancer 
(4) 0.8 (20) 3.9  (94) 
18.1 
(248) 
47.8 
 (153) 
29.5 
4.01 
HPV vaccination will prevent 
most cases of genital warts 
(12) 2.3 (43) 8.3 (113) 
21.8 
(237) 
45.7 
(114) 
22.0  
3.77 
HPV vaccine will be cost 
effective 
(5) 1.0 (8) 1.5 (134) 
25.8 
(211) 
40.7 
(161) 
31.0 
3.99 
It benefits SA patients to learn 
more about HPV and the vaccine 
(4) 0.8 (10) 1.9 (42) 8.1 (240) 
46.2 
(223) 
43.0 
4.29 
It benefits SA patients to become 
vaccinated against HPV 
(4) 0.8 (12) 2.3 (103) 
19.8 
(223) 
43 
(177) 
34.1 
4.07 
 
 Perceived Barriers.  In a similar fashion perceived barriers related to the HPV vaccine 
were measured and these can be categorized into three groups: clinical, social, or system barriers. 
The overall perceived barrier mean scores were low to neutral (1.54 to 3.98).  The greatest 
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perceived barriers were having concerns about parental or patient lack of education and 
understanding about HPV, and cost if the patient did not have insurance coverage or did not 
qualify for vaccine assistance programs.  The lowest perceived barriers were reluctance to 
discuss sexuality and STIs and a belief that HPV and the vaccine should only be discussed with 
the patients by their primary care providers.   Surprisingly, time to discuss HPV during care was 
not reported as a barrier by the majority of the participants (see Table 7). 
Table 7: Perceived Barriers 
 (n) % Mean 
score 
 Strongly 
disagree 
Disagree Neither Agree Strongly 
agree 
 
Clinical (70) 
13.5 
(174) 
33.5 
(123) 
23.7 
(125) 
24.1 
(27) 5.2 2.74 
Concern- HPV vaccine safety 
Concern- HPV vaccine efficacy (61) 
11.8 
(191) 
36.8 
(118) 
22.7 
(129) 
24.9 
(20) 3.9 2.72 
Social  
 
(9) 1.7 
 
 
(38) 7.3 
 
 
(40) 7.7
 
 
(299) 
57.6 
 
 
(133) 
25.6 
 
 
3.98 Concern- parental or patient lack of education and understanding 
about HPV 
Concern- HPV vaccinated teens 
will practice riskier sex 
(112) 
21.6 
(198) 
38.2 
(100) 
19.3 
(86) 
16.6 
(23) 4.4 2.44 
Reluctant to discuss sexuality and 
STIs with patients 
(292) 
56.3 
(195) 
37.6 
(17) 3.3 (9) 1.7 (6) 1.2 1.54 
System  
 
(24) 4.6 
 
 
(68) 
13.1 
 
 
(210) 
40.5 
 
 
(162) 
31.2 
 
 
(55) 
10.6 
 
 
3.30 Vaccine cost-if patient does not have coverage or qualify for 
assistance 
Reluctant to discuss HPV related 
to time constraints 
(151) 
29.1 
(235) 
45.3 
(82) 
15.8 
(41) 
7.9 
(10) 1.9 2.08 
HPV and the vaccine should only 
be discussed by the primary care 
provider 
(199) 
38.3 
(212) 
40.8 
(66) 
12.7 
(32) 
6.2 
(10) 1.9 1.92 
 
 Experience.  Data on both personal and clinical nursing experience related to HPV and 
cervical cancer (N=519) were also gathered.  Approximately 50% of the participants reported a 
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personal or an immediate family or friend ever having had an abnormal Pap test or cervical 
cancer.  The nurses’ level of clinical experience was collected with 4 items.  Interestingly, many 
of these nurses reported clinical experiences caring for patients who have a history of HPV, 
managing Pap test results, recommending and/or giving the HPV vaccine to patients where they 
work.  Over 28% of the nurses reported ever discussing the initiation of HPV education or 
vaccination for sexual assault patients where they work (see Table 8).  
Table 8: Experience with HPV 
  (n) % 
Personal history of an abnormal Pap test or cervical cancer (212) 40.8 
History of family or friend having an abnormal Pap test or cervical cancer (261) 50.3 
Currently care for patients with a history of HPV or manage Pap results (269) 51.8 
Currently recommend/ give HPV vaccine to patients in non forensic setting (220) 42.4 
Currently recommend/ give HPV vaccine to patients in forensic setting (203) 39.1 
You or others where you work ever discussed initiating HPV 
education/vaccination for sexual assault patients 
(148) 28.5 
  
 Self efficacy.  The nurses’ self efficacy for practice change was evaluated with three 
questions, and the reported self efficacy was very high (mean scores ranging from 4.27 to 4.31). 
The nurses were overwhelmingly confident in their ability to adapt to practice changes, 
comfortable bringing new ideas for change to nursing leadership, and were confident in 
discussing new ideas with other non nursing health professionals (see Table 9).   
Table 9: Self Efficacy 
 (n) % Mean 
score 
 Strongly 
disagree 
Disagree Neither Agree Strongly 
agree 
 
Confident in ability to adapt to 
practice changes 
(34) 6.6 0 (9) 1.7 (202) 
38.9 
(274) 
52.8 
4.31 
Comfortable bringing new ideas 
for practice change to nursing 
leadership 
(33) 6.4 (2) 0.4 (10) 1.9 (202) 
38.9 
(272) 
52.4 
4.31 
Confident in discussing new ideas (34) 6.6 (1) 0.2 (17) 3.3 (204) (263) 4.27 
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with other non nursing health 
professionals 
39.3 50.7 
 
 Forensic nurses’ level of knowledge, attitudes, and beliefs as related to sample 
characteristics. To further explore nurses’ level of knowledge, attitudes, and beliefs (including 
normative beliefs, perceived barriers, and perceived benefits), the relationship between these 
constructs and sample characteristics were examined.  The purpose was to discover and explain 
relationships between the study’s independent variables (IVs) and the sample characteristics.  
Analysis of covariance (ANCOVA) and regression analyses were used to examine associations 
between the sample characteristics and level of knowledge, attitudes, and beliefs.  Sample 
characteristics examined included: 1) age; 2) highest nursing degree; 3) years of general nursing 
experience; 4) years of forensic nursing experience; 5) type of primary nursing practice (i.e.: 
women’s health, medical surgical, pediatrics, emergency, psychiatric, primary care, community 
health, other, and forensic only); 6) type of forensic nursing practice (i.e.: SANE-A, SANE-P, 
corrections, child abuse, forensic emergency, forensic geriatrics, forensic psychiatric, forensic 
education, forensic legal nurse, and death investigation); and 7) sources of HPV information.  All 
sample characteristic variables were mutually exclusive categories except type of forensic 
practice and sources of information.  Race and gender were not included in the analysis due to 
the limited variability in those sample characteristics.  
 Correlations for each of the original independent variables (now dependent variable 
(DV)) (knowledge, attitudes, normative beliefs, perceived benefits and perceived barriers) with 
the mutually exclusive sample variables were completed.  Pearson correlations (r) or Spearman’s 
rho were examined for significance (α ≤ .05) and strength (r or rho value ≥ .50).  Then, an 
ACNOVA with each new DV and IVs (age, level of nursing education, years as a nurse and 
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years as a forensic nurse were entered into the model as covariates and primary practice (which 
is categorical) was entered in as a factor was completed.  Regressions for type of forensic 
nursing practice and sources of HPV information (non-mutually exclusive variables) were 
performed independently. 
 Knowledge.  A total knowledge score (the summed 32 items) was used during analysis to 
understand associations for the measured cumulative HPV knowledge.  A perfect knowledge 
score was 32; the mean score was 26.61.  Nurses who identified a non forensic primary practice 
in either women’s health/ OB/GYN or community health had the highest total knowledge scores 
Primary care nurses had the lowest reported mean knowledge scores (see Table 10).  .  
Table 10: Mean Scores on Total Knowledge (total= 32.0, mean =26.61) 
  Mean n Std. Deviation 
Age 20-29 27.05 34 2.34 
 30-39 26.27 115 3.02 
 40-49 26.79 162 2.75 
 50-59 26.57 153 2.76 
 60+ 26.81 32 2.48 
Highest nursing degree Associates  26.57 150 2.84 
 Bachelor’s 26.40 188 2.82 
 Master’s  26.97 144 2.66 
 Doctoral 26.86 23 2.71 
Years nurse 0-4 25.58 34 2.78 
 5-10 26.69 93 3.07 
 11-16 26.76 102 2.78 
 17 or more 26.66 281 2.66 
Years forensic nurse 0-4 26.34 211 2.80 
 5-10 26.94 176 2.82 
 11-16 26.60 85 2.46 
 17 or more 26.73 41 2.94 
Type of primary practice Forensics only 27.02 42 2.64 
 Med/surgical 26.04 21 2.59 
 Pediatrics 26.96 31 2.66 
 WH, OB/GYN 27.34 64 2.34 
 Emergency 26.34 212 2.85 
 Psychiatric 26.75 16 2.88 
 Primary care 25.45 22 2.64 
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 Community health 27.80 15 2.14 
 Other 26.55 94 2.94 
 
 The sample characteristics of age, highest nursing degree, years as a nurse, years as a 
forensic nurse were not significantly correlated with the total knowledge scores.  Women’s 
health nurses positively correlated (p= .025, rho= .098) and primary care nurses negatively 
correlated (p= .044, rho= -.088) with knowledge.  With the ANCOVA, only type of primary 
nursing practice was significantly associated with knowledge (p= .048, F= 1.62).  The adjusted 
means scores for the covariates ranged; with the highest as community health (27.78), women’s 
health (27.44) and pediatrics (27.07), and the lowest adjusted mean scores were for primary care 
(25.32), medical surgical (26.33) and emergency (26.34).  Further analyses for type of forensic 
practice and sources of HPV information were completed with regression.  Neither type of 
forensic practice nor sources of HPV information were significantly associated with knowledge.  
 Vaccine attitudes.  The total vaccine attitude score (summed individual items) equaled 
40, with a mean score of 33.69.  Community health nurses, like the knowledge scores, had the 
highest average mean scores for total vaccine attitudes.  Nurses with the reported highest 
educational level an associate degree had lowest mean vaccine attitude scores and nurses 
reporting a doctoral degree had the highest (see Table 11).     
Table 11: Mean Scores on Total Vaccine Attitudes (total= 40.0, mean=33.69) 
  Mean  n Std. Deviation 
Age 20-20 34.35 34 4.87 
 30-39 32.80 115 7.90 
 40-49 34.10 162 7.00 
 50-59 34.1 153 6.28 
 60+ 34.96 32 5.17 
Highest degree Associates  32.96 150 8.33 
 Bachelor’s 33.14 188 7.11 
 Master’s  34.65 144 5.66 
 Doctoral 36.82 23 3.52 
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Years nurse 0-4 34.76 34 4.51 
 5-10 32.33 93 8.74 
 11-16 32.09 102 8.33 
 17 or more 34.53 281 5.95 
Years forensic nurse 0-4 32.67 211 7.85 
 5-10 33.76 176 7.08 
 11-16 35.18 85 5.42 
 17 or more 35.29 41 4.11 
Type of primary practice Forensics only 32.83 42 7.51 
 Med/surgical 31.85 21 7.81 
 Pediatrics 35.48 31 4.20 
 WH, OB/GYN 33.40 64 7.56 
 Emergency 33.36 212 7.12 
 Psychiatric 35.37 16 5.51 
 Primary care 33.04 22 7.15 
 Community health 36.20 15 5.67 
 Other 34.27 94 7.10 
 
 Highest nursing degree (p= .004, r= .126) and years as a forensic nurse (p= .002, r= 
.139) were significant and positively correlated to vaccine attitudes.  Performing the ANCOVA 
revealed that variables: level of nursing education (p = .043, F= 4.13) and years as a forensic 
nurse (p = .022, F= 5.28) were significantly associated with vaccine attitudes.  The regression 
analyses for type of forensic nursing practice and sources of HPV information were not statically 
significant.  
 Beliefs.  Beliefs associated with the following three variables were examined: normative 
beliefs, perceived vaccine benefits, and perceived vaccine barriers (total summed score used for 
each).   Normative beliefs had a total possible score of 33.0 and a mean score of 25.56.  Nurses 
who reported the highest degree as either Master’s or Doctorate had higher than mean normative 
beliefs.  Interestingly, nurses with only 0-4 years experience had higher mean scores than the 
other nursing experience groups, but the opposite was true for years of forensic nursing 
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experience.  Nurses who reported more years as a forensic nurse had greater mean scores (see 
Table 12).  
 Similar to vaccine attitudes, both nursing education (p= .000, r= .181) and years as a 
forensic nurse (p= .000, r= .173) had significant positive correlations with normative beliefs.  
Reporting the type of primary practice as a medical/surgical nurse (p= 0.23, rho= -.100) had a 
significant negative correlation.  With the ANCOVA, highest nursing education (p= .000, F= 
12.39), years as a nurse (p=.034, F= 4.52) and years of forensic practice (α= .006, F= 7.63) were 
all significantly associated with normative beliefs.  Type of forensic practice was not 
significantly associated with normative beliefs in the regression.  Participant reports of obtaining 
HPV information from academic lectures (p= .004, B= 1.26, CI= .415 to 2.11) was positively 
associated with normative beliefs. 
Table 12: Mean Scores on Normative Beliefs (total= 33.0, mean= 25.56) 
 
  Mean n Std. Deviation 
Age 20’s 25.02 34 4.01 
 30’s 25.52 115 4.18 
 40’s 25.70 162 3.38 
 50’s 25.83 153 3.80 
 60+ 25.56 32 4.42 
Highest degree Associates  25.15 150 4.27 
 Bachelor’s 24.90 188 4.07 
 Master’s  26.56 144 3.13 
 Doctoral 27.91 23 2.85 
Years nurse 0-4 26.32 34 3.14 
 5-10 25.04 93 4.60 
 11-16 25.28 102 4.15 
 17 or more 25.70 281 3.69 
Years forensic nurse 0-4 24.90 211 4.18 
 5-10 25.59 176 3.92 
 11-16 26.60 85 3.28 
 17 or more 26.78 41 3.07 
Type of primary practice Forensics only 25.52 42 4.53 
 Med/surgical 23.66 21 3.11 
 Pediatrics 25.41 31 3.37 
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 WH, OB/GYN 25.82 64 3.66 
 Emergency 25.62 212 4.14 
 Psychiatric 25.56 16 2.89 
 Primary care 25.54 22 3.94 
 Community health 25.53 15 4.86 
 Other 25.76 94 3.60 
  
 Perceived vaccine benefits had a possible total score of 35.0 and the mean was 28.5 
overall.  Again, mean scores appeared to rise related to advancing nursing education as well as 
years as a forensic nurse (until practicing 17 or more years).  Those who report being a pediatric 
nurse had the very highest mean scores for perceived benefits of vaccines (see Table 13).  
 The sample characteristics that significantly correlated to perceived benefits were: 
highest level of nursing education (p= .001, r= .146), type of primary nursing as pediatrics (p= 
.048, rho= .087), and primary nursing practice as other (p=.046, rho= .087).  ANCOVA analysis 
revealed only highest nursing education (p = .006, F= 7.66) as significantly associated with 
perceived benefits.  Several types of forensic practice were statistically significant with the 
regression analysis.  Forensic practice in death investigation (p=.029, B= -12.40, CI= -22.91 to -
1.88) and SANE-P (p=0.27, B= -9.90. CI= -18.08 to 1.71) were negatively associated; however, 
forensic practice as a legal nurse consultant (p=.019, B= 12.52, CI=3.07 to 21.98), general 
sexual assault (p=.047, B= 5.28, CI= .115 to 10.45), and SANE-A (p=.006, B=8.34, CI=3.65 to 
13.04) were all positively associated with perceived benefits.  Finally, obtaining HPV 
information from an academic lecture was a significant positive predictor of perceived benefits 
(p=.036, B= 1.06, CI= .070 to 2.066). 
Table 13: Mean Scores on Perceived Benefits (total= 35.0, mean= 28.50) 
  Mean n Std. Deviation 
Age 20-29 28.61 34 4.27 
 30-39 28.06 115 4.98 
 40-49 28.90 162 4.26 
68 
 
 50-59 28.70 153 4.44 
 60+ 28.18 32 5.18 
Highest degree Associates  28.20 150 4.73 
 Bachelor’s 27.70 188 5.04 
 Master’s  29.83 144 3.92 
 Doctoral 29.91 23 3.11 
Years nurse 0-4 28.61 34 3.77 
 5-10 28.3 93 5.41 
 11-16 28.50 102 5.33 
 17 or more 28.57 281 4.21 
Years forensic nurse 0-4 27.85 211 5.11 
 5-10 28.99 176 4.56 
 11-16 29.08 85 3.89 
 17 or more 28.58 41 3.39 
Type of primary practice Forensics only 28.04 42 4.29 
 Med/surgical 26.76 21 2.96 
 Pediatrics 30.09 31 3.37 
 WH, OB/GYN 28.42 64 4.87 
 Emergency 28.05 212 4.96 
 Psychiatric 29.18 16 4.44 
 Primary care 29.00 22 5.08 
 Community health 28.80 15 5.25 
 Other 29.35 94 4.10 
 
 Perceived vaccine barriers had a possible total score of 40.0 and an overall mean of 
20.72.  Barriers overall were fairly low for the participants.  Advanced education appeared to 
decrease barrier mean scores, as did years as a nurse and as a forensic nurse.  The groups with 
the very lowest perceived barriers scores were nurses with a doctoral education and pediatric 
nurses.  Community health nurses and being a nurse for 0-4 years had the highest perceived 
barriers (see Table 14). 
 The correlations revealed that age, level of education, years as a nurse and years as a 
forensic nurse all had negative correlations to perceived barriers.  Level of nursing education (p= 
.000, r= -.238), years as a nurse (p= .016, r= -.107), and years as a forensic nurse (p= .000, r= -
.163), were all significantly correlated with perceived barriers.  Reporting type of primary 
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practice as pediatrics (p= .024, rho= -.099) was significant and negatively correlated, where as 
women’s health, primary care, primary practice other, and primary practice in forensics only 
were also negatively correlated however not statistically significant.  Again, with the ANCOVA 
only level of nursing education (p= .000, F= 17.44) and years as a forensic nurse (p = .008, F= 
7.17) were associated with barriers.  Interestingly, obtaining HPV information from the media 
(p= .008, B= 1.17, CI= .309 to 2.04) was a positive predictor of barriers; however obtaining 
information from academic articles (p = .006, B= -1.19, CI -2.04 to -.338) and academic lectures 
(p = .004, B = -1.40, CI= -2.36 to -.438) were significant and negatively associated with 
perceived barriers.  None of the types of forensic practice were statistically significant predictors 
with regression. 
Table 14: Mean Scores on Perceived Barriers (total= 40.0, mean= 20.72) 
  Mean n Std. Deviation 
Age 20-19 21.26 34 3.97 
 30-39 20.93 115 4.57 
 40-49 20.46 162 4.37 
 50-59 20.43 153 4.56 
 60+ 21.18 32 4.25 
Highest degree Associates  21.86 150 4.41 
 Bachelor’s 21.04 188 4.47 
 Master’s  19.61 144 4.36 
 Doctoral 17.60 23 4.00 
Years nurse 0-4 22.35 34 4.76 
 5-10 21.16 93 3.96 
 11-16 20.69 102 4.66 
 17 or more 20.42 281 4.53 
Years forensic nurse 0-4 21.55 211 4.37 
 5-10 20.57 176 4.73 
 11-16 19.77 85 3.98 
 17 or more 19.51 41 4.58 
Type of primary practice Forensics only 19.85 42 4.12 
 Med/surgical 21.95 21 4.47 
 Pediatrics 18.96 31 4.26 
 WH, OB/GYN 20.34 64 4.57 
 Emergency 21.13 212 4.68 
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 Psychiatric 21.18 16 3.91 
 Primary care 20.40 22 4.18 
 Community health 22.00 15 3.90 
 Other 20.61 94 4.45 
 
Aim 2: Determine the level of forensic nurses’ support about incorporating HPV 
preventative strategies into the routine care for sexual assault patients 
 Overall, the level of support that forensic nurses reported was very high.  The four 
ordinal categories for level of support were: (1) do not support any change to practice; 2) support 
for providing written HPV educational information; 3) support for providing written educational 
information and recommendation for HPV vaccine in discharge instructions; and 4) support for 
providing written educational information, recommendation for HPV vaccine in discharge 
instructions, and support for initiation of the vaccination series at point of care.  Of the 519 
nurses, 2.1% (n=11) were in category 1, 11.9% (n=62) were in category 2, 33.3% (n=173) were 
in category 3, and overwhelmingly 52.6% (n=273) were in category 4 (the highest level of 
cumulative support).  
 Almost the entire sample (98%) supported providing HPV education at time of care post 
sexual assault.  Approximately 86% of the nurses supported change to written discharge 
instructions/ paperwork that would includes recommendation for HPV vaccination.  Lastly, 53% 
of the nurses indicated that HPV vaccination should be initiated during care in the ED post 
sexual assault (see Figure 1). 
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Figure 1 
 
 
Aim 3: Identify factors that are associated with nurses’ support of integrating HPV 
prevention strategies into the routine care for sexual assault patients 
 Independent variable properties.  Seven measures were used in this survey to collect 
data on the independent variables.  These included: knowledge, experience with HPV, attitudes 
toward vaccines, normative beliefs, self efficacy, perceived benefits, and perceived barriers.  
Survey questions and measure development were previously discussed in Chapter 3 and are 
summarized in Appendix E and F. 
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 Psychometric analyses of the measures adapted for this study, as discussed in Chapter 3, 
were conducted on the final data set (see Appendix F items for each scale).  The developed 
measures (scales) had excellent reliability ranging from alphas 0.77 to 0.97, except for the 
knowledge and experience with HPV measures, which initially had moderate/fair reliability 
(alphas 0.55 and 0.46 respectively).  The three item self efficacy in practice change measure had 
a Cronbach’s alpha (α) of 0.97.  Vaccine attitudes (8 items) had an alpha of 0.94 and normative 
beliefs (6 items) were 0.77.  The 7 items measuring perceived benefits had an alpha = .89 and the 
8 items measuring perceived barriers an alpha = .70.  Both the knowledge and experience with 
HPV measures were revised for the final analyses (Aim 3); however descriptive data on the full 
measure were provided in this chapter. 
 Description of revisions to the knowledge measure.  Knowledge about HPV and the 
HPV vaccine was assessed with 6 core areas, and each core area had several questions for the 
participant to answer.  These included: 1) HPV transmission knowledge (5 questions); 2) cervical 
cancer viral association (4 questions); 3) HPV infectious consequences (8 questions); 4) HPV 
preventative strategies (4 questions); 5) if HPV can live in the skin without visual signs and 
symptoms (1 question); and 6) risk factors for HPV (10 questions).  Thus the instrument has 32 
questions/response options.  HPV knowledge scores were analyzed and reviewed for each 
question and then cumulatively.  
 Psychometrics for the HPV knowledge measure were evaluated after data collection.  
First, the internal consistency of the original 32 items was evaluated and the Cronbach’s alpha 
(α) was 0.554.  Due to the large number of items and less than optimal internal reliability, a 
determination was made to examine the psychometrics of the measure in detail prior to running 
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the final model.  Reliability analysis was performed (see Tables 15 and 16).  Item to total score 
correlations and alpha if deleted values were used to pare down the overall scale.   
Table 15: Reliability Statistics- 32 Item Knowledge 
 
Cronbach’s Alpha N of Items 
0.554 32 
 
Table 16: Item Total Statistics- 32 Item Knowledge 
 
Items Scale mean if 
item deleted 
Scale 
variance if 
item deleted 
Corrected 
item-total 
correlation 
Cronbach’s 
alpha if item 
deleted 
HPV transmission 
     Sexual intercourse 
     Oral Genital contact 
     Genital to genital contact 
     Blood 
     Needle 
 
25.62 
25.77 
25.64 
25.69 
25.69 
 
7.67 
7.69 
7.65 
7.29 
7.26 
 
.014 
-.068 
.025 
.242 
.268 
 
.555 
.573 
.555 
.538 
.536 
Cervical Cancer Associated 
     HSV 
     Chlamydia 
     HIV 
     HPV 
 
25.84 
25.83 
25.86 
25.62 
 
6.93 
6.88 
6.94 
7.65 
 
.267 
.296 
.248 
.082 
 
.528 
.524 
.531 
.553 
HPV prevention 
     Abstaining 
     Condoms 
     Pap testing 
     Vaccination 
 
25.64 
25.66 
26.13 
25.63 
 
7.67 
7.61 
8.04 
7.70 
 
-.011 
.028 
-.215 
-.047 
 
.557 
.556 
.608 
.557 
HPV Causes 
     Genital warts 
     Cervical cancer 
     Anal cancer 
     Head and neck cancer 
     Vaginal discharge 
     Burning with urination 
     Open sores 
     Itching 
 
25.71 
25.62 
25.85 
26.12 
26.03 
26.01 
26.00 
26.17 
 
7.43 
7.68 
7.42 
7.62 
6.42 
6.43 
6.49 
6.54 
 
.112 
.000 
.035 
-.066 
.408 
.409 
.387 
.350 
 
.550 
.555 
.563 
.585 
.500 
.500 
.504 
.511 
HPV can be present 
without visual signs or 
symptoms 
25.63 7.63 .070 .553 
HPV risk factors 
     Multiple sex partners 
 
25.62 
 
7.68 
 
.000 
 
.555 
74 
 
     Sex prior to age 18 
     History of STIs 
     History of genital warts 
     Sex w/o a condom 
     Drug use 
     Cigarette use 
     Tampon use 
     OCP use 
     Poor diet 
25.68 
25.66 
25.72 
25.63 
26.02 
25.87 
25.68 
25.74 
25.81 
7.70 
7.71 
7.49 
7.62 
6.77 
7.09 
7.25 
7.13 
6.93 
-.055 
-.060 
.059 
.108 
.264 
.173 
.298 
.253 
.287 
.564 
.562 
.555 
.552 
.527 
.543 
.534 
.534 
.526 
 
 Items were removed if they had negative or near zero corrected item total correlations 
and if the result from the Cronbach’s alpha with the item deleted was higher than the original 
alpha.  This procedure was performed in a slow step by step process, always considering clinical 
considerations of items. 
 The final revised knowledge scale used in the Aim 3 models consisted of 14 items.  This 
new knowledge scale had an alpha of 0.768.  See Table 17 for reliability statistics and Table 18 
for item total statistics.  The items used in the final knowledge scale appear in Table 18. 
Table 17: Reliability Statistics- 14 Item Knowledge 
 
Cronbach’s Alpha N of Items 
.768 14 
 
Table 18: Item Total Statistics- 14 Item Knowledge 
 
Items Scale mean if 
item deleted 
Scale 
variance if 
item deleted 
Corrected 
item-total 
correlation 
Cronbach’s 
alpha if item 
deleted 
HPV transmission 
     Blood 
     Needle 
 
9.50 
9.50 
 
7.73 
7.69 
 
.295 
.329 
 
.762 
.760 
Cervical Cancer Associated 
     HSV 
     Chlamydia 
     HIV 
 
9.65 
9.65 
9.67 
 
7.23 
7.26 
7.27 
 
.365 
.354 
.326 
 
.756 
.757 
.760 
HPV Causes 
     Vaginal discharge 
     Burning with urination 
     Open sores 
     Itching 
 
9.84 
9.82 
9.82 
9.99 
 
6.78 
6.67 
6.74 
6.80 
 
.461 
.514 
.485 
.447 
 
.746 
.740 
.743 
.747 
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HPV risk factors 
     Drug use 
     Cigarette use 
     Tampon use 
     OCP use 
     Poor diet 
 
9.83 
9.69 
9.49 
9.56 
9.63 
 
6.92 
7.35 
7.69 
7.47 
7.22 
 
.407 
.280 
.360 
.350 
.393 
 
.752 
.764 
.759 
.757 
.753 
  
Description of the revisions to the experience with HPV measure.  The original measure 
to assess for experience with HPV included both personal and clinical experience questions and 
comprised of 6 items.  When the internal reliability was evaluated on the full measure, the α = 
0.466.  Next, the same step by step process was undertaken (as for knowledge) to examine 
optimal internal reliability in order to determine the best final scale.  Reliability analysis was 
performed (see Tables 19 and 20).  Item to total score correlations and alpha if deleted values 
were used were employed to pare down the overall scale.   
Table 19: Reliability Statistics- 6 Item Total Experience 
 
Cronbach’s Alpha N of Items 
.466 6 
 
Table 20: Item Total Statistics- 6 Item Total Experience 
 
Item  Scale mean if 
item deleted 
Scale 
variance if 
item 
deleted 
Corrected 
item-total 
correlation 
Cronbach’s 
alpha if item 
deleted 
Experience with: 
     Personal history of an    
           abnormal pap 
     Family history of an  
           abnormal pap 
    Caring for patients with  
           HPV or abnormal pap 
    Currently recommend or  
          give HPV vaccine to  
          patients: 
          Non-forensic setting 
          Forensics (SA Patients) 
 
 
2.12 
 
2.03 
 
2.01 
 
 
 
2.11 
2.14 
 
 
2.00 
 
1.93 
 
1.74 
 
 
 
1.64 
1.64 
 
 
.064 
 
.108 
 
.257 
 
 
 
.355 
.360 
 
 
.510 
 
.489 
 
.407 
 
 
 
.348 
.347 
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    In work setting, discussed  
          initiating HPV education 
          or vaccination for SA 
          patients 
 
 
 
2.24 
 
 
 
1.79 
 
 
 
.276 
 
 
 
.398 
 
Items were removed if they had negative or near zero corrected item total correlations 
and if the result from the Cronbach’s alpha if item deleted was higher than the original alpha. 
This was done in a slow step-by-step process, always considering clinical considerations of 
items.  
There were two questions on the original six item measure that asked for personal 
experience information and those were:  “Has your health care provider ever told you that you 
had an abnormal Pap smear result or cervical cancer?” and “Has anyone in your immediate 
family or friends ever had an abnormal Pap smear result or cervical cancer?  Interestingly, the 
two personal items had the lowest total item correlations and the alpha if deleted was lower than 
the original alpha for the total scale.  What this means is the experience measure with both 
personal and clinical experience was weaker than the clinical experience measure alone.   
Therefore, for the final analysis in Aim 3, it was determined that only a measure of 
clinical experience with HPV would be utilized.  This was determined to be the best fit for both 
psychometric reasons, as well as practical outcome reasons.  One of the goals of this study was 
to work toward policy change, and nurses’ previous personal experiences with HPV cannot be 
altered with an intervention, whereas clinical experience can (see Table 21 and 22 for the 
reliability analyses for the clinical experience measure).  
Table 21: Reliability Statistics- Clinical Experience 
 
Cronbach’s Alpha N of Items 
.603 4 
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Table 22: Item Total Statistics- Clinical Experience 
 
Item  Scale mean if 
item deleted 
Scale 
variance if 
item 
deleted 
Corrected 
item-total 
correlation 
Cronbach’s 
alpha if item 
deleted 
Experience with: 
    Caring for patients with  
           HPV or abnormal pap 
    Currently recommend or  
          give HPV vaccine to  
          patients: 
          Non-forensic setting 
          Forensics (SA Patients) 
    In work setting, discussed  
          initiating HPV education 
          or vaccination for SA 
          patients 
 
 
1.10 
 
 
 
1.19 
1.23 
 
 
 
1.33 
 
 
1.18 
 
 
 
1.01 
1.01 
 
 
 
1.14 
 
 
.256 
 
 
 
.449 
.462 
 
 
 
.378 
 
 
.628 
 
 
 
.479 
.470 
 
 
 
.536 
 
 Model 1: Planned model with ordinal outcome variable.  The final model for Aim 3 
was completed as planned with the outcome variable as four ordinal categories.  The newly 
revised knowledge scale and clinical experience scale were utilized.  The seven identified 
independent variables were standardized.  Because the number of items varied from measure to 
measure, standardized scores were used to allow for optimal comparisons of coefficients.  
Significance was set at p ≤ 0.05. 
Collinearity assessment. The correlation matrix was examined prior to model analysis.  
All of the independent variables significantly correlated with the outcome variable (level of 
support) except self efficacy.  Both the new knowledge scale and perceived barriers had negative 
Pearson correlations (r) related to level of support. It was surprising that the knowledge score 
had a negative relationship.  Despite significance, the r values for each of the independent 
variables indicated weak linear relationships (r value < 0.50).  
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Many of the independent variables are significantly correlated with each other with a 
range of r values indicating weak to moderate positive or negative relationships.  Perceived 
benefits, perceived barriers, and normative beliefs all correlated significantly with all variables 
except knowledge.  Knowledge was correlated only with clinical experience and level of support. 
Surprisingly, knowledge was negatively correlated with clinical experience.  However, it 
was not surprising that perceived barriers were negatively correlated with all of the other 
independent variables.  The strongest correlation was between perceived benefits and normative 
beliefs (p= .000, r= .653) (see Table 23).  All of the independent variables were entered into the 
final model analysis.  
Table 23: Correlation Matrix (N= 519) 
 
 Knowledge Clinical 
Experience 
Perceived 
barriers 
Perceived 
benefits 
Normative 
beliefs 
Vaccine 
attitudes 
Self 
efficacy 
Level 
of 
support 
Knowledge r 
 
α 
1 -.138** 
 
.002 
-.073 
 
.097 
.059 
 
.180 
.040 
 
.360 
-.006 
 
.893 
.054 
 
.219 
-.115** 
 
.009 
Clinical 
Experience 
r 
 
α 
 1 -.267** 
 
.000 
.242** 
 
.000 
.130** 
 
.003 
.084 
 
.057 
-.048 
 
.271 
.204** 
 
.000 
Perceived 
barriers 
r 
 
α 
  1 -.428** 
 
.000 
-.403** 
 
.000 
-.258** 
 
.000 
-.103* 
 
.019 
-.256** 
 
.000 
Perceived 
benefits 
r 
 
α 
   1 .653** 
 
.000 
.535** 
 
.000 
.235** 
 
.000 
.313** 
 
.000 
Normative 
beliefs 
r 
 
α 
    1 .493** 
 
.000 
.274** 
 
.000 
.201** 
 
.000 
Vaccine 
attitudes 
r 
 
α 
     1 .479** 
 
.000 
.224** 
 
.000 
Self 
efficacy 
r 
 
α 
      1 .031 
 
.482 
Level of 
support 
r 
 
α 
       1 
Pearson Correlation (r), Significance (α) (2- tailed) 
** correlation is significant at the 0.01 level (2-tailed) 
* correlation is significant at the 0.05 level (2-tailed) 
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 Ordinal logistic regression.  An ordinal logistic regression was performed to examine 
how the independent variables are related to the probabilities of different levels of support.  All 
seven independent variables were used in this regression.  The coefficient for each independent 
variable (B) represents how probabilities of level of support change as values on the independent 
variables change.  These movements depend upon where the individual participant started on the 
scale to begin with.   
Four independent variables were significant.  Both clinical experience (p= .029, B= .122, 
CI= .013 to .232) and perceived benefit (p= .000, B= .283, CI= .135 to .431) moved individuals 
up on the level of support scale (high clinical experience and high perceived benefit predicted the 
probability of having a higher level of support).  Both perceived barriers (p= .002, B= -.184, CI= 
-.300 to -.068) and, interestingly, knowledge (p= .002, B= -.167, CI= -.274 to -.060) moved 
individuals down on the level of support scale (high perceived barriers and high knowledge 
scores predicted the probability of having a lower level of support) (see Table 24).  
Table 24: Logistic regression- Parameter Estimates 
 
  
 
 
Estimate 
 
 
Std. 
Error 
 
 
 
Wald 
 
 
 
df
 
 
 
Sig. 
95.0% Confidence 
Interval 
 Lower       Upper 
 Bound       Bound
Threshold  
  [Level of Support = 1] 
  [Level of Support = 2] 
  [Level of Support = 3] 
Location 
         Self Efficacy 
         Vaccine attitudes 
         Normative Beliefs 
         Perceived Benefits 
         Perceived Barriers 
         Clinical experience 
         Knowledge 
 
-2.287 
-1.194 
-.066 
 
-.076 
.124 
-.074 
.283 
-.184 
.122 
-.167 
 
.140 
.074 
.057 
 
.060 
.068 
.071 
.075 
.059 
.056 
.055 
 
265.97 
262.79 
1.312 
 
1.567 
3.335 
1.093 
14.128 
9.652 
4.766 
9.423 
 
1 
1 
1 
 
1 
1 
1 
1 
1 
1 
1 
 
.000 
.000 
.252 
 
.211 
.068 
.296 
.000 
.002 
.029 
.002 
 
-2.562 
-1.339 
-.178 
 
-.194 
-.009 
-.214 
.135 
-.300 
.013 
-.274 
 
-2.012 
-1.050 
.047 
 
.043 
.257 
.065 
.431 
-.068 
.232 
-.060 
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Among these interesting findings, unexpectedly, the participants reported 
overwhelmingly high levels of support.  As discussed previously, roughly 86% of the nurses fell 
in the support Categories 3 and 4 on the ordinal scale.  Therefore, these results are predicting 
probabilities of movements up and down the support scale at the very top end (all with high 
levels of support). 
 To understand the predicted probability of participants falling into which category of 
support (level of support 1, 2, 3, or 4), a support index was developed.  The support index is a 
variable that optimally predicts the probability of being in a support category.  It is the weighted 
linear combination scale score of the 7 variables, where the estimate (B) serves as the weights. 
This index most accurately predicts which category of support each individual falls into.  The 
following graph shows how probabilities of having the outcome (Category 1, 2, 3, or 4) vary as a 
function of the index.  It demonstrates that even if an individual has either a -1 (low over all 
score) or 1 (high score), the most likely probability will always be in the 3rd or 4th level of 
support.  The vast majority of index values range between -1.0 to 1.0.  For example, the 
participants with the lowest index score still have the highest probability of being in Category 3. 
There are very few people in Category 1 or 2 (see Figure 2).  
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Figure 2 
 
To further understand the data at the level of the independent variable, a plot for 
standardized scale scores for each independent variable by level of support was developed.  The 
following diagram highlights where scores for that predictor variable are based on which level of 
support.  Thus, it becomes clear that an individual in support category 1 has the lowest perceived 
benefits for vaccination and the highest perceived barriers.  It is important, however, to take into 
consideration that the vast majority (86%) of the participants fall into categories 3 and 4 (see 
Figure 3).  
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Figure 3: Plots for Standardized Scale Score for Each Independent Variable by Level of Support 
 
In conclusion, and based on the finding that the vast majority of participants (86%) fall 
into support Category 3 or 4, it was determined that the optimal way to understand predictors 
would be to transform the outcome variable into a dichotomous variable.  This new dichotomous 
outcome variable would allow a better understanding between participants in Category 4 (the 
highest level of support) as compared to those indicating the other levels of support (Category 1, 
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2, or 3).  This new dichotomous outcome variable (which essentially occurred naturally) will 
help to delineate characteristics of essentially Category 3 and 4 in more detail.  Again both 
categories (3 and 4) are supportive of integrating HPV strategies into their care, so now this new 
analysis will highlight differences between those in the highest two categories of support; those 
who support including HPV recommendations on the discharge instructions and those who 
support initiating HPV vaccine at point of care.  
Model 2: Final Model, dichotomous outcome variable. Based on the findings of the 
originally planned model for Aim 3, a post hoc analysis was undertaken to optimally explain the 
data.  The two-category level of support outcome variable was created, thus placing participants 
in either level of support Category 4 (highest level of support) or level of support Categories 1, 2, 
3 (moderate/high level support).  Using these two groups, the data are essentially evenly 
distributed: Category 4 accounts for 52.6% of participants and Categories 1, 2, and 3 accounts 
for 47.4% (N=519).  Lastly, having the outcome evenly distributed also has the added benefit of 
producing more statistical power for the analysis.  See Figure 4 for a histogram depicting the 
dichotomous outcome variable.  
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Figure 4: Histogram with 2 Category Outcome Variable 
 
Collinearity assessment.  Similar to Model 1, the correlation matrix was examined prior 
to this final model analysis.  The matrix revealed the same pattern as was described previously.  
All of the independent variables were significantly correlated with the outcome variable (level of 
support) except self efficacy.  The correlations for knowledge and perceived barriers to level of 
support remained negative and all of the linear relationships continued to have r values in the 
weak range (.1 to .3) (see Table 25).  Again, all of the independent variables were included in 
this final analysis. 
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Table 25: Correlation Matrix Final Analysis (N= 519) 
 
 Level 
of 
support 
Knowledge Clinical 
Experience 
Perceived 
barriers 
Perceived 
benefits 
Normative 
beliefs 
Vaccine 
attitudes 
Self 
efficacy 
Level of 
support 
r 
 
α 
1 -.129** 
 
.003 
.192** 
 
.000 
-.204** 
 
.000 
.228** 
 
.000 
.132** 
 
.003 
.131** 
 
.003 
.004 
 
.931 
Knowledge r 
 
α 
 1 -.138** 
 
.002 
-.073 
 
.097 
.059 
 
.180 
.040 
 
.360 
-.006 
 
.893 
.054 
 
.219 
Clinical 
Experience 
r 
 
α 
  1 -.267** 
 
.000 
.242** 
 
.000 
.130** 
 
.003 
.084 
 
.057 
-.048 
 
.271 
Perceived 
barriers 
r 
 
α 
   1 -.428** 
 
.000 
-.403** 
 
.000 
-.258** 
 
.000 
-.103* 
 
.019 
Perceived 
benefits 
r 
 
α 
    1 .653** 
 
.000 
.535** 
 
.000 
.235** 
 
.000 
Normative 
beliefs 
r 
 
α 
     1 .493** 
 
.000 
.274** 
 
.000 
Vaccine 
attitudes 
r 
 
α 
      1 .479** 
 
.000 
Self 
efficacy 
r 
 
α 
       1 
Pearson Correlation (r), Significance (α)(2- tailed) 
** correlation is significant at the 0.01 level (2-tailed) 
* correlation is significant at the 0.05 level (2-tailed) 
 
Logistic regression.  Logistic regression was utilized to examine the probabilities of 
influence the independent variables had on the dichotomous support outcome variable.  All seven 
independent variables, the standardized scale scores, were used in this regression.  
 This model elucidates that knowledge, clinical experience, perceived benefits, and 
perceived barriers are all predictors of the highest level of support (Category 4).  Knowledge (p = 
.003, OR= .744, CI= .615 to .899) and perceived barriers (p = .010, OR= .757, CI= .613 to .936), 
like Model 1, remain negative predictors.  These two variables are associated with decreasing the 
odds of an individual being in Category 4.  These independent variables are continuous, so 1 
standard deviation increase in level of knowledge is associated with 25.6% lower odds (.744 -1.0 
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= -25.6) and an increase in perceived barrier is associated with 24.3% lower odds (.757 -1.0 = -
24.3) of being in Category 4.  Clinical experience (p = .029, OR= 1.242, CI= 1.02 to 1.50), and 
perceived benefits (p = .003, OR= 1.50, CI= 1.14 to 1.96), are associated with increased odds of 
being in Category 4.  A one standard deviation increase in clinical experience with HPV is 
associated with 24.2% higher odds (1.242 -1.0 = 0.24) and an increase in perceived benefit is 
associated with 50% increased odds (1.50 -1.0 = 0.50) of being in Category 4 (see Table 26).  
Table 26: Logistic Regression, 2 Category Level of Support 
 
Model B SE Wald df Sig Exp (B) 
Constant  .116 .093 1.55 1 .212 1.123 
Self Efficacy -.102 .109 .868 1 .352 .903 
Vaccine attitudes .094 .125 .563 1 .453 1.09 
Normative beliefs -.118 .130 .820 1 .365 .889 
Perceived benefits .405 .137 8.75 1 .003 1.50 
Perceived barriers -.278 .108 6.57 1 .010 .757 
Clinical experience .216 .099 4.73 1 .029 1.24 
Knowledge -.296 .098 9.08 1 .003 .744 
 
To understand the predicted probability of being in which one of the two categories of 
support, a new support index was developed.  This linear combination of weighted total scale 
score creates the most accurate prediction for which individuals will fall into what category.  The 
following graph plots the curve predicting membership in Category 4.  The mean for the support 
index (dichotomous) was 0.12, with a standard deviation of 0.71.  The normal distribution curve 
is centered slightly above zero and is not skewed (see Figure 5). 
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Figure 5: Histogram of Support Index- 2 Category Outcome Variable 
 
If you refer to Figure 6, with a mean score (0.12) an individual would have about 50% 
probability of being in Category 4 (highest level of support).  
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Figure 6: Probability of Level of Support by Support Index 
 
 
 Participants who are most likely to have moderate/high support (Category 1, 2, or 3) are 
described by the following characteristics.  They tend to have higher knowledge and perceived 
barriers, but lower clinical experience, perceived benefits, and vaccine attitude scores.  The 
standard deviations around knowledge and clinical experience were the tightest, meaning there is 
less variability or diversity in the scores for these participants potentially in this category.  These 
descriptive results are reflective of the linear regression results (see Table 27). 
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Table 27: Descriptive Statistics for Characteristics of Those with Moderate/High Support 
 
 N Minimum Maximum Mean Standard 
Deviation 
Knowledge 
Clinical Experience 
Perceived Barrier 
Perceived Benefits 
Normative Beliefs  
Vaccine Attitudes 
Self Efficacy 
Valid N (listwise) 
230 
230 
230 
230 
230 
230 
230 
230 
-2.93 
-1.23 
-1.94 
-4.65 
-4.48 
-3.66 
-3.31 
1.24 
1.82 
4.28 
1.40 
1.38 
.898 
.705 
.341 
-.575 
.555 
-.646 
-.352 
-.350 
.012 
.789 
.715 
.867 
.908 
1.091 
1.021 
.868 
 
 The characteristics of participants most likely to have the very highest level of support 
(Category 4) tended to have higher levels of clinical experience, perceived benefits, and vaccine 
attitudes.  They also had lower perceived barriers and knowledge scores.  There was the least 
diversity in perceived benefit scores and the greatest range of variability in knowledge scores 
(see Table 28).  Again, these descriptive likelihoods are reflective of the regression results. 
Table 28: Descriptive Statistics for Characteristics of Those with the Very Highest Support 
 N Minimum Maximum Mean Standard 
Deviation 
Knowledge 
Clinical Experience 
Perceived Barrier 
Perceived Benefits 
Normative Beliefs  
Vaccine Attitudes 
Self Efficacy 
Valid N (listwise) 
289 
289 
289 
289 
289 
289 
289 
289 
-3.62 
-1.23 
-2.82 
-2.27 
-2.44 
-3.66 
-3.31 
1.24 
1.82 
2.50 
1.40 
1.89 
.898 
.705 
 
-.271 
.458 
-.441 
.514 
.280 
.278 
-.009 
1.066 
.956 
.871 
.737 
.820 
.890 
1.094 
 
 Complementary analysis of model summary.  For practical clinical purposes to 
understand and help inform changes in education or policy, a complementary analysis of final 
model (2 category level of support) summary was completed.  All items from the statistically 
significant (previously summed) independent variables were extracted and examined 
individually.  To hold constant the rest of the model, the standardized scores for the other 
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independent variables remained in the model as controls.  The purpose of this complementary 
analysis was to check to see what individual items from the significant previously summed 
independent variables might be most relevant.  This analysis included item individualizing: 
perceived benefit, clinical experience, perceived barriers, and new knowledge.   
 Few individual items were significant in this analysis.  Knowing that cervical cancer is 
not associated with Chlamydia (p = .003, OR = 2.50) was significant and increased the odds of 
the nursing having the highest level of support.  Other variables significantly increased the odds 
of having the highest level of support were: clinical experience caring for patients with a history 
of HPV or managing Pap test results (p = .005, OR = 1.83) and having an increased perceived 
benefit for sexual assault patients to be vaccinated (p = .001, OR = 2.13).  In other words, nurses 
who reported currently caring for patients who have a history of HPV or managing Pap test 
results had an increased odds of 1.83 times and nurses who reported a higher perceived benefit 
for sexual assault patients to become vaccinated against HPV had an increased odds of 2.13 
times of being in Category 4. 
 Two of the individual knowledge items were associated with decreasing the odds of the 
nursing being in Category 4.  Knowing that cervical cancer is not associated with Herpes 
Simplex Virus (HSV) (p = .031, OR= 0.501) and that HPV is not transmitted by needle stick (p 
=.045, OR= .156) both decreased the odds of being in Category 4.  These odds of decrease were 
much smaller that the above described items that increased the odds of being in Category 4 (see 
Table 29). 
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Table 29: Logistic Regression to Examine Individual Items 
 
  B S.E. Wald df Sig. Exp(B) 
Normative beliefs 0.038 0.149 0.064 1 0.801 1.038
Vaccine Attitudes 0.117 0.139 0.704 1 0.401 1.124
Self Efficacy -0.07 0.122 0.333 1 0.564 0.932
Clinical Experience             
Caring for patients with  
     HPV/ abnormal Pap 0.602 0.213 7.961 1
 
0.005 1.826
Currently recommend or  
     give HPV vaccine to  
     patients: 
       
Non Forensic setting 0.038 0.238 0.026 1 0.872 1.039
Forensic (SA) -0.049 0.252 0.038 1 0.846 0.952
In work setting, discuss  
    or initiate HPV edu or 
    vaccine for SA patients 0.023 0.263 0.008 1
 
 
0.930 1.023
Knowledge             
HPV risk Factors                  
Poor diet -0.252 0.314 0.642 1 0.423 0.777
OCPs use 0.186 0.366 0.258 1 0.612 1.204
tampons use -0.063 0.538 0.014 1 0.907 0.939
cigarette use -0.214 0.281 0.578 1 0.447 0.808
drug use -0.126 0.233 0.293 1 0.588 0.882
HPV causes        
Itching -0.004 0.25 0.000 1 0.988 0.996
Open sores -0.258 0.269 0.917 1 0.338 0.773
Burning with urine -0.178 0.297 0.357 1 0.550 0.837
Vaginal discharge 0.195 0.273 0.512 1 0.474 1.215
Cervical Cancer 
Associated 
       
HIV -0.059 0.278 0.046 1 0.831 0.942
Chlamydia 0.920 0.311 8.752 1 0.003 2.509
HSV -0.691 0.302 5.239 1 0.022 0.501
HPV Transmission        
Needle -1.861 0.891 4.364 1 0.037 0.156
Blood 0.533 0.847 0.395 1 0.530 1.703
Perceived barriers        
System        
Only with PCP -0.214 0.124 2.973 1 0.085 0.807
Time -0.179 0.125 2.064 1 0.151 0.836
Cost -0.105 0.111 0.883 1 0.347 0.901
Social        
Reluctant to discuss sex 
     or STIs 0.224 0.172 1.691 1
 
0.194 1.251
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Concern for riskier  
     sexual practices 0.006 0.115 0.002 1
 
0.960 1.006
Concern r/t parent or  
     patient lack of edu./  
     understanding 0.033 0.124 0.072 1
 
 
0.789 1.034
Clinical        
Efficacy -0.268 0.153 3.057 1 0.080 0.765
Safety 0.021 0.158 0.018 1 0.894 1.021
Perceived benefits        
Benefits SA patients to  
     become vaccinated 0.757 0.221 11.732 1
 
0.001 2.131
Benefits SA patients to  
     learn more 0.095 0.226 0.175 1
 
0.676 1.099
Vaccine cost effective -0.148 0.183 0.656 1 0.418 0.863
Vaccine will prevent:        
     Genital warts -0.023 0.138 0.029 1 0.865 0.977
     Most cervical cancer -0.011 0.184 0.004 1 0.952 0.989
Benefits outweigh risks -0.095 0.249 0.145 1 0.704 0.91
Vaccine will help  
     patients health -0.173 0.241 0.514 1
 
0.474 0.841
Constant 0.206 1.918 0.011 1 0.915 1.228
 
Conclusion 
 The analyses and results for Aim 1, 2, and 3 were explored and explained in detail. 
Overall, the participants were female Caucasian experienced nurses who had a baccalaureate or 
higher degree.  All of the nurses who participated cared for sexual assault patients, and the 
majority identified themselves as either SANE-A or SANE-P.  Their knowledge level about HPV 
and the vaccine was generally high, as were mean scores on all of the independent variables 
except perceived barriers.  The lower mean scores for perceived barriers are intuitively 
connected to having higher levels of support. 
 Overwhelmingly, the nurses reported high levels of support and the vast majority fell into 
Category 3 or 4.  This finding means that at the very least, these nurses are highly supportive of 
providing education, information, and instructions at discharge for HPV vaccination.  Greater 
standardized mean scores for clinical experience and perceived benefits increased the odds of the 
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nurse having the highest level of support (Category 4), over all the other categories of support 
together.  Knowledge and perceived barriers were negative predictors, decreasing the odds of the 
nurse falling info Category 4, as compared to all other levels of support together.  Perceived 
benefits was the most influential predictor of all; a high perceived benefit increased the odds of 
being in Category 4 by 50%.  Descriptively, the characteristics of participants most likely to fall 
into Category 4 included high levels of experience, high perceived benefits, and a high level of 
positive vaccine attitudes.  
 Finally, a complementary analysis of the final model examining individual items to see if 
there were any individual item predictors was completed.  The nurses who reported currently 
caring for patients who have a history of HPV or managing Pap test results and nurses who 
reported a higher perceived benefit for sexual assault patients to become vaccinated increased the 
odds of being in Category 4. 
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Chapter 5: Discussion 
 This dissertation study helps to fill a gap in the HPV provider research.  This study 
provides a beginning understanding of nurses’ knowledge, attitudes, and beliefs related to the 
HPV virus and vaccine.  The participants were an international group of forensic nurses (93.4% 
U.S.) who care for sexual assault patients (N=519).  The objective was to identify the factors 
associated with these nurses’ level of support regarding incorporation of HPV preventative 
strategies into the routine care for patients post sexual assault. 
As described previously, patients with a history of sexual assault are at increased risk for 
HPV and HPV related diseases due to the following factors: increased risk for re-victimization, 
increased risk for a greater number of lifetime sexual partners, increased risk for STIs including 
HPV, lower odds of obtaining routine cervical cancer screenings, and an increased risk for 
abnormal cervical cytology (Farley, Golding, & Minkoff, 002; Fisher, et al., 2003; Kahn, Zimet, 
et al., 2005; Sadler et al, 2011).  This risk is coupled by the fact that HPV primary and catch up 
vaccination rates are currently not on target to meet national goals and herd immunity for HPV 
has not been achieved.  Efforts to increase vaccination are necessary and care post sexual assault 
is a window of opportunity to continue efforts to educate and immunize an at risk adolescent 
population. 
Discussion of Findings 
 Numerous investigators have documented that provider recommendation is a strong 
facilitating factor for HPV vaccination uptake (Conroy et al., 2009; Reiter, Brewer, Gottlief, 
McRee, & Smith, 2009).  This study was one of the first to uncover nurses’ support related to 
vaccination.  The participants in this study reported overwhelming high levels of support for 
HPV education, recommendation, and vaccination for sexual assault patients.  Of the nurses, 
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only 2.1% were not supportive of some type of approach to integrate HPV prevention strategies 
into routine sexual assault care.  Eleven percent of the nurses were supportive of providing 
educational materials alone, 33% were supportive of education materials plus including HPV 
recommendations on the discharge paperwork, and 52% were supportive of educational 
materials, discharge instructions, and initiation of HPV vaccine at point of care.   
The nurses’ general knowledge, vaccine attitudes, normative beliefs, and perceived 
benefits were all highly positive.  The nurses’ perceived barriers to vaccination were low.  Many 
of the sample characteristics were significantly associated with these independent variables.  
Overall general knowledge was very high (average total score 87.5% correct) and a few types of 
general nursing practice were significantly correlated with knowledge: being a women’s health 
nurse (positive) and primary care nurse (negative).  Achieving higher levels of nursing education 
were positively correlated and associated with vaccine attitudes, normative beliefs, and perceived 
benefits, but negatively correlated and associated with vaccine barriers.  Likewise, years as a 
forensic nurse was positively correlated and associated with vaccine attitudes and normative 
beliefs, and negatively correlated and associated with vaccine barriers.  Lastly identifying as a 
SANE-A was a positive predictor of perceived benefits. 
Where nurses obtained their HPV information also appeared to be an influential factor on 
the studies independent variables.  Those who obtained information from an academic lecture 
were more likely to have higher normative beliefs and perceived benefits, but lower perceived 
barriers; whereas obtaining HPV information from the media was a positive predictor of 
perceived barriers.   
The original planned ordinal logistic regression model with the outcome variable as the 4 
level of support categories examined how the independent variables corresponded to the 
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probabilities of different levels of support and how these probabilities changed as values on the 
independent variables changed.  The results revealed that clinical experience and perceived 
benefit moved individuals up on the level of support scale and knowledge and perceived barriers 
moved individuals down.  Surprisingly, the participants (approximately 85%) reported their level 
of support in only the top 2 categories, essentially making the outcome results dichotomous. 
The study’s final model had a dichotomous outcome variable of support, inclusion in the 
very highest category of support (Category 4) or all else (Category 1, 2, 3).  This helped to 
optimally explain what the characteristic and predictors are for the highest category of support.  
The new (two) categories were approximately evenly distributed and the results essentially 
mirrored the originally planned ordinal model.  This model explicated that knowledge and 
perceived barrier were significant factors that decreased the likelihood of the nurse being in 
Category 4, whereas clinical experience with HPV and perceived benefit increased the likelihood 
of the nurse being in Category 4.  Perceived benefits were the overall strongest predictor of 
support.  Normative beliefs, vaccine attitudes, and self efficacy were not significant predictors. 
In the existing provider literature, knowledge levels have ranged from high to low.  Many 
physicians may still have confusion related to the types of cancers HPV can cause, particularly 
anal and head and neck cancers, and OB/GYNs have tended to have the highest level of 
knowledge as compared to other physician specialties (Saraiya, Rosser, & Cooper, 2012).  This 
pattern was also true for the nurse participants in this study: 76.9% knew that types of HPV can 
cause anal cancers and only 49.7% knew types of HPV can cause cancers of the glands in the 
head and neck.  Type of primary practice was also indicative of level of knowledge in this study.  
The women’s health/ OB/GYN and community health nurses had the highest overall knowledge 
scores.  
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Previously, Kahn, Zimet, et al. (2005) identified high levels of knowledge as a variable 
associated with intention to vaccinate for physicians; however, in this study, high levels of 
knowledge moved nurses down on the support scale.  All nurses in this study had relatively high 
knowledge about HPV; however nurses with the highest levels of knowledge had 25.6 % lower 
odds of being in Category 4, support for vaccination at points of care.  One possible explanation 
for why those with the very highest level of knowledge were less supportive of initiating the 
vaccine at ED point of care post sexual assault may be related to concerns associated with the 
multiple dose nature of the vaccine and need to follow up for subsequent vaccinations (this was 
not assessed specifically as a potential barrier in this study).  Despite the importance of assessing 
for and understanding provider baseline knowledge, it is not a concept that has been fully 
established as a predictor of behavioral change, intention, or support.  In this study, perceived 
benefits, a concept explicated in the Health Belief Model, was the most influential factor of level 
of support.  
One may intuitively connect that women’s health providers (physicians or nurses) have 
more experience caring for patients who engage or have engaged in sexual acts, as well as 
managing the care of patients with HPV and abnormal Pap tests.  Kahn, Zimet, et al. (2005) 
reported that experience caring for sexually active adolescent patients was associated with 
intention to vaccinate.  In this study, 100% of the participants care for sexual assault patients; 
therefore, these nurses all have a baseline of experience caring for patients who have had some 
type of sexual contact.  However, the reported level of clinical experience related to HPV was 
significant and positively associated with these nurses’ level of support.  Nurses with high levels 
of clinical experience related to HPV had 24.2% higher odds of having the highest level of 
support for HPV vaccination (Category 4).   
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Provider perceived barriers for HPV vaccination have been documented previously.  
Some of the barriers reported in the literature have been: 1) perceived cost for patients and lack 
of awareness of vaccine assistance programs; 2) perceived parental and patient lack of education 
and understanding; and 3) provider comfort discussing sexual activity or the sexual connection to 
this virus and vaccine, as well as perceived concern that vaccination implies condoning sexual 
activity (Daley et al., 2011; Kahn et al., 2009; McCave, 2010).  Vadaparampil and colleagues 
(2011) also reported that providers with low perceived barriers were more likely to recommend 
the HPV vaccine to their patients.  This study’s findings are similar to those reported by previous 
researchers.  The respondents reported the greatest perceived barriers as concerns about parental 
or patient lack of education and understanding, as well as cost if the patient did not have 
insurance or qualify for vaccine assistance programs.  However, unlike the work of previous 
researchers, one of the lowest perceived barriers was reluctance to discuss sexuality and STIs.  
Surprisingly, these nurses did not perceive the time associated with adding additional 
responsibilities into routine care as a barrier.  Potentially, this may be related to the altruistic and 
dedicated nature of nurses who care for victims of sexual assault.  Anecdotally these nurses 
demonstrate high levels of commitment to ensuring that all aspects of their health needs are met 
during this time of crisis.  Also sexual assault nurses who provide forensic evidence collection 
and care in the ED are not assigned to any other patients; they provide one on one care and have 
time without competing demands.  A high perceived barrier was associated with 24.3% lower 
odds of being in the highest category of support.  
In this study, perceived benefit was the strongest overall predictor of support.  High 
levels of perceived benefit were significantly associated with level of support and increased the 
odds of being in Category 4 by 50%.  High levels of nursing education and increased years as a 
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forensic nurse were significantly associated with perceived benefits, as well as obtaining HPV 
information from academic lectures.  Lastly, a perceived a benefit for sexual assault patients to 
become vaccinated increased the odds of being in Category 4 (OR=2.13).  This was similar to the 
physician level of support described by McCave (2010):  personal belief in the positive impact of 
vaccination was reported by physicians who most often provided the vaccine to their patients.   
Implications for Nursing  
Clinical.  This study helped to highlight HPV as a health risk post sexual assault and 
elucidated a potential need for improvement in patient education and guidelines for care.  
Hopefully, any interest and insights generated by participation will lead to the nurses including 
this knowledge into their practice.  In turn, changes in clinical practice will have a positive 
impact on the patients, families, and communities they live in and care for.  Post sexual assault, 
patients have many fears and exposure to STIs is among them.  If nurses have a greater 
understanding and awareness of HPV and its potential health sequellae, then they will be able to 
comfortably and confidently address these issues.  Patients post sexual assault need to be aware 
that exposure to the HPV virus was possible and have the tools to mitigate these risks.  These 
tools include:  information and education, access to vaccination for future prophylaxis (important 
in case they were not exposed and/or coverage for strains they were not exposed to), and 
understanding the importance of and access to recommended routine cancer screenings.  
 Historically, IAFN members are known to be passionate advocates for the care and rights 
of sexual assault patients.  The participants in this study also reported high levels of self efficacy 
to practice change.  These two factors together may help contribute to a growing national 
awareness and advocacy for changes in practice guidelines to begin to incorporate HPV 
preventative strategies into the care of sexual assault patients.  Level of support has been 
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documented as very high, and nurses working with nurse leaders can make simple changes to 
existing policies.  
Education.  Based on the findings, the nurses’ overall basic knowledge related to HPV 
and the HPV vaccine is high.  Educational interventions might not be necessary to meet basic 
educational needs, but perhaps a higher level of complexity to help nurses stay up to date on the 
latest developments related to this virus, and vaccination should be the focus of future 
educational work.  Because these nurses care for patients who have been exposed to numerous 
STIs,  it stands to reason that they would have a solid core understanding of all STIs including 
HPV, and this was the case. 
 Educational efforts can capitalize on helping nurses become aware of the CDC’s 
recommendations for HPV vaccination.  Reported normative beliefs were high and the nurse 
participants indicated the highest level of professional regard for the CDC and following their 
recommendations.  Ninety four percent (n=489) of the participants indicated that they were likely 
to very likely to recommend the HPV vaccine to their patients if they were following CDC 
guidelines.  It was also apparent that promoting transfer of educational information by academic 
lecture or academic article may be the most beneficial.  Obtaining HPV information from 
academic lectures (p= .036) was positively associated with perceived benefits, and obtaining 
HPV information from academic lectures and academic articles was negatively associated with 
perceived barriers (p= .004 and p= .006 respectively).  Professional journals and conferences 
can be significant ways to disseminate information.  Schools of nursing need to incorporate 
information on forensic nursing, sexual assault, and STI information, including HPV and its links 
to cancer, into their course work and clinical experiences.  Education with clinical experiences or 
case studies may be a great facilitator of support. 
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 Policy.  In order to make policy changes, a few steps need to occur.  First, results need to 
be disseminated to key leaders at the local and national levels.  These stakeholders include 
employers of SANEs in community, hospital, and/or government settings, as well as the IAFN 
on the national level.  For example, in Massachusetts (MA), the Commonwealth’s SANEs are 
employed by the Department of Public Health.  The Directors of the SANE program work 
closely with other state organizations including the police and the crime lab.  Evaluation and 
revision of the existing rape kit, which includes the standardized discharge paperwork and step 
by step protocols for care, is done on a bi-annual basis.  Therefore, in order to make the 
necessary changes to care and discharge instructions to include HPV preventative strategies, 
discussions with these key stakeholders will need to occur.  The same would be true at the 
national level in order for the IAFN to incorporate HPV information into the national standards 
and guidelines for SANE-A and SANE-P education.  Changes to educational guidelines at the 
national level will then impact curriculums at the level of the schools of nursing.  
 Another interesting finding related to policy was revealed through exploring vaccine 
attitudes.  As the HPV vaccine became available and emerged onto the national stage, much 
controversy existed over the proposal for mandatory vaccination laws.  Kahn et al. (2009) 
reported on Texas physicians’ beliefs related to mandatory vaccinations specific to HPV and out 
of their participants, nearly 50% of the physicians (n=1,122) agreed or strongly agreed that the 
vaccine should be mandated for girls (11-12 years).  The Kahn et al. study was conducted prior 
to approval of HPV vaccination for males.  In this current study, participants were asked if they 
believed that vaccines should be required for contagious diseases.  Sixty eight percent of the 
participants reported that they agreed or strongly agreed (n=356).  This question was assessing 
general vaccine attitudes and was not HPV specific, but it is reflective of a high level of support 
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for required vaccinations.  It is also important to note that this question did have the very lowest 
overall mean score out of all the vaccine attitude questions. 
Future Research  
There are several limitations of this study and future research is needed.  The limitations 
include the cross sectional design and the self report methodology of the convenience sample of 
IAFN members.  This survey captured the one time snapshot of the participants’ attitudes, beliefs 
and knowledge level.  The findings are not likely generalizable to all nurses who care for sexual 
assault patients.  This was a convenience sample, did not capture the full population of nurses 
who care for sexual assault patients, and was homogenous in race and ethnicity.  Many nurses 
may choose not to join national professional organizations for several reasons, but potentially 
due to the expense.  Lastly, due to the early stage of research for nurses, in particular the unique 
population of forensic nurses, the best attempt was made to utilize validated measures when 
possible, but adaptations were made to existing tools.  This can lead to problems related to 
validity. 
 Roughly 1500 nurses who care for sexual assault patients had the opportunity to 
participate and of this population, approximately 36% responded.  This is an excellent response 
rate based on the history of the IAFN organization’s survey response data.  Ideally, the response 
rate could be higher; however it is comparable with a meta-analysis of 56 web-based surveys 
whose investigators reported response rates ranging from 35% to 40% (Cook, Heath, & 
Thompson, 2000).  Selection bias cannot be discarded with the existing response rate, and 
potentially participants were those who are more supportive of vaccination.  
Despite the limitations, several strengths should be highlighted.  This study provides data 
on a large pool of nurses from an international (mostly national) sample.  Thus, it differs from 
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other HPV related research typically involving regional samples.  This study is also based on a 
conceptual model that integrates constructs from two highly utilized theories in the existing HPV 
research.  Lastly, this study is also one of the first whose intent was to explore nurses’ roles in 
facilitating HPV vaccination.   
 There are several logical next steps for future research.  First, in order to capture 
viewpoints from the larger population of nurses who care for sexual assault patients, future 
researchers need to focus on nurses who are employed by hospitals and state organizations.  For 
example, in Massachusetts, the Department of Public Health (2012) employs the state’s SANE 
team that cares for sexual assault patients in over 20 hospitals and 6 regions.  Many of these 
nurses may not have access to this survey through the IAFN due to a lack of professional 
membership.  Second, it will be important to survey a more diverse population of nurses 
(including diversity of race, ethnicity, and gender).  
 Next, future researchers should expand beyond nurses who care for sexual assault 
patients and examine the general nursing population, in particular nurses who care for pediatric 
and adolescent populations, as well as nurses and advanced practice nurses including nurse 
practitioners and nurse midwives.  Nurses are among the most trusted members of American 
society and are influential members of both the health care provider community and the 
communities in which they live.  At this point, researchers have yet to uncover what nursing’s 
full role is and how nurses can potentially impact HPV vaccination rates.  Nurse practitioners are 
prescribers, primarily provide primary care and health education, and tend to establish practices 
in more socio-economic and racial/ethnically diverse communities.  Unfortunately, national data 
have identified uninsured and minority groups as being at risk for low levels of vaccination and 
vaccination series completion, and racial disparities are apparent with the HPV virus and cancer 
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(Dempsey, Cohn, Dalton, & Ruffin, 2011; Javanbakht, Stahlman, Walker, Gottlieb, et al., 2012).  
Therefore, it is logical to assess nurse practitioners’ knowledge, attitudes, beliefs, and intentions 
for vaccination. 
Conclusion 
 Forensic nurses provide care for many adolescents and young adults within the age range 
for HPV vaccination.  These sexual assault patients are at risk for acquiring HPV.  The nurses 
currently discuss, offer treatment for, and provide education and instructions about all other 
STIs.  They currently offer or provide medication these STIs, as well as opportunity for 
vaccination for Tetanus or Hepatitis B.  The latest science supports a view of HPV acquisition 
risk as important to consider for this population of patients and the existence of an opportunity to 
change practice guidelines and recommendations. 
 The nurses in this national sample reported a high level of knowledge, as well as positive 
vaccine attitudes and beliefs.  The nurses are overwhelmingly supportive of (98%), at the very 
least, of making a practice change that includes screening for a history of HPV vaccination and 
providing HPV education (ideally in a written information sheet).  Even more promising is the 
fact that the majority indicated support for taking prevention one step further: 86% indicated 
support for education, as well as a change to the written discharge instructions to include 
recommendation for HPV vaccination.  Finally, 53% of the nurses supported offering HPV 
vaccination at point of care.  Nurses reporting the highest level of support are most likely to 
report the highest perceived benefits for vaccination.  
The evidence is clear that actions should be taken to update current guidelines and 
SANE/ sexual assault care standards.  Information and interventions to promote positive 
perceived benefits for vaccination can be considered, and potentially disseminated through 
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professional and academic organizations, publication, and/or conferences, as well as in basic 
nursing education.  It is important to always remember that vaccination is just one way to reduce 
the health burden of HPV related diseases, so nurses have the responsibility to continue to 
promote routine cancer screenings despite vaccination status.  Vaccination is not a substitute for 
routine screening and care, especially because these patients may have already been exposed to 
the virus.  Lastly, risks for STIs are a major concern for patients post sexual assault and HPV 
should be included the discussion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
References 
Ajzen, I. (1991). The theory of planned behavior. Organizational, behavior and human decision  
 processes, 50, 179-211. 
Ajzen, I. (1985). From intentions to actions: A theory of planned behavior. In J.Kuhl & J. 
Beckman (Eds.), Action-control: From cognition to behavior (pp. 11-39). Heidelberg: 
Springer 
Allen, J., Othus, M., Shelton, R., Li, Y., Norman, N., Tom, L., & del Carmen, M. (2010). 
 Parental decision making about the HPV vaccine. Cancer Epidemiology, Biomarkers, & 
 Prevention,19,2187-2198. 
Allen, J.D., Coronado, G., Williams, R., Glenn, B., Escoffery, C., Fernandez, M., Tuff, R., 
 Wilson, K., & Mullen, P. (2010). A systematic review of measures used in studies of 
 human  papillomavirus (HPV) vaccine acceptability. Vaccine, 28, 4027-4037. 
Allen, J., Mohllajee, A., Shelton, R., Othus, M., Fontenot, H., & Hanna, R. (2009). Stage of  
adoption of the human papillomavirus vaccine among college women. Preventive 
Medicine, 48,420-425. DOI: 10.1016/j.ypmed.2008.12.005 
American Cancer Society (2011). Global Cancer Facts & Figures, 2nd edition. Atlanta, GA: 
 American Cancer Society. 
American College of Obstetricians and Gynecologists (ACOG) (2009). Update on immunization  
and pregnancy: tetanus, diphtheria, and pertussis vaccination. ACOG Committee 
Opinion, No. 438. Obstetrics & Gynecology, 114, 398-400. 
Becker, P. (2005). Conceptual frameworks: Issues for manuscript review and the dissemination 
of research findings. Research in Nursing & Health, 28, 363-364. 
Bertram, C. & Niederhauser, V. (2008). Understanding human papillomavirus: An Internet  
107 
 
survey of knowledge, risk, and experience among female and male college students in 
Hawaii. American Journal of Health Education, 39, 15-23. 
Brewer, N. & Fazekas, K. (2007). Predictors of HPV vaccine acceptability: a theory informed,  
systematic review. Preventive Medicine, 45, 107-114. DOI: 
10.1016/j.ypmed.2007.05.013 
Burgess, A., & Holmstrom, L. (1974). Rape trauma syndrome. American Journal of 
Psychiatry, 131, 981-986. 
Burns, N. & Grove, S. (2005). The practice of nursing research: Conduct, critique, and 
utilization (5th ed.). St. Louis, MO: Elsevier Saunders. 
Campbell, J. (2002). Health consequences of intimate partner violence. Lancet, 359, 1331-1336. 
Campbell, R. (November, 2004). The effectiveness of sexual assault nurse examiner 
(SANE) programs. VAWnet Applied Research Forum, 1-8. 
Centers for Disease Control and Prevention (2012). Healthy People 2020. Retrieved July 23, 
2012 from www.cdc.gov/nchs/healthy_people/hp2020.htm 
Centers for Disease Control and Prevention (2011a). 2011 Recommended immunizations for 
 children 7 through 18 years old. Retrieved online October 11, 2011
 www.cdc.gov/vaccines/teens. 
Centers for Disease Control and Prevention (2011b). HPV vaccine info for young women-fact  
sheet. Retrieved from http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-young-women-
htm 
Centers for Disease Control and Prevention (2009). Genital HPV Infection- Fact Sheet.  
 Retrieved from http://www.cdc.gov/std/hpv/stdfact-hpv.htm 
Conroy, K., Rosenthal,S., Zimet, G., Jin, Y., Bernstein, D., Glynn, S., & Kahn, J. (2009). Human 
108 
 
 papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to 
 vaccination. Journal of Women’s Health, 18, 1679-1686. DOI: 10.1089/jwh.2008.1329. 
Constantine, N. & Jerman, P. (2007). Acceptance of human papillomavirus vaccination among  
 Californian parents of daughters: A representative statewide analysis. Journal of 
 Adolescent Health, 40, 108-115. DOI: 10.1016/j.jadohealth.2006.10.007 
Cook, C., Heath, F. & Thompson, R. (2000). A meta-analysis of response rates in web-internet- 
 based surveys. Education Psychology Measures, 60(6), 821-836. 
Daley, M., Crane,L., Markowitz, L., Black, S., Beaty, B., Barrow, J. et al. (2011). Human 
 papillomavirus vaccination practices: a survey of US physicians 18 months after 
 licensure. Pediatrics, 126,425-433. DOI: 10.1542/peds.2009-3500 
Dempsey, A., Cohn, L., Dalton, V. & Ruffin, M. (2011). Worsening disparities in HPV vaccine  
utilization among 19-26 year old women. Vaccine, 29, 528-534. DOI: 
10.1016/j.vaccine.2010.10.051. 
Denny-Smith, T., Bairan, A., & Page, M. (2006). A survey of female nursing students’  
knowledge, health beliefs, perceptions of risk, and risk behaviors regarding human 
papillomavirus and cervical cancer. Journal of the American Academy of Nurse 
Practitioners, 18, 62-69. DOI: 10.1111/j.1745-75599.2006.00100.x 
Derhammer, F., Lucente, V., Reed, J., & Young, M. (2000). Using a SANE 
interdisciplinary approach to care of sexual assault victims. Journal on Quality 
Improvement, 26(8), 488-495. 
Dorell, C., Stokley, S., Yankey, D., Liang, J., & Markowitz, L. (2011). National and state 
 vaccination coverage  among adolescents aged 13 through 17 years—United States, 
 2010. Morbidity and  Mortality Weekly Report, 60 (33), 1117-11123 
109 
 
Eaton, D.K., Kann, L, Kinchen, S., Shanklin, S., Ross, J., Hawkins, J., et al. (2008). Youth risk 
behavior surveillance-United States, 2007. Mortality and Morbidity Weekly, 57(SS-4), 1-
131.  
Ericksen, J., Dudley, C., McIntosh, G., Ritch, L., Shumay, S., & Simpson, M. (2002). 
Clients’ experiences with a specialized sexual assault service. Journal of Emergency 
Nursing, 28(1), 86-90. 
Farley, M., Golding, J., & Minkoff, J. (2002). Is a history of trauma associated with a reduced 
 likelihood of cervical cancer screening? The Journal of Family Practice, 51, 827-831. 
Feemster, K., Winters, S., Fiks, A., Kinsman, S., & Kahn, J. (2008).  Pediatricians’ intention to  
 recommend the human papillomavirus (HPV) vaccine to 11-to 12-year-old girls 
 postlicensing. Journal of Adolescent Health, 43, 408-411. DOI: 
 10.1016/j.jadohealth.2008.06.012. 
Fishbein. M., & Ajzen, I. (1975). Belief, attitude, intention, and behavior. Reading, MA:  
 Addison-Wesley 
Fisher, B., Cullen, F, & Turner, M. (2000). The sexual victimization of college women 
(Report No. 182369). Washington, DC: U.S. Department of Justice, National Institute of 
Justice. 
Fisher, B., Daigle, L, Cullen, F., & Turner, M. (2003). Acknowledging sexual victimization as 
 rape: Results from a national-level study. Justice Quarterly, 20 (3), 535-574. 
Frampton, D. (1998). Sexual assault: The role of the advanced practice nurse in 
identifying and treating victims. Clinical Nurse Specialist, 12(5), 177-182. 
110 
 
Gavin, L., MacKay, A., Brown, K., Harrier, S., Ventura, S., Kann, L. et al. (2009). Sexual and 
 reproductive health of persons aged 10-24 years—United States, 2002-2007. Morbidity 
 and Mortality Weekly Report, 58(SS06), 1-58. 
Gerend, M., Shepherd, J., & Monday, K. (2008). Behavioral frequency moderates the effects of  
message framing on HPV vaccine acceptability. Annals of Behavioral Medicine, 35, 221-
229. DOI: 10.1007/s12160-008-9024-0 
Gibson, J. (2000). Forensic nursing: a competent practice. On the Edge, 6(3), 22-26. 
Gillespie, M., Rubinchik, S., Hoel, B. & Sutkowski, N. (2009). Human papillomavirus and 
oropharyngeal cancer: what you need to know in 2009. Current Treatment Options in 
Oncology, 10, 296-307. DOI: 10.1007/s11864-009-0113-5. 
Girardin, B.W. (2005). The sexual assault nurse examiner: A win-win solution. Topics in 
Emergency Medicine, 27(2), 124-131. 
Goff, S., Mazor, K., Gagne, S., Corey, K. & Blake, D. (2011). Vaccine counseling: a content  
analysis of patient-physician discussions regarding human papilloma virus vaccine. 
Vaccine, 29, 7343-7349. DOI: 10.1016/j.vaccine.2011.07.082. 
Herrero, R., Wacholder, S., Rodriguez, A. Solomon, D., Gonzalez, P., Kreimer, A., et al. (2011).  
Prevention of persistent human papillomavirus (HPV) infection by a HPV 16/18 vaccine: 
a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer 
Discovery, October, 408-419. DOI: 10.1158/2159-8290.CD-11-0131 
Hoots, B., Palefsky, J., Pimenta, J., & Smith, J. (2008). Human papillomavirus type distribution 
 in anal cancer and anal intraepithelial lesions. Internationational Journal of Cancer, 124, 
 2375-2383. DOI: 10.1002/ijc.24215 
International Association of Forensic Nurses. (2011). Web page information. Retrieved January  
111 
 
 2012 from www.iafn.org. 
Janz, N. & Becker, M. (1984). The health belief model: a decade later. Health Education  
 Quarterly, 11, 1-47. 
Jeffreys, A.J., Wilson, V., & Thein, S.L. (1985). Individual-specific ‘fingerprints’ of DNA.  
 Nature, 316, 76-79. 
Jeffreys, A., J., Brookfield, J.F., & Semeonoff, R. (1985). Positive identification of an 
immigration test-case using human DNA fingerprints. Nature, 317, 818-819. 
Javanbakht, M., Stahlman, S., Walker, S., Gottlieb, S., Markowitz, L., Liddon, N., Plant, A. &  
Guerry, S. (2012). Provider perceptions of barriers and facilitators of HPV vaccination in 
a high risk community. Vaccine, 30, 4511-4516. DOI: 10.1016/j.vaccine.2012.04.062. 
Kahn, J., Cooper, H., Vadaparampil, S., Pence, B., Weinberg, A., LoCoco, S., & Rosenthal, S. 
 (2009). Human papillomavirus vaccine recommendations and agreement with mandated 
 human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of 
 Texas physicians. Cancer Epidemiology, Biomarkers, & Prevention, 18,2325-2332. DOI: 
 10.1158/1055-9965.epi-09-0184 
Kahn, J., Huang, B., Rosenthal, S., Tissot, A., & Burk, R. (2005). Coercive sexual experiences 
 and subsequent human papillomavirus infection and squamous intraepithelial lesions in 
 adolescent and young adult women. Journal of Adolescent Health, 36, 363-371. DOI: 
 10.1016/j.jadohealth.2004.07.016  
Kahn, J., Rosenthal, S., Jin, Y., Huang, B., Namakydoust, A., & Zimet, G. (2008). Rates of  
human papillomavirus vaccination, attitudes about vaccination, and human 
papillomavirus prevalence in young women. Obstetrics & Gynecology, 111, 1103-1110. 
Kahn, J., Rosenthal, S., Hamann, T., & Bernstein, D. (2003). Attitudes about human  
112 
 
 papillomavirus vaccine in young women. International Journal of STD & AIDS, 14, 300-
 306.  
Kahn, J., Zimet, G., Bernstein, D., Riedesel, J., Lan, D., Huang, B., & Rosenthal, S. (2005).  
Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice 
characteristics, knowledge, and attitudes. Journal of Adolescent Health, 37, 502-510. 
Kreimer, A, Rodriguez, A., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., Gonzalez, P., 
 et al. (2011). Proof-of-principle evaluation of the efficacy of fewer than three doses of a 
 bivalent HPV 16/18 vaccine. Journal of the  National Cancer Institute, 103, 1444-1451.  
 DOI: 10.1093/jnci/djr319 
Ludlow, L. (2009).  Lecture, and handouts, Presented in ED 667, Boston College. 
Magid, D.J., Houry, D., Koepsell, T.D., Ziller, A., Soules, M.R., Jenny, C. (2004). The  
epidemiology of female rape victims who seek immediate medical care: Temporal trends 
in the incidence of sexual assault and acquaintance rape. Journal of Interpersonal 
Violence, 19(1). 3-12. 
Marur, S., D’Souza, G., Westra, W., & Forastiere, A. (2010). HPV-associated head and neck  
cancer: a virus-related cancer epidemic. Lancet Oncology, 11, 781-789. DOI: 
10.1016/S1470-2045(10)70017-6. 
Massachusetts Department of Public Health (2012). SANE Program. Retrieved online June 20,  
 2012 from www.mass.gov/dph/SANE 
McCave, E. (2010). Influential factors in HPV vaccination uptake among providers in four 
 states. Journal of Community Health, 35,645-652. 
Mertler, C. & Vannatta, R. (2005). Advanced and multivariate statistical methods: practical  
 applications and interpretation (3rd edu.). Glendale, CA: Pyrczak Publishing 
113 
 
Millen, J., Ginde, A., Anderson, A., Fang, P., & Camargo, C. (2009). Multicenter study of  
knowledge about human papillomavirus and attitudes among emergency department 
patients. Journal of Pediatric and Adolescent Gynecology, 22, 356-359. DOI: 
10.1016/j.jpag.2009.03.001  
National Cancer Institute (2005). Theory at a glance: A guide for health promotion practice. 2nd  
edition. United States Department of Health and Human Services. National Institutes of 
Health Publications No. 05-3896. 
National Cancer Institute (2011a). Fact Sheet: HPV and cancer. US National Institutes of  
 Health. Retrieved from http://www.cancer.gov/cancertopics/factsheet/risk/hpv 
National Cancer Institute (2011b). Fact Sheet: HPV vaccines. US National Institutes of Health, 
 Retrieved from http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine 
O’Connell, A. (2006). Logistic regression models for ordinal response variables.  Series:  
 Quantitative applications in the social sciences. Thousand Oaks, CA: Sage Publications 
Parkins, D. (2006). The global health burden of infection-associated cancers in the year 2002. 
 International Journal of Cancer, 118, 3030-3044. 
Patterson, D., Campbell, R., Townsend, S. (2006). Journal of Nursing Scholarship,38(2), 
180-186. 
Polit, D. & Beck, C. (2008). Nursing research: Generating and assessing evidence for nursing 
practice (8th ed.). Philadelphia, PA: Lippincott, Williams, & Wilkins. 
Raso, M. (October, 12, 2011). Personal communication regarding note of authorization.  
 Membership Director, IAFN. 
Reiter, P., Brewer, N., Gottlieb, S., McRee, A., & Smith, J. (2009). Parents’ health beliefs and  
114 
 
HPV vaccination of their adolescent daughters. Social Science & Medicine, 69 (3), 475-
480. DOI: 10.1016/j.socscimed.2009.05.024. 
Reiter, P., Stubbs, B., Panozzo, C., Whitesell, D., & Brewer, N. (2011). HPV and HPV vaccine 
education intervention: effects on parents, healthcare staff, and school staff. American 
Association for Cancer Research. Published online Sept, 23, 2011. DOI:10.1158/1055-
9965.epi-11-0562 
Riedesel, J., Rosenthal, S., Zimet, G., Bernstein, D., Huang, B., Lan, D., & Kahn, J. (2005). 
Attitudes about human papillomavirus vaccine among family physicians. Journal of 
Pediatric and Adolescent Gynecology, 18, 391-398. 
Sadler, A., Mengeling, M., Syrop, C., Torner, J., & Booth, B. (2011). Military service, life span 
sexual assault exposures, and cervical cytologic abnormalities. Journal of Women’s 
Health, 0,1-4, DOI:10.1089/jwh.2010.2399 
Saraiya, M., Rosser, J., Cooper, C.P. (2012). Cancers that U.S. physicians believe the HPV 
vaccine prevents: findings from a physician survey, 2009. Journal of Women’s Health, 
21, 111-117. DOI: 10.1089/jwh.2011.3313. 
Schwarcz, S. & Whittington, W. (1990). Sexual assault and sexually transmitted diseases: 
detection and management in adults and children. Reviews of Infectious Diseases, 12, 
S682-S690. 
Sievers, V., Murphy, S., Miller, J. (2003). Sexual assault evidence collection more 
accurate when completed by sexual assault nurse examiners: Colorado’s experience. 
Journal of Emergency Nursing, 29, 511-514. 
Slade, B., Leidel, L., Vellozzi, C., Woo, E., Hua, W., Sutherland, A., Izurieta, H., Ball, R., 
Miller, N., Braun, M., Markowitz, L., & Iskander, J. (2009). Postlicensure safety 
115 
 
surveillance for quadrivalent human papillomavirus recombinant vaccine. Journal of the 
American Medical Association, 302, 750-757. 
Small, S. & Patel, D. (2012). Impact of HPV vaccine availability on uptake. The Journal for 
Nurse Practitioners, 8, 61-66. 
Spybrook, J., Bloom, H., Congdon, R., Hill, C., Martinez, A., & Raudenbush, S.(October 16,  
 2011). Optimal design plus empirical evidence: documentation for the “Optimal Design” 
 software. Optimal Design Plus Version 3.0, published online. 
Taylor, A., West, S., & Aiken, L. (2006). Loss of power in logistic, ordinal logistic, and probit 
 regression when an outcome variable is coarsely categorized. Educational and 
 Psychological Measurement, 66, 228-239. DOI: 10.1177/0013164405278580 
Taylor, D., & Woods, N. (1996). Changing women’s health, changing nursing practice.  
Journal of Obstetric, Gynecologic, and Neonatal Nursing, 25, 791-802. 
Titelman, A., Stringer, M., Nguyen, G., Hanlon, A., Averbuch, T., & Stimpfel, A. (2011). Social 
cognitive and clinical factors associated with HPV vaccine initiation among urban , 
economically disadvantaged women. Journal of Obstetric, Gynecologic, and Neonatal 
Nursing, 40, 1-11. DOI: 10.1111/j.1552-6909.2011.01297.x 
Tjaden, P., & Thoennes, N. (2000). Prevalence, incidence and consequences of violence against 
women: findings from the National Violence Against Women Study. Research in Brief. 
1998; U.S. Department of Justice, NCJRS, 17283. 
Trent, M., Clum C., & Roche (2007). Sexual victimization and reproductive health outcomes in 
 urban youth. Ambulatory Pediatrics, 7, 313-316. 
116 
 
Tjaden, P., & Thoennes, N. (2000). Prevalence, incidence and consequences of violence against 
women: findings from the National Violence Against Women Study. Research in Brief. 
1998; U.S. Department of Justice, NCJRS, 17283. 
Vadaparampil, S., Kahn, J., Salmon, D., Lee, J., Quinn, G., Roetzheim, R., Bruder, K., Malo, T., 
 Proveaux, T., Zhao, X., Halsey, N. & Giuliano, A. (2011). Missed clinical opportunities:  
provider recommendations for HPV vaccination for 11-12 year old girls are limited. 
Vaccine, 29, 8634-8641. DOI: 10.1016/j.vaccine.2011.09.006. 
Weinstock, H., Berman, S., & Cates Jr., W. (2004). Sexually transmitted diseases among 
 American youth: incidence and prevalence estimates, 2000. Perspectives on Sexual and 
 Reproductive health, 36 (10), 6-10. 
Weiss, A. & Dym, H. (2011). Oral lesions caused by human papillomavirus. The Clinical  
Advisor. Retrieved from January 10 2011 issue, www.clinicaladvisor.com/oral-lesions-
caused-by-human-papillomavirus/article/193918/ 
 
117 
 
Appendix A: Permission 
October, 12, 2011 
 
To Whom it May Concern, 
 
Please accept this as a notice of authorization allowing Holly 
Fontenot, to access the IAFN member email database at some point 
in 
the future for 3 email blasts. The total expected cost will be 
$300. 
 
Best, Marisa 
 
--  
Marisa Raso 
Membership Director 
International Association of Forensic Nurses 
1517 Governor Ritchie Highway | Suite 208 
Arnold, MD 21012 
Phone 410.626-7805 EXT 101  | Fax 410.626-7804 
mraso@iafn.org 
http://www.iafn.org 
 
Our new address after Nov 1st will be: 
IAFN 
6755 Business Parkway 
Ste 303 
Elkridge, Maryland 21075 
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Appendix B: Email’s IAFN Membership 
First Email 
 
Please Volunteer! I need your help! 
Complete this 10 minute survey for a chance to: 
 Win an Apple iPad ! 
Please complete the Intersection of HPV and Sexual Assault Survey. You have a GREAT 
chance to win. By participating, you can help design educational programs to provide nurses 
with the latest up to-date information on sexually transmitted infections, including HPV. You 
will be entered into a prize drawing to win an Apple iPad. MORE THAN ONE iPad will be 
given away! 
This study is being conducted by a fellow IAFN member as her PhD dissertation research. To 
learn more please click the following link. 
https://bcnursing.qualtrics.com/SE/?SID=SV_50ZQaMOPZyhk580 
Holly B. Fontenot, RN, PhD(c), WHNP-BC, SANE 
 
Holly.fontenot@bc.edu; 617-552-1845 
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Second Email 
 
I want to express my GREAT THANKS to the many nurses who have participated in the 
Intersection of HPV and Sexual Assault Survey!! 
 
There has been one lucky winner of an Apple iPad and there will be ONE MORE!!! 
 
So it is not too late to help and it is not too late to win! 
 
By participating, you can help design educational programs to provide nurses with the latest up-
to-date information on sexually transmitted infections, including HPV.  
 
This study is being conducted by a fellow IAFN member as her PhD dissertation research. To 
learn more please click here. 
 
Holly B. Fontenot, RN, PhD(c), WHNP-BC, SANE 
Holly.fontenot@bc.edu; 617-552-1845 
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Final Email 
 
Thank you to all who participated in the Intersections of HPV and Sexual Assault Survey! 
 
I will look forward to sharing my results with you in the future. I appreciate all of the work you 
do and I thank you for your time. Congratulations to the 2 winners of the Apple iPads! 
 
Sincerely, 
 
Holly B. Fontenot, RN, PhD(c), WHNP-BC, SANE 
holly.fontenot@bc.edu 
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Appendix C: Informed Consent 
 
Consent to Participate 
You were selected to participate in the Intersection of HPV and Sexual Assault Survey because 
you are an IAFN member and a nurse. The purpose of this research study is to understand 
forensic nurses’ knowledge, beliefs, and attitudes about the human papillomavirus (HPV) and the 
HPV vaccine.  
 
If you agree to be in this study, you will be asked to complete an on-line survey. The survey 
should take about 10-15 minutes to complete.  It contains questions about your general practice, 
knowledge about HPV, and views on the HPV vaccination. You are free to withdraw or skip 
questions for any reason, without penalties.  
 
The survey is anonymous and your participation is voluntary. There is no way that you can be 
identified and linked to your responses, therefore ensuring your confidentiality and anonymity. 
All data collected will be kept on the primary researcher’s secure computer in a locked office. If 
you choose not to participate, it will not affect your current or future relations with the IAFN or 
with Boston College.  
 
There are no direct benefits for participating in this study, but knowledge gained from this study 
may increase your awareness of HPV.  There are minimal risks or discomforts anticipated from 
participation in this survey. 
 
Individuals who decide to participate can choose to be entered into a prize drawing (you will be 
provided a separate link after completing the survey to enter the drawing- you are only able to 
enter the drawing if you complete the survey). There is no way to trace prize drawing 
participants back to the original survey. We will be giving away Apple i-pads!!! You will be 
contacted via email from the prize link if you are one of the winners.  
 
If you have any questions or concerns regarding this research you may contact Holly Fontenot, 
PhD(c), WHNP-BC, SANE, the Principal Investigator, at holly.fontenot@bc.edu or 617-552-
1846.  If you have any questions about your rights as a research participant, you may contact the 
Office for Research Protections, Boston College, at 617-552-4778 or irb@bc.edu. 
 
This study was reviewed by the Boston College Institutional Review Board (IRB) and its 
approval was granted on March 19, 2012.  Regulatory agencies, Boston College IRB, and 
internal auditors all reserve the right to review research records. 
 
If you are ready to participate and agree to the statements above, please press the “Consent 
Given” button below.  
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Appendix E: Survey 
 
Intersection of HPV and Sexual Assault Survey 
1. Age _____Years 
2. Gender  _____M/F 
3. Race:  Caucasian _____,  African descent______, Asian______ 
4. Ethnicity: Hispanic_____, Non Hispanic _____, Native American ______,  
Pacific Islander_____ 
5. What was your first nursing preparation 
a. Licensed practical nurse 
b. Associate degree 
c. Bachelor’s degree 
d. Master’s degree 
6. What is your highest level of nursing education 
a. Associate degree 
b. Bachelor’s degree 
c. Master’s degree 
d. Doctoral degree 
7. What is your highest degree obtained, non nursing 
a. No other degrees 
b. Associate degree 
c. Bachelor’s degree 
d. Master’s degree 
e. Doctoral degree 
8. How many years have you been a nurse?  _____ 
9. Years worked in forensic practice? ______ 
10. Forensic area(s) in which you function 
a. Child abuse and neglect 
b. Corrections and custody 
c. Death investigation/ coroners 
d. Emergency/ trauma or critical care 
e. Forensic geriatrics 
f. Forensic nurse education, research, counseling, or epidemiology 
g. Forensic psychiatric mental health (youth or adults) 
h. Intimate partner violence 
i. Legal nurse consultant 
j. Nursing practice involving assessment of intentional or non-intentional injuries 
k. Sexual assault 
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l. Adult sexual assault forensic exams 
m. Pediatric sexual assault forensic exams 
11. What is your area of primary practice besides forensics? 
a. Forensics only 
b. Medical or surgical 
c. Pediatrics 
d. Women’s health, OB/GYN 
e. Emergency  
f. Psychiatric nursing 
g. Primary care 
h. Community health 
i. Other _______ 
12. Do you care for Sexual Assault patients (direct or indirect care) including: (check all that 
apply) 
____education 
____ counseling 
____ follow-up care 
____ research 
____ policy development 
Other________ 
 
13. Have you ever heard of the human papillomavirus (HPV)? (yes/no) 
 
14. Your primary source(s) of HPV information has been from (check all that apply): 
____Professional organizations (newsletter, journals, list serves) 
____Articles in academic journals 
____Professional conferences or meetings 
____Academic lectures or grand rounds 
____Promotion materials from industry 
____Colleagues 
____Another health care provider   
____General news media (TV, magazines, radio, Internet) 
____Personal knowledge 
 
 
15. Has your health care provider ever told you that you had an abnormal Pap smear result or 
cervical cancer? (Yes/ No/ NA) 
16. Has anyone in your immediate family or friends ever had an abnormal Pap smear result 
or cervical cancer? (Yes/ No/ NA) 
17. Do you currently care for patients who have a history of HPV or manage Pap test results? 
(Yes/ No/ NA) 
18. Do you currently recommend or give the HPV vaccine to patients where you practice: 
Non forensic setting? (Yes/ No/ NA) 
Forensic setting: sexual assault patients specifically? (yes /no /NA)  
19. Have you or other health providers you work with ever discussed initiating HPV 
education or vaccination for sexual assault patients? (Yes/No/ NA) 
126 
 
 
 
 
20. The following questions are on a likert scale (1 strongly disagree, to 6 strongly agree) 
I am confident in my ability to adapt to practice changes 
I am comfortable bringing new ideas for practice change to nursing leadership 
I am confident in discussing new ideas for practice with other non nursing health professionals 
 
21. HPV can be transmitted by: (yes/no/I don’t know- after each answer item) 
sexual intercourse 
oral to genital contact 
genital to genital contact 
blood transfusions 
sharing needles 
 
22. Cervical cancer and pre-cancerous cells are associated with the presence of: (yes/no/I don’t 
know) 
herpes simplex virus 
human papillomavirus 
Epstein-barr virus, HIV  
 
23. Prevention strategies for HPV include: (yes/no/I don’t know) 
delay the onset of sexual activity 
using condoms 
annual  Pap screening test 
receiving the HPV vaccine  
 
24. HPV can cause: (yes/no/I don’t know) 
genital warts 
cervical cancer 
anal cancer 
cancer in the glands of the head or neck 
vaginal discharge 
burning with urination 
itching 
open sores 
 
25. HPV can live in the skin without causing growths or changes (yes/no/ I don’t know) 
 
26. Risk factors for getting HPV are: (yes/no/I don’t know) 
multiple sex partners 
sexual intercourse prior to age 18 
taking illegal drugs 
having a history of sexually transmitted infections 
smoking cigarettes 
having genital warts 
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using tampons 
using oral contraceptives 
poor diet 
having sex without a condom 
 
27. The following  questions are on a Likert scale (1 strongly disagree to 6 strongly agree): 
Vaccines are important to prevent diseases that can be spread person to person 
If there was a vaccine that prevented the common cold I would want my patients to get 
 vaccinated 
If there were a vaccine that prevented cancer I would want my patients to get vaccinated 
I believe that vaccines should be required for contagious diseases that can be spread person 
 to person 
In general, I would recommend the HPV vaccine to persons in my family? 
In general, I would recommend the HPV vaccine to my friends? 
In general, I would recommend the HPV vaccine to any patient?  
Specifically, I would recommend the HPV vaccine to sexual assault patients?  
 
28. The following questions are on a Likert scale: 
Thinking about each of the following individuals or groups, how much would they approve of 
 or disapprove of you recommending the HPV vaccine? (1 strongly disapprove to 6 
strongly approve) 
Family 
Friends 
Your religious or faith organization 
 
You would most likely make HPV vaccine recommendations to your patients if you following 
recommendations from the following organizations/ individuals: (1 very unlikely to 6 
very likely) 
Nursing and medical colleagues 
US Centers for Disease Control and Prevention (CDC) 
IAFN  
  
29. The following questions are on a Likert scale (1 strongly disagree, to 6 strongly agree) 
Getting the HPV vaccine will help patients stay healthier 
The benefits of getting the HPV vaccine outweigh the potential risks 
HPV vaccination will prevent most cases of cervical cancer 
HPV vaccination will prevent most cases of genital warts 
HPV vaccine will be cost effective 
It would be a benefit to sexual assault patients to learn more about HPV and the HPV vaccine 
It would be a benefit to sexual assault patients to become vaccinated against HPV  
 
30. The following questions are on a Likert scale (1 strongly disagree, to 6 strongly agree) 
I have concerns about HPV vaccine safety 
I have concerns about HPV vaccine efficacy 
I have concerns about parental or patient lack of education and understanding about HPV 
I have concerns that HPV vaccinated teens will practice riskier sex 
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I am reluctant to discuss sexuality and STIs with my patients 
The vaccine costs too much money if my patient did not have insurance coverage or qualify for 
 vaccine assistance programs 
I am reluctant to discuss HPV related to time constraints in nursing practice 
HPV and the HPV vaccine should only be discussed by the patient’s primary care provider  
 
 
The HPV vaccine is not curative, nor does it provide post exposure prophylaxis; however 
the HPV vaccine does provide future protection against cervical and other cancers as well 
as genital warts. This vaccine is recommended by the CDC for all patients male and female 
ages 9-26 regardless of past sexual experiences. 
 
31.  If there were to be a change in practice guidelines related to the care of the patient during a 
sexual assault examination what would you be supportive of:  (Choose ONE) 
a. I am not supportive of any changes that incorporate HPV education or HPV vaccination 
for sexual assault patients 
b. Written educational materials about the HPV virus and vaccine should be provided to 
sexual assault patients in their discharge packet/ paperwork  
c. Written educational materials about the HPV virus and vaccine should be provided in 
their discharge packet/paperwork, and recommendations for HPV vaccination should be 
included in the written discharge instructions for sexual assault patients  
d. Written educational materials about the HPV virus and vaccine should be provided, 
recommendations for HPV vaccination should be included in the written discharge 
instructions, and if possible the HPV vaccination series should be initiated during the care 
of a sexual assault patient  
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Appendix F: Psychometrics and survey development  
(italic= adaptation done or question developed for this survey; response patterns are in survey appendix D) 
Construct General 
Definition 
Sources used 
as a guide for 
measure 
development 
Psycho-
metrics 
Questions (adaptations and additional questions are italic) 
Knowledge Level of 
familiarity and 
understanding 
of HPV  
Adapted from 
CDC info 
sheet and 
Denny-Smith 
et al. 
Denny-
Smith et al. 
∝ൌ 0.95 
HPV can be transmitted by: sexual intercourse, oral to genital contact, 
blood transfusions, maternal fetal transmission, sharing needles, 
inanimate objects  
Cervical cancer and pre cancer cells are associated with the presence 
of: herpes simplex virus, human papillomavirus, Epstein-barr virus, 
HIV  
Prevention strategies for HPV include: delay the onset of sexual 
activity, using condoms, annual pap screening test, receiving the HPV 
vaccine 
HPV can cause: genital warts, cervical cancer, anal cancer, cancer in 
the glands of the head or neck, vaginal discharge, burning with 
urination, itching, open soars  
HPV can live in the skin without causing growths or changes  
Risk factors for getting HPV are: multiple sex partners, sexual 
intercourse prior to age 18, taking illegal drugs, having a history of 
sexually transmitted infections, smoking cigarettes, having genital 
warts, using tampons, using oral contraceptives, poor diet, having sex 
without a condom  
Experience Having Bertram & Content and Has your health care provider ever told you that you had an abnormal 
pap smear result or cervical cancer 
Has anyone in your immediate family or friends ever had an abnormal 
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personal or 
professional 
familiarity with 
HPV 
Niederhauser; 
Allen, 
Mohllaje, 
Shelton, 
Othus,  
Fontenot, & 
Hanna, (2009) 
face validity pap smear result or cervical cancer  
Do you currently work with patients that have a history of HPV or 
manage pap tests results  
Do you currently recommend or give the HPV vaccine to patients 
where you work 
 
Attitudes  Positive or 
negative 
evaluation of 
vaccines 
Allen, Othus 
et. al, 2010 
α = 0.76 Vaccines are important to prevent diseases that can be spread person 
to person 
If there was a vaccine that prevented the common cold would you 
want your patients to get vaccinated 
If there were a vaccine that prevented cancer would you want your 
patients to get vaccinated 
I believe that vaccines should be required for contagious diseases that 
can be spread person to person 
In general, I would recommend the HPV vaccine to persons in your 
family? 
In general, I would recommend the HPV vaccine to friends? 
In general, I would recommend the HPV vaccine to any patient?  
Specifically, I would recommend the HPV vaccine to sexual assault 
patients? 
Self 
efficacy 
Confidence and 
comfort with 
Developed for 
this survey 
Content and 
face validity
I am confident in my ability to adapt to practice changes 
I am comfortable brining new ideas for practice change to nursing 
leadership 
I am confident in discussing new ideas for practice with other non 
nursing health professionals 
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practice 
changes 
Normative 
beliefs 
Individuals 
perception 
about a 
behavior that is 
influenced by 
judgment of 
significant 
others and 
professional 
organizations 
Allen, Othus 
et. al, 2010 
 
Riedesel et al., 
2005 
α=0.84 
 
 
α=0.84 
Thinking about each of the following individuals or groups, how much 
would they approve of or disapprove of your recommending the HPV 
vaccine? Family, friends, religious or faith organizations 
 
Likelihood of recommending HPV following the vaccine 
recommendations of the following organizations/individuals: CDC, 
colleagues, IAFN 
 
 
Perceived 
benefits 
Beliefs about 
the 
effectiveness of 
taking action to 
Gerend, 
Shepherd, 
Monday, 2008 
 
α =0.86 
 
 
 
Getting the HPV vaccine will help my patients stay healthier 
The benefits of getting the HPV vaccine outweigh the potential risks 
 
HPV vaccination will prevent most cases of cervical cancer 
HPV vaccination will prevent most cases of genital warts 
HPV vaccine will be cost effective 
 
It would be a benefit to sexual assault patients to learn more about 
HPV and the HPV vaccine 
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reduce risk of 
HPV 
Feemster et 
al., 2008 
α =0.74 
 
It would be a benefit to sexual assault patients to become vaccinated 
against HPV   
 
Perceived 
barriers 
Beliefs about 
the material 
and 
psychological 
costs of taking 
action 
Kahn, Cooper, 
Vadaparampil, 
2009  
 
Feemster et al. 
2008 
α = 0.82 
 
 
 
α = 0.88, 
0.81, 0.72 
 
Clinical: 
I have concerns about HPV vaccine safety 
I have concern about vaccine efficacy 
Social: 
I have concern about parental or patient lack of education and 
understanding about HPV 
Concern that vaccinated teens will practice riskier sex 
Your own reluctance to discuss sexuality and STIs 
System barriers: 
It costs too much money if my patient did not have insurance coverage 
or qualify for vaccine assistance programs 
Reluctant to discuss HPV related to time 
HPV and the HPV vaccine should only be discussed by the patient’s 
primary care provider 
Support 
related to 
potentials 
for change 
in practice 
guidelines 
 Developed for 
this survey 
Content and 
face validity
I am not supportive of any changes that incorporate HPV education or 
HPV vaccination for sexual assault patients 
Written educational materials about the HPV virus and vaccine should 
be provided to sexual assault patients  
Written educational materials about the HPV virus and vaccine should 
be provided as well as recommendations for HPV vaccination should 
be included in the written discharge instructions for sexual assault 
patients  
Written educational materials about the HPV virus and vaccine should 
be provided, recommendations for HPV vaccination should be 
included in the written discharge instructions, and the HPV 
vaccination series should be initiated during the care for a sexual 
assault patient 
 
